Journal Spotlight

Journal of Clinical Oncology Literature Update

The ASCO Post  / October 10, 2017

STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology.  Sorafenib Dosing and Outcomes in Hepatocellular Cancer  Kim A....

Skin Cancer

Blood-Based Biomarker: Predicting Efficacy of Immunotherapy in Patients With Melanoma

Caroline Helwick  / October 10, 2017

IN WHAT APPEARS TO BE the largest blood-based biomarker study of a checkpoint inhibitor, an RNA transcript–based gene classifier was able to predict for melanoma patients’ response to tremelimumab. The study was recently published in the Journal for ImmunoTherapy of Cancer.1  Philip Friedland...

Skin Cancer

Overview of the Phase III MSLT-II Trial

Matthew Stenger  / October 10, 2017

Mark B. Faries, MD THE PHASE III MSLT- II TRIAL showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel-node metastasis, although a benefit was observed in regional disease control. The findings were repo...

Colorectal Cancer

Nivolumab in Advanced DNA Mismatch Repair–Deficient or Microsatellite Instability–High Colorectal Cancer

Matthew Stenger  / October 10, 2017

Michael J. Overman, MD Scott Kopetz, MD Thierry André, MD THE PHASE II CHECKMATE 142 TRIAL has shown that nivolumab (Opdivo) produces durable responses in previously treated recurrent or metastatic DNA mismatch repair–deficient (dMMR)/ microsatellite instability–high (MSI-...

Thyroid Cancer
Prostate Cancer
Lung Cancer
Survivorship
Palliative Care

News From JCO and JOP

Matthew Stenger  / September 25, 2017

STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP). Future installments wi...

Skin Cancer

No Improvement in Melanoma-Specific Survival With Completion Dissection vs Observation for Sentinel-Node Metastasis

Matthew Stenger  / September 25, 2017

Mark B. Faries, MD THE PHASE III MSLT- II TRIAL showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel-node metastasis, although a benefit was observed in regional disease control. The findings were repo...

Hematologic Malignancies
Lymphoma

New Response Evaluation Criteria for Lymphoma Clinical Trials: RECIL 2017

Matthew Stenger  / September 25, 2017

New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the RECIST criteria used for solid tumors.1 The new criteria were reported by Anas Younes, MD, of Memorial Sloan Kettering Cance...

Prostate Cancer

Long-Term Follow-up in PIVOT Trial Shows No Significant Benefit of Surgery vs Observation for Overall or Prostate Cancer Mortality

Matthew Stenger  / September 10, 2017

After 19.5 years of follow-up in the PIVOT trial, radical prostatectomy was not associated with significantly improved all-cause or prostate cancer mortality vs observation among men with localized prostate cancer.1 The long-term follow-up was reported in The New England Journal of Medicine by Timot...

Solid Tumors
Hematologic Malignancies
Breast Cancer
Lung Cancer
Prostate Cancer
Multiple Myeloma
Kidney Cancer

Journal of Clinical Oncology Literature Update

Matthew Stenger  / September 10, 2017

Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer t...

Symptom Management

New ASCO Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment

The ASCO Post  / August 25, 2017

Paul J. Hesketh, MD AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzap...

Hepatobiliary Cancer

CheckMate 040: Nivolumab Is Active in Advanced Hepatocellular Carcinoma

Matthew Stenger  / August 25, 2017

“Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.” — Anthony B. El-Khoueiry, MD NIVOLUMAB (OPDIVO) has been found to produce durable responses in patients with advanced hepatocellular carcinoma in the phase I/...

Prostate Cancer

ASCO/Cancer Care Ontario Joint Guideline Update: Brachytherapy for Patients With Prostate Cancer

Matthew Stenger  / August 25, 2017

Joseph Chin, MD D. Andrew Loblaw, MD AS REPORTED by Joseph Chin, MD, of London Health Sciences Centre, London, Ontario, and colleagues in the Journal of Clinical Oncology, ASCO and Clinical Care Ontario (CCO) have issued a joint update to the prior CCO guideline on use of brachythe...

Breast Cancer

Anti–Trop-2 Antibody-Drug Conjugate Produces Durable Responses in Metastatic Triple-Negative Breast Cancer

Matthew Stenger  / August 25, 2017

“Sacituzumab govitecan induced early and durable responses in heavily pretreated patients with metastatic triple-negative breast cancer.” — Aditya Bardia, MD, MPH, and colleagues AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, of Massachusetts G...

Thyroid Cancer

Trends in Thyroid Cancer Incidence and Mortality in the United States

Matthew Stenger  / August 10, 2017

Cari M. Kitahara, PhD, MHS THE REPORTED INCIDENCE of thyroid cancer has markedly increased in the United States in recent decades, largely reflecting an increase in reported rates of papillary thyroid cancer. It has been unclear whether the increase in incidence is reflected in mortality ra...

Thyroid Cancer

U.S. Preventive Services Task Force Recommends Against Screening for Thyroid Cancer in Asymptomatic Individuals

Matthew Stenger  / August 10, 2017

Kirsten Bibbins-Domingo, MD, PhD AS REPORTED in JAMA, the U.S. Preventive Services Task Force (USPSTF) has recommended against thyroid cancer screening in asymptomatic individuals.1 The current USPSTF statement is an update of a 1996 USPSTF recommendation statement. The recommendation was b...

Leukemia

Improved Overall Survival With Blinatumomab vs Chemotherapy in Advanced Acute Lymphoblastic Leukemia

Matthew Stenger  / August 10, 2017

Hagop Kantarjian, MD IN THE PHASE III TOWER TRIAL reported in The New England Journal of Medicine, Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that blinatumomab (Blincyto) treatment improved overall survival vs chemotherapy in heavily pre...

Breast Cancer

MammaPrint Test Addressed in ASCO Breast Cancer Guideline Update

The ASCO Post  / August 10, 2017

Vered Stearns, MD Ian Krop, MD, PhD New recommendations on the use of the MammaPrint genomic test issued on July 10 will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the ASCO 2016 clinical practice guideline on the...

Breast Cancer

Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

Matthew Stenger  / August 10, 2017

As reported in the Journal of Clinical Oncology by Sukhbinder Dhesy-Thind, MD, MSc, FRCPC, of Juravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying age...

Bladder Cancer

Pembrolizumab Improves Overall Survival vs Chemotherapy in Second-Line Therapy for Advanced Urothelial Carcinoma

Matthew Stenger  / July 25, 2017

“Pembrolizumab was associated with significantly longer overall survival … and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma.” — Joaquim Bellmunt, MD, PhD, and colleagu...

Head and Neck Cancer

Pembrolizumab Is Active in Platinum- and Cetuximab-Refractory Head and Neck Cancer

Matthew Stenger  / July 25, 2017

“Results from this study indicate that pembrolizumab is an active agent for a patient population with limited options.” — Joshua Bauml, MD, and colleagues IN THE PHASE II KEYNOTE-055 trial, pembrolizumab (Keytruda) was found to produce durable responses in patients with p...

Lung Cancer

No Survival Benefit When Pravastatin Is Added to Standard Chemotherapy in Small Cell Lung Cancer

Matthew Stenger  / July 25, 2017

Read a perspective on this study by Rowan T. Chlebowski, MD, PhD, FASCO, here. In a UK phase III study (LUNGSTAR) reported in the Journal of Clinical -Oncology, Michael J. Seckl, MD, PhD, of Imperial College London, and colleagues found that adding pravastatin to first-line standard chemothera...

Lymphoma

Pembrolizumab Is Highly Active in Relapsed/Refractory Classical Hodgkin Lymphoma

Matthew Stenger  / July 10, 2017

Robert Chen, MD Craig H. Moskowitz, MD AS REPORTED in the Journal of Clinical Oncology by Robert Chen, MD, of City of Hope National Medical Center, and colleagues, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keyt...

Pancreatic Cancer

Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Patients With Resected Pancreatic Cancer

Matthew Stenger  / July 10, 2017

“The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.” — John P. Neoptolemos, MD IN THE EUROPEAN phase III ESPAC-4 trial reported in The Lancet, John P. Neoptolemos, MD, of th...

Breast Cancer

No Efficacy Difference Between Adjuvant Letrozole and Anastrozole in Postmenopausal Women With Early Breast Cancer

Matthew Stenger  / July 10, 2017

As reported in the Journal of Clinical Oncology by Ian E. Smith, MD, of The Royal Marsden Hospital and Institute of Cancer Research, and colleagues, final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopau...

Issues in Oncology
Survivorship

Second Cancers May Be Deadlier in Child, Adolescent, and Young Adult Patients

The ASCO Post  / July 10, 2017

Second cancers in children and adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients between the ages of 15 and 39 overall, a new study by researchers at the University of California, Davis has...

Leukemia

Adding Idelalisib to Bendamustine/Rituximab in Relapsed/Refractory CLL

Matthew Stenger  / July 10, 2017

As reported by Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet Oncology, interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase δ inhibitor idelalisib (Zydelig) to bendamustine/rituximab (Rituxan) in pat...

Breast Cancer

Two Studies Show Scalp Cooling Reduces Hair Loss in Women Receiving Chemotherapy for Breast Cancer

Matthew Stenger  / July 10, 2017

An interim analysis of the SCALP trial, reported in JAMA by Julie Nangia, MD, of Baylor College of Medicine, and colleagues, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling.1 The ...

Myelodysplastic Syndromes

Mutations in Myelodysplastic Syndrome Associated With Poorer Outcome After Stem Cell Transplantation

Matthew Stenger  / July 10, 2017

In a study reported in The New England Journal of Medicine, R. Coleman Lindsley, MD, PhD, of Dana-Farber Cancer Institute, and colleagues found that a number of mutations present in patients with myelodysplastic syndromes (MDS) were associated with poorer clinical outcome after allogeneic hematopoie...

Issues in Oncology

Annual Report to the Nation: Cancer Death Rates Continue to Decline

The ASCO Post  / July 10, 2017

Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the National Cancer Institute.1 The report finds that...

Colorectal Cancer

ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers in Colorectal Cancer

Matthew Stenger  / June 25, 2017

“Clinicians should order mutational tests for the RAS and BRAF genes and deficient–mismatch repair status testing in patients with colorectal cancer to guide cancer therapy and for identification of patients at high risk for Lynch syndrome….” — Antonia R. Sepulveda, MD, Ph...

Neuroendocrine Tumors

177Lu-Dotatate Improves Progression-Free Survival in Advanced Progressive Midgut Neuroendocrine Tumors

Matthew Stenger  / June 25, 2017

Jonathan R. Strosberg, MD In the phase III NETTER-1 trial reported in The New England Journal of Medicine, Jonathan R. Strosberg, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues found that the addition of the targeted radiotherapeutic agent lutetium-177 (177Lu)-Dotatate t...

Survivorship

Decreasing but Still Elevated Risk for Subsequent Neoplasms in Survivors of Childhood Cancer

Matthew Stenger  / June 25, 2017

“The risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s, although the risk was lower compared with those diagnosed in the 1970s.” — Lucie M. Turcotte, MD, MPH, and colleagues In a retrospective m...

Hematologic Malignancies
Palliative Care

Lack of Access to Transfusions Limits Hospice Use by Patients With Hematologic Malignancies

The ASCO Post  / June 10, 2017

Oreofe Odejide, MD, MPH A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Oreofe O...

Multiple Myeloma

Lenalidomide, Bortezomib, and Dexamethasone With or Without Transplantation in Younger Myeloma Patients

Matthew Stenger  / June 10, 2017

In the French phase III IFM 2009 trial reported in The New England Journal of Medicine by Michel Attal, MD, of the Institut Universitaire du Cancer de Toulouse-Oncopole, and colleagues, consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was associated...

Lung Cancer

Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer

Matthew Stenger  / June 10, 2017

In the phase III OAK trial reported in The Lancet by Achim Rittmeyer, MD, of Lungenfachklinik Immenhausen, Germany, and colleagues, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small ...

Prostate Cancer

Survival Benefit of Adding Antiandrogen Therapy to Radiation in Recurrent Prostate Cancer: Final Results of RTOG 9601

Matthew Stenger  / June 10, 2017

As reported in The New England Journal of Medicine by W.U. Shipley, MD, of Massachusetts General Hospital and Harvard Medical School, and colleagues in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial shows that the addition of antiandroge...

Prostate Cancer

Ipilimumab vs Placebo in Metastatic Chemotherapy-Naive, Castration-Resistant Prostate Cancer Without Visceral Metastases

Matthew Stenger  / June 10, 2017

In the phase III CA184-095trial reported in the Journal of Clinical Oncology, Tomasz M. Beer, MD, FACP, of the Knight Cancer Institute, Oregon Health and Science University, and colleagues found that ipilimumab (Yervoy) did not increase overall survival vs placebo in men with asymptomatic or minimal...

Prostate Cancer

ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer

The ASCO Post  / May 25, 2017

On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...

Breast Cancer
Genomics/Genetics

Suboptimal Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer

Matthew Stenger  / May 25, 2017

“Only 52.9% of high-risk patients had a genetic test, representing a missed opportunity to prevent ovarian and other cancer deaths among mutation carriers and their families. ” — Allison W. Kurian, MD, and colleagues In a population-based study reported in a research lett...

Breast Cancer
Genomics/Genetics

Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer

Matthew Stenger  / May 25, 2017

“These findings emphasize the need to address challenges in personalized communication about genetic testing.” — Allison W. Kurian, MD, and colleagues As reported in the Journal of Clinical Oncology by Allison W. Kurian, MD, of Stanford University School of Medicine, and ...

Kidney Cancer

ASCO Clinical Practice Guideline: Management of Small Renal Masses

Matthew Stenger  / May 25, 2017

“Partial nephrectomy for small renal masses is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach.” — Antonio Finelli, MD (left), Paul Russo, MD, and collea...

CNS Cancers
Geriatric Oncology

Short-Course Radiotherapy Plus Temozolomide Improves Survival in Older Patients With Glioblastoma

Matthew Stenger  / May 25, 2017

James R. Perry, MD In a phase III trial reported in The New England Journal of Medicine, James R. Perry, MD, of Sunnybrook Health Sciences Centre, Toronto, and colleagues found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged at least 65 years...

Leukemia

First-in-Human Clinical Trial in Children and Young Adults With Leukemia

The ASCO Post  / May 25, 2017

Michael C.V. Jensen, MD Colleen Annesley, MD After phase I results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, published by Gardner et al in Blood,1 showed T-cell immunotherapy to be effective in sending 93% of patients with relapsed or refractory acu...

CNS Cancers
Genomics/Genetics

Key Gene Controlling Tumor Growth in Gliomas Pinpointed

The ASCO Post  / May 25, 2017

John Yu, MD Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and may strongly influence survival rates of patients. The findings, published by Edwards et al in Scientific Reports,1 may move physicians closer to th...

Bladder Cancer

CheckMate 275 Supports FDA Approval of Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy

Matthew Stenger  / May 25, 2017

"Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.” — —Padmanee Sharma, MD...

Breast Cancer
Symptom Management

Zoledronic Acid Every 12 Weeks Noninferior to Every 4 Weeks in Skeletal-Related Event Rate for Breast Cancer With Bone Metastases

Matthew Stenger  / May 25, 2017

Gabriel N. Hortobagyi, MD In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule with reg...

Breast Cancer
Symptom Management

OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases

Robert Coleman, MD, FRCP  / May 25, 2017

During the course of the trial, denosumab has partially displaced zoledronic acid as the bone-targeted agent of choice…. Whether the frequency of administration of denosumab can also be reduced is not known. — Robert Coleman, MD, FRCP Bisphosphonates were first synthesize...

Issues in Oncology

Cancer Mortality Trends in the United States Vary Widely by County From 1980 to 2014

Matthew Stenger  / May 10, 2017

Cancer mortality declined overall in the United States between 1980 and 2014. Over this same period, there were important changes in trends, patterns, and differences in cancer mortality among U.S. counties. These patterns may inform further research into improving prevention and t...

Multiple Myeloma

Adding Daratumumab to Lenalidomide/Dexamethasone Increases Progression-Free Survival in Previously Treated Multiple Myeloma

Matthew Stenger  / April 25, 2017

The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the contr...

Breast Cancer

Equivalent Response Rates With Trastuzumab or a Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer

Matthew Stenger  / April 25, 2017

Among women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. — Hope S. Rugo, MD, and colleagues In part 1 of the Heritage stu...

Issues in Oncology

Study Finds Link Between Telomere Length and Sociodemographic Circumstances Linked to Neighborhood

The ASCO Post  / April 25, 2017

Shannon Lynch, PhD, MPH Researchers at Fox Chase Cancer Center have begun to establish a biologic basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Prog...

Survivorship

ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers

Matthew Stenger  / April 10, 2017

Jean-Bernard Durand, MD Saro H. Armenian, DO, MPH As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult...

Survivorship

Cardiac Dysfunction in Survivors of Adult Cancers

Daniel J. Lenihan, MD  / April 10, 2017

The commitment of all involved to produce a balanced and sensible document, which might actually help clinicians decide how to manage potential cardiac dysfunction in adult cancer survivors, should be enthusiastically celebrated. — Daniel J. Lenihan, MD The success of can...

Palliative Care

ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care

Matthew Stenger  / April 10, 2017

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Patients in clinical trials may benefit from the support of palliative care. — Betty R. Ferrell, PhD, an...

Breast Cancer

Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Declining Mortality Reflecting Improved Systemic Therapy

Matthew Stenger  / March 25, 2017

Women were more likely to have breast cancer that was overdiagnosed than to have earlier detection of a tumor that was destined to become large. — H. Gilbert Welch, MD, and colleagues In a study using Surveillance, Epidemiology, and End Results (SEER) data reported in The...

Lung Cancer

Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC

Matthew Stenger  / March 25, 2017

First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC. — Jean-Charles Soria, MD, and colleagues In the phase III ASCEND-4 trial reported...

Multiple Myeloma

Adding Bortezomib to Lenalidomide/Dexamethasone Improves Survival in Patients With Newly Diagnosed Multiple Myeloma

Matthew Stenger  / March 25, 2017

In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progression-free and overall survival and had an acceptable risk-benefit profile. — Brian G.M. Durie, MD, and colleagues In the ph...

Breast Cancer

Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Advanced Breast Cancer

Matthew Stenger  / March 10, 2017

Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor–positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care f...

Issues in Oncology
Survivorship

Many Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial

The ASCO Post  / February 25, 2017

For many cancer survivors, telehealth supported their independence and offered them reassurance. However, it is all down to personal preference, as some cancer survivors still preferred traditional methods of care. — Anna Cox, PhD, and colleagues Researchers from the Scho...

Leukemia

Study Finds Children, Parents Overreport Adherence to Leukemia Treatment

The ASCO Post  / February 25, 2017

New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in Bloo...

Lung Cancer

Osimertinib Improves Progression-Free Survival vs Platinum/Pemetrexed in EGFR T790M–Positive NSCLC

Matthew Stenger  / February 25, 2017

Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced [NSCLC] in whom disease had progressed during first-line EGFR-[tyrosine kinase inhibitor] therapy. — Tony S. Mok, MD, and colleagues In the phase ...

Lung Cancer

Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer

Geoffrey R. Oxnard, MD  / February 25, 2017

The AURA3 study confirms the fundamental role of EGFR T790M testing in patients with acquired EGFR tyrosine kinase inhibitor resistance in order to plan subsequent treatment. — Geoffrey R. Oxnard, MD The AURA3 study—reported by Mok and colleagues and reviewed in this issu...

Hepatobiliary Cancer

Regorafenib Improves Survival in Patients With Hepatocellular Carcinoma Progressing on Sorafenib

Matthew Stenger  / February 25, 2017

Regorafenib is the only systemic treatment shown to provide survival benefit in [hepatocellular carcinoma] patients progressing on sorafenib treatment. — Jordi Bruix, MD, and colleagues In the phase III RESORCE trial reported in The Lancet, Jordi Bruix, MD, Head of the Ba...

Hepatobiliary Cancer

Regorafenib in Second-Line Setting for Hepatocellular Carcinoma: Balancing Benefit With Toxicity

Josep M. Llovet, MD, PhD  / February 25, 2017

We now have a new drug in the armamentarium for the management of advanced hepatocellular carcinoma, which was a clear unmet need. — Josep M. Llovet, MD, PhD During the past 40 years, hundreds of randomized trials testing treatments for advanced hepatocellular carcinoma h...

Breast Cancer

First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer

Matthew Stenger  / February 25, 2017

The duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. — Gabriel N. Hortobagyi, MD, and colleagues ...

Breast Cancer

Results From MONALEESA-2: Are All CDK4/6 Inhibitors Equal?

Sara M. Tolaney, MD, MPH  / February 25, 2017

Given these compelling results and the manageable toxicity profiles seen, the combination of an aromatase inhibitor plus a CDK4/6 inhibitor should be the standard first-line treatment for the majority of patients with advanced hormone receptor–positive breast cancer. — Sara...

Lymphoma

Circulating Tumor DNA Profiling Identifies Clonal Evolution Patterns and Permits Classification of Tumor Subtypes in DLBCL

Matthew Stenger  / February 10, 2017

We anticipate that ctDNA will have broad utility for dissecting tumor heterogeneity within and between patients with lymphomas and other cancer types, with applications for the identification of adverse risk groups, the discovery of resistance mechanisms to diverse therapies, and t...

Lymphoma

Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma

Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD  / February 10, 2017

Although the field of circulating tumor DNA for DLBCL is young and clinical validation is needed, this technology is sure to become part of routine clinical decision-making. — Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD Technologic advances for detecting and an...

Neuroendocrine Tumors

Telotristat Ethyl Reduces Frequency of Bowel Movements in Patients With Metastatic Neuroendocrine Tumors and Carcinoid Syndrome

Matthew Stenger  / February 10, 2017

Among patients with carcinoid syndrome not adequately controlled by stable-dose somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in [bowel movement] frequency and [urinary] 5-HIAA. — Matthew ...

Neuroendocrine Tumors

Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction

Bhavana Konda, MD, MPH, and Manisha H. Shah, MD  / February 10, 2017

The development of telotristat ethyl for treatment of carcinoid syndrome represents a step in the right direction for improving the quality of life of these patients. — Bhavana Konda, MD, MPH (left), and Manisha H. Shah, MD The multihumoral manifestations of neuroendoc...

Pancreatic Cancer
Gastrointestinal Cancer
Colorectal Cancer

‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon

The ASCO Post  / February 10, 2017

Prasenjit Dey, PhD Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The Uni...

CNS Cancers

ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma

Matthew Stenger  / January 25, 2017

Erik P. Sulman, MD, PhD Susan M. Chang, MD As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation ther...

Head and Neck Cancer

Nivolumab Improves Overall Survival in Recurrent Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck

Matthew Stenger  / January 25, 2017

Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. — Robert L. Ferris, MD, PhD, and colleagues In the phase III C...

Leukemia

Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years

Matthew Stenger  / January 25, 2017

With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that [imatinib] can safely be discontinued in patients with a sustained deep molecular response with no late molecular recurrence. — Gabriel Etienne, MD, PhD, and colleagues As report...

Gynecologic Cancers

Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer

Matthew Stenger  / January 25, 2017

Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of [germline] BRCA mutations or homo...

Breast Cancer

Addition of Palbociclib to Letrozole in Previously Untreated Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Matthew Stenger  / December 25, 2016

In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the addition of palbociclib (Ibrance) to letrozole significantly improved progression-f...

Genomics/Genetics
Bladder Cancer

Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma

Matthew Stenger  / December 25, 2016

In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative t...

Breast Cancer

Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation

The ASCO Post  / December 25, 2016

On November 17, 2016, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients may benefit from accelerat...

Issues in Oncology

Concerns About Safety of Generic Oncology Drugs Made in Developing Countries

Matthew Stenger  / December 10, 2016

No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. — Y. Tony Yang, ScD, and colleagues In an article in The Lancet Oncology, Y. Tony Yan...

Issues in Oncology

The FDA Ensures Quality and Safety of Generic Drugs in the United States

Kathleen Uhl, MD, John R. Peters, MD, and Howard Chazin, MD, MBA  / December 10, 2016

The FDA’s approval process ensures that brand-name and generic drugs meet rigorous standards for safety and efficacy. Postapproval safety surveillance monitoring along with drug product quality testing enables the FDA to ensure drug product safety and quality. —...

CNS Cancers

No Progression-Free Survival Difference With Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma

Matthew Stenger  / December 10, 2016

Temozolomide vs Radiotherapy in Low-Grade Glioma No significant progression-free survival difference was observed between temozolomide and radiotherapy in patients with high-risk low-grade glioma. No differences in health-related quality of life or global cognitive function were observed. ...

Palliative Care

Palliative Care Improves Quality of Life, Relieves Symptoms

The ASCO Post  / December 10, 2016

We need to find ways of integrating palliative care concepts in patients’ usual care experiences, so it isn’t a luxury, but a standard part of health care for those living with serious illness. — Dio Kavalieratos, PhD, and colleagues People living with serious illness who...

Breast Cancer

Another Step Forward for Genomic Assays in Early-Stage Breast Cancer: Findings With MammaPrint in the MINDACT Trial

Harold J. Burstein, MD, PhD  / November 25, 2016

The emerging data on genomic predictors in estrogen receptor–positive breast cancer suggest that the best treatment decisions are going to be made by integrating clinical, pathologic, and genomic measures. — Harold J. Burstein, MD, PhD Genomic assays have had a powerful i...

Kidney Cancer

Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy

Matthew Stenger  / November 25, 2016

Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a cost of a higher rate of toxic events. ...

Kidney Cancer

Adjuvant Sunitinib for Renal Cell Carcinoma: Not Ready for Prime Time

Sumanta Kumar Pal, MD  / November 25, 2016

The time gained from adjuvant sunitinib therapy in disease-free survival is equivalent to time spent on treatment, implying a net zero gain. If a moderate trend toward benefit was observed, perhaps one could be more open-minded about this strategy. — Sumanta Kumar Pal, MD ...

Lung Cancer

Pembrolizumab Improves Outcomes vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC

Matthew Stenger  / November 25, 2016

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. — Martin Reck, MD, PhD, and ...

Kidney Cancer

Phase III Trial Shows No Survival Benefit of Adding First-Line IMA901 Vaccine to Sunitinib in Advanced Renal Cell Carcinoma

Matthew Stenger  / November 25, 2016

IMA901 did not improve overall survival when added to sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. — Brian I. Rini, MD, and colleagues In the phase III IMPRINT trial reported in The Lancet Oncology, Brian I. Rini, MD, of the Clevelan...

Sarcoma

Adding Olaratumab to Doxorubicin Increases Overall Survival in Advanced Soft-Tissue Sarcoma

Matthew Stenger  / November 25, 2016

William D. Tap, MD As reported by William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet, the addition of the anti-PDGFRα (platelet-derived growth factor receptor alpha) antibody olaratumab to doxorubicin resulted in prolonged progression-free and overal...

Sarcoma

Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma

Margaret von Mehren, MD  / November 25, 2016

Margaret von Mehren, MD The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase i...

Survivorship

Adult Survivors of Childhood Cancers Report Long-Term Health Issues

Jo Cavallo  / November 25, 2016

Kirsten K. Ness, PT, PhD Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental healt...

Kidney Cancer

Study Finds Cabozantinib of Clinical Benefit vs Sunitinib in Advanced Renal Cell Carcinoma

Jo Cavallo  / November 25, 2016

A randomized phase II clinical trial evaluating cabozantinib (Cabometyx) compared with standard-of-care sunitinib (Sutent) as first-line therapy for patients with advanced renal cell carcinoma has found that cabozantinib reduced the rate of disease progression or death by 34% compared with sunitinib...

Breast Cancer
Genomics/Genetics

Chemotherapy May Be Avoidable in Some Women With Early-Stage Breast Cancer Based on Clinical and Genomic Risks

Matthew Stenger  / November 10, 2016

Given these findings, approximately 46% of women with breast cancer who are at high clinical risk might not require chemotherapy. — Fatima Cardoso, MD, and colleagues In the phase III MINDACT trial reported in The New England Journal of Medicine, Fatima Cardoso, MD, of Ch...

Bladder Cancer

Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy

The ASCO Post  / November 10, 2016

What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...

Colorectal Cancer

New Blood Test for Colorectal Cancer Recurrence: Twice as Sensitive as CEA Test

The ASCO Post  / November 10, 2016

In a new report published by Young et al in Cancer Medicine,1 a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard-of-care co...

Breast Cancer

Breast Cancer Study Finds Higher Mortality Rate in Black Women Than White Women, and the Disparity Is Growing

The ASCO Post  / October 25, 2016

The Avon Foundation for Women recently released a new study on the racial disparities in breast cancer mortality in the 50 largest cities in the United States between 2005 and 2014. Published in Cancer Epidemiology,1 the study was conducted by Sinai Urban Health Institute in collaboration with the B...

Gynecologic Cancers

SGO and ASCO Clinical Practice Guideline on Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer

Matthew Stenger  / October 25, 2016

Alexi A. Wright, MD, MPH All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy to determine whether they are candidates for primary cytoreductive surgery. — Alexi A. Wright, MD, MPH...

Gynecologic Cancers

What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

David M. Gershenson, MD  / October 25, 2016

Regardless of how much progress we make in this area, we will never be completely rid of physician bias or the fact that there will always be variability in gynecologic oncologists’ surgical skills and intraoperative decision-making. — David M. Gershenson, MD Ever since t...

Breast Cancer

Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ

Matthew Stenger  / October 25, 2016

Monica Morrow, MD Meena S. Moran, MD A positive margin, defined as ink on ductal carcinoma in situ, is associated with a significant increase in ipsilateral breast tumor recurrence; this increased risk is not nullified by the use of whole-breast irradiation. — Monica Morrow...

Breast Cancer

New SSO-ASTRO-ASCO Clinical Practice Guideline Clarifies the Question of Margins for Breast-Conserving Surgery in Ductal Carcinoma in Situ

Jay R. Harris, MD  / October 25, 2016

In 2014, the Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) published a “Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer.”1 A multidisciplinary expert guideline used a met...

Issues in Oncology

Barriers and Opportunities Reported in the Study of Human Papillomavirus Education and Immunization Efforts

The ASCO Post  / October 25, 2016

Human papillomavirus (HPV) vaccination rates remain low across the United States, with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination rates...

Head and Neck Cancer

Rise in Oropharyngeal Cancer Incidence in the UK Not Solely Driven by HPV

The ASCO Post  / October 25, 2016

The rise in the incidence of oropharyngeal squamous cell carcinoma in the United Kingdom from 2002 to 2011 was not solely attributable to a rise in the incidence of human papillomavirus (HPV)-positive disease, according to a study published in Cancer Research,1 which reported that the proportion of ...

Prostate Cancer

Similar 10-Year Survival With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Clinically Localized Prostate Cancer

Matthew Stenger  / October 10, 2016

At a median of 10 years, prostate cancer–specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitori...

Prostate Cancer

Risk of Metastasis With Active Monitoring in PSA-Detected Localized Prostate Cancer: The ProtectT Trial

Anthony V. D’Amico, MD, PhD  / October 10, 2016

It would be prudent to advise a man who is otherwise in good health, has a life expectancy beyond the 10-year median follow-up of the ProtecT study, and wishes to avoid metastatic prostate cancer and its treatment-related side effects that monitoring places him at potentially incre...

Prostate Cancer

Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?

Andrew J. Armstrong, MD, ScM, FACP, W. Robert Lee, MD, and Judd Moul MD, FACS  / October 10, 2016

The PROTECT trial provides the first real level 1 evidence comparing treatments and may offer important data for such men to determine the net risks and benefits for their initial treatment choice over about a 10-year follow-up. — Andrew J. Armstrong, MD, ScM, FACP, W. Robert Lee, MD, and...

Multiple Myeloma

Study Finds Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

Matthew Stenger  / October 10, 2016

Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and examethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone and was associated with infusion-related reaction...

Multiple Myeloma

Daratumumab Plus Bortezomib/Dexamethasone: Changing the Treatment Paradigm in Relapsed or Refractory Myeloma

Kenneth C. Anderson, MD  / October 10, 2016

These results with the addition of daratumumab to bortezomib/dexamethasone represent a significant prolongation of progression-free survival, associated with the highest rates and extent of response yet achieved with any therapy for relapsed multiple myeloma. — Kenneth C. A...

Lung Cancer

Phase III Trial Finds No Survival Benefit of Adding Ipilimumab to Etoposide/Platinum in Newly Diagnosed Extensive-Stage SCLC

Matthew Stenger  / October 10, 2016

Addition of ipilimumab to chemotherapy did not prolong [overall survival] versus chemotherapy alone in patients with newly diagnosed extensive-stage disease SCLC. — Martin Reck, MD, PhD, and colleagues In a phase III trial (CA184-156) reported in the Journal of Clinical O...

Lung Cancer

Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)

Jeffrey Crawford, MD  / October 10, 2016

For now, initial management of small cell lung cancer continues to be driven by chemotherapy with platinum and etoposide. Meanwhile, management of small cell lung cancer post chemotherapy is undergoing a rapid and much-needed revolution. — Jeffrey Crawford, MD Ever since ...

Pain Management
Survivorship

ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers

Matthew Stenger  / October 10, 2016

Clinicians may prescribe a trial of opioids in carefully selected patients with chronic pain who do not respond to more conservative management and who continue to experience pain-related distress or functional impairment. — Judith A. Paice, PhD, RN, and colleagues As rep...

Pain Management
Survivorship

A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors

Rajiv Shah, MD, and Robert A. Swarm, MD  / October 10, 2016

This summary of well-informed and thoroughly documented management strategies for pain in adult cancer survivors is sorely needed in health care, because multiple coalescing factors place cancer pain survivors at significant risk for poor pain control. — Rajiv Shah, MD, a...

Lung Cancer

First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC

Matthew Stenger  / September 25, 2016

Scott Gettinger, MD Naiyer A. Rizvi, MD The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging effi...

Lung Cancer

Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC

Karen Kelly, MD  / September 25, 2016

There is no question that immune checkpoint inhibitors have a role in untreated advanced lung cancer. How they will be integrated into the upfront setting and which patients are likely to benefit are areas of active research. — Karen Kelly, MD For the majority of patients...

Issues in Oncology

ASCO and AACI Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials

Matthew Stenger  / September 25, 2016

[T]he Initiative’s stakeholder survey and workshop are good first steps toward identifying major inefficiencies and potential solutions for alleviating regulatory and administrative burdens on cancer clinical trials. — Julie M. Vose, MD, MBA, FASCO As reported in the Jour...

Breast Cancer

Everolimus in Advanced HER2-Positive Breast Cancer With PIK3CA Mutation, PTEN Loss, or Hyperactive PI3K Pathway

Matthew Stenger  / September 25, 2016

This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2–positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive [progression-free survival] benefit from everolimus. ...

Prostate Cancer

Continuation of Docetaxel May Improve Survival in Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  / September 25, 2016

Ronald de Wit, MD The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid) or docetaxel/prednisone, in the phase III Mainsail trial. de M...

Prostate Cancer

Testosterone-Related Genetic Mutation Associated With Poorer Survival in Prostate Cancer

Matthew Stenger  / September 25, 2016

A collaborative Cleveland Clinic–Mayo Clinic team of researchers has shown for the first time that patients with advanced prostate cancer are more likely to die earlier of their disease if they carry a specific testosterone-related genetic abnormality. The findings, published by Hearn et al in The L...

Colorectal Cancer

New USPSTF Recommendations for Colorectal Cancer Screening

Matthew Stenger  / September 25, 2016

As reported in JAMA, the U.S. Preventive Services Task Force ­(USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF recomme...

Colorectal Cancer

Updated USPSTF Guidelines for Colorectal Cancer Screening: More Methods, More Challenges for Patients and Providers Alike

Alexander R. Ende, MD, and William M. Grady, MD  / September 25, 2016

As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography [...

Breast Cancer

ASCO, ASTRO, and SSO Issue Joint Update to Guideline on Postmastectomy Radiotherapy for Women With Breast Cancer

The ASCO Post  / September 25, 2016

We still don’t have a single, validated formula that can determine who needs postmastectomy radiotherapy, but we hope that the research evidence summarized in this guideline update will help doctors and patients make more informed decisions. — Stephen B. Edge, MD Earlier ...

Breast Cancer

Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer

Matthew Stenger  / September 25, 2016

Veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone, specifically in triple-negative breast cancer. — Hope S. Rugo, MD, and colleagues As reported by Hope S. Rugo, MD, and John W. Park, MD,...

Breast Cancer

I-SPY 2: Separating Contenders From Pretenders in Breast Cancer

William M. Sikov, MD, FACP  / September 25, 2016

While identifying appropriate agents for testing in larger randomized trials, the pressure to generate data that can lead to drug approval may make it more difficult to explore alternative regimens in the hope of improving efficacy and/or reducing toxicity and could result in rejec...

Prostate Cancer

Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk

The ASCO Post  / September 25, 2016

While a previous study suggested an association, our results show no connection between vasectomies and overall risk of prostate cancer, or of dying from prostate cancer, and should provide some reassurance to men considering vasectomy. — Eric J. Jacobs, PhD In a new stud...

Prostate Cancer

European Studies Compare Conventional vs Hypofractionated Radiotherapy for Localized Prostate Cancer

Matthew Stenger  / September 10, 2016

Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localized prostate cancer. — David Dearnaley, FRCR, and colleag...

Prostate Cancer

Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?

Talha Shaikh, MD, and Eric M. Horwitz, MD  / September 10, 2016

At the very least, we can conclude that hypofractionated radiotherapy is noninferior to conventionally fractionated radiotherapy but not necessarily better. These results allow us to be confident we are not losing efficacy when using hypofractionation, but its impact on late effe...

Skin Cancer

Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy

The ASCO Post  / September 10, 2016

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer Discovery...

Lymphoma

Continued ABVD vs Omission of Bleomycin (AVD) After Negative Imaging Findings in Advanced Hodgkin Lymphoma

Matthew Stenger  / September 10, 2016

Although the results fall just short of the specified noninferiority margin, the omission of bleomycin from the ABVD regimen after negative findings on interim PET resulted in a lower incidence of pulmonary toxic effects than with continued ABVD but not significantly lower efficacy...

Lymphoma

Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma

Richard I. Fisher, MD  / September 10, 2016

Several new agents with significant activity in relapsed or refractory Hodgkin lymphoma have been developed in the past few years. Until study results with these newer agents are available, ABVD enters its 41st year as the standard initial treatment of patients with advanced Hodgki...

Issues in Oncology

Global Curriculum in Surgical Oncology Outlined by Society of Surgical Oncology and European Society of Surgical Oncology

Matthew Stenger  / September 10, 2016

[We have developed] a global curriculum [that] may be considered as a foundational scaffolding for training surgical oncologists worldwide. — Chandrakanth Are, MBBS, MBA, FRCS, FACS, and colleagues As reported by Chandrakanth Are, MBBS, MBA, FRCS, FACS, of the University ...

CNS Cancers

Effect of Radiosurgery Alone vs With Whole-Brain Radiotherapy on Cognitive Function in Patients With Brain Metastases

The ASCO Post  / September 10, 2016

Physicians from Carolinas HealthCare System’s Neurosciences Institute and Levine Cancer Institute are among the authors of a recent study published by Brown et al in JAMA.1 The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared wi...

Lymphoma

Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin

Matthew Stenger  / September 10, 2016

Nivolumab might be a new treatment option for a patient population with a high unmet need [patients with classical Hodgkin lymphoma after failure of both ASCT and brentuximab vedotin]. Ongoing follow-up will help to assess the durability of response. — Anas Younes, MD, and ...

Lymphoma

Nivolumab in Recurrent Classical Hodgkin Lymphoma: Refreshingly Supportive Data

Stephen M. Ansell, MD, PhD  / September 10, 2016

The use of anti–PD-1 therapy is likely to become a key part of future therapeutic approaches in Hodgkin lymphoma and is now being incorporated into earlier lines of therapy in this disease. — Stephen M. Ansell, MD, PhD It is commonly said that if something is too good to ...

Leukemia

Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion

Matthew Stenger  / September 10, 2016

Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukemia, providing a new therapeutic option for this very poor prognosis population. — Stephan Stilgenbauer, MD, and col...

Breast Cancer

New SSO, ASTRO, ASCO Joint Ductal Carcinoma in Situ Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health-System Costs

Matthew Stenger  / September 10, 2016

Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ treated with breast-conserving surgery with whole-breast irradiation. The new guideline has the potential to save many women from unnecessary surgeries, while...

Breast Cancer

ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapies for HER2-Negative and HER2-Positive Breast Cancers

Matthew Stenger  / August 25, 2016

No phase III evidence exists for the addition of trastuzumab to some chemotherapy regimens, such as docetaxel/cyclophosphamide. However, those regimens might be in use and are reasonable options, particularly for mitigating cardiotoxicity in certain patients. — Neelima Dend...

Breast Cancer

ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer

Sara M. Tolaney, MD, MPH  / August 25, 2016

Anthracycline/taxane regimens remain a standard of care for high-risk disease, and [docetaxel/cyclophosphamide] can be considered in low-risk patients or in those with significant cardiac risk factors. — Sara M. Tolaney, MD, MPH ASCO has published an adaptation of the 201...

Prostate Cancer

Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer

Matthew Stenger  / August 25, 2016

In men with low-risk prostate cancer, the efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over 8.2 weeks, although an increase in late [gastrointestinal]/genitourinary adverse events was observed in patients treated with [hypofractionated...

Prostate Cancer

Hypofractionated Radiotherapy: Balancing Benefits vs Risks in Men With Localized Prostate Cancer

Paul L. Nguyen, MD  / August 25, 2016

Although some clinicians may eagerly switch to a hypofractionated regimen as their new standard, others may choose to do it on a case-by-case basis, such as for patients who have minimal baseline genitourinary symptoms. — Paul L. Nguyen, MD Radiation for prostate cancer t...

Breast Cancer

ASCO Endorses Cancer Care Ontario Recommendations on Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decisions in Early-Stage, Operable Breast Cancer

Matthew Stenger  / August 25, 2016

The ASCO panel endorses the recommendations with minor suggested revisions and highlights three areas that warrant further consideration: tumor histology and adjuvant therapy recommendations, risk stratification tools and proposed Oncotype DX [recurrence score] thresholds to guide ...

Colorectal Cancer

ESMO Releases New Consensus Guidelines on the Management of Metastatic Colorectal Cancer

The ASCO Post  / August 25, 2016

The European Society for Medical Oncology (ESMO) has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalized approach to treatment. These guidelines were published by Van Cutsem et al in Annals of Oncology.1 Eric Van Cutse...

Gynecologic Cancers

Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test

The ASCO Post  / August 25, 2016

Receiving an invitation to undergo screening for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine.1 The study explored the impact of invitation and reminder letters on cervical cancer screening parti...

Breast Cancer

Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Hormone Receptor–Positive Metastatic Breast Cancer

Matthew Stenger  / August 25, 2016

The addition of bevacizumab to letrozole improved [progression-free survival] in hormone receptor–positive [metastatic breast cancer], but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. — Maura N. Dickler, MD, and colleagues In a ph...

Breast Cancer

Prevalence of Estrogen Receptor Mutations in Patients With Metastatic Breast Cancer

The ASCO Post  / August 25, 2016

A new study published online by JAMA Oncology examined the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.1 The activation of the estrogen receptor is a feature of most breast cancers in which estrogen receptor expression is detected. An aromata...

Leukemia

Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Matthew Stenger  / August 25, 2016

The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease. — Hagop M. Kantarjian, MD, and colleagues ...

Lymphoma

Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL

Matthew Stenger  / August 25, 2016

In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab (Ga...

Issues in Oncology

Economic Crisis Associated With Increased Cancer Mortality

Matthew Stenger  / August 10, 2016

Unemployment increases are associated with rises in cancer mortality; universal health coverage seems to protect against this effect. — Mahiben Maruthappu, MA, and colleagues The global economic crisis has been associated with increased unemployment and reduced public-sec...

Issues in Oncology

Effects of the Global Economic Crisis on Cancer Care

Kenneth L. Kehl, MD  / August 10, 2016

The results of this study, plus the coverage gaps still in existence among those states that have declined to expand Medicaid under the ACA, raise the question of whether mortality due to treatable cancer in the United States is higher than it could otherwise be. — Kenneth ...

Lymphoma

Reduced-Intensity Related-Donor Haploidentical vs HLA-Matched Sibling-Donor Hematopoietic Cell Transplantation in Lymphoma

Matthew Stenger  / August 10, 2016

[Reduced intensity or nonmyeloablative conditioning] followed by haplo-hematopoietic cell transplantation with [post-transplantation cyclophosphamide] should be considered an acceptable option for patients with lymphoma without matched sibling donors. — Nilanjan Ghosh, MD, ...

Lymphoma

Is Post-Transplantation Cyclophosphamide Disruptive Technology?

Matt Kalaycio, MD, FACP  / August 10, 2016

If chronic graft-vs-host disease rates are reduced without an increase in relapse rates, post-transplant cyclophosphamide may not only extend a transplant option to virtually everybody who stands to benefit from it, but it may also replace standard graft-vs-host disease prophylaxis...

Issues in Oncology

New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade

The ASCO Post  / August 10, 2016

American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for ...

Breast Cancer

ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer

Matthew Stenger  / July 25, 2016

Hope S. Rugo, MD As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic brea...

Breast Cancer

ASCO Guideline on Endocrine Therapy for Metastatic Breast Cancer: Reaffirming Principles for Making Treatment Decisions

William J. Gradishar, MD, FASCO, FACP  / July 25, 2016

Endocrine therapy has been a mainstay of breast cancer treatment for over a century, and the prospects are bright that understanding the molecular pathways driving disease progression and resistance to endocrine agents will lead to the rational development of additional agents to i...

Pancreatic Cancer

ASCO Guideline on Potentially Curable Pancreatic Cancer

Matthew Stenger  / July 25, 2016

Multidisciplinary collaboration to formulate treatment and care plans and disease management should be the standard of care. — Alok A. Khorana, MD As reported in the Journal of Clinical Oncology by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, ASCO has release...

Pancreatic Cancer

ASCO 2016 Guidelines for the Treatment of Pancreatic Cancer: Why Another Guideline?

Ramesh K. Ramanathan, MD  / July 25, 2016

There is a common theme in all the guidelines. The goal is high-quality and cost-effective care. Clinical trials are always the ‘standard of care’ and should be offered in all stages. — Ramesh K. Ramanathan, MD The 5-year survival rate of those diagnosed with pancreatic c...

Pancreatic Cancer

ASCO Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer

Matthew Stenger  / July 25, 2016

Patients should have full assessment of symptom burden, psychological status, and social supports as early as possible—preferably at the first visit. In most cases, this will indicate a need for a formal palliative care consult and services. — Edward P. Balaban, DO, FASCO, ...

Pancreatic Cancer

ASCO Guideline on Metastatic Pancreatic Cancer

Matthew Stenger  / July 25, 2016

Every patient should be offered information about clinical trials, which include therapeutic trials in all lines of treatment as well as palliative care, biorepository/biomarker, and observational studies. — Davendra P.S. Sohal, MD, MPH As reported in the Journal of Clini...

Breast Cancer

Greatest Benefit of Adjuvant Exemestane in Premenopausal Women at Higher Risk of Breast Cancer Recurrence

Matthew Stenger  / July 10, 2016

Premenopausal women with hormone receptor–positive, HER2-negative disease and high recurrence risk… may experience improvement of 10% to 15% in 5-year breast cancer–free interval with exemestane plus ovarian function suppression vs tamoxifen alone. — Meredith M. Regan, ScD,...

Breast Cancer

Detection of Breast Cancer With Ultrasound vs Tomosynthesis in Women With Mammography-Negative Dense Breasts

Matthew Stenger  / July 10, 2016

The ASTOUND interim analysis shows that ultrasound has better incremental [breast cancer] detection than tomosynthesis in mammography-negative dense breasts at a similar [false-positive] recall rate. — Alberto S. Tagliafico, MD, and colleagues As reported in the Journal o...

Multiple Myeloma

Addition of Ixazomib to Lenalidomide/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

Matthew Stenger  / June 25, 2016

The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited. — Philippe Moreau, MD, and colleagues In the phase III TOURMALINE-MM-1...

Multiple Myeloma

Ixazomib: A Relevant Addition to Myeloma Therapy

S. Vincent Rajkumar, MD  / June 25, 2016

In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the th...

Issues in Oncology
Global Cancer Care

European Demand for Radiotherapy Expected to Rise Approximately 16% Over Next Decade

The ASCO Post  / June 25, 2016

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published by ­Borras et al in Radiotherapy and Oncology.1 These projections came fro...

Breast Cancer
Gastroesophageal Cancer
Gastrointestinal Cancer

Pembrolizumab Active in PD-L1–Positive Advanced Gastric Cancer and Triple-Negative Breast Cancer

Matthew Stenger  / June 25, 2016

In this population of patients with recurrent or metastatic PD-L1-positive gastric cancer, pembrolizumab had a manageable toxicity profile and promising antitumour activity… . — Kei Muro, MD and colleagues The KEYNOTE-012 phase Ib trial assessed single-agent pembrolizumab (Keytru...

Gastroesophageal Cancer
Gastrointestinal Cancer

Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is Likely to Respond?

David H. Ilson, MD, PhD  / June 25, 2016

Immune checkpoint inhibitors have emerged as one of the most promising new areas of drug development in oncology. Broad activity has been observed for these agents across a spectrum of hematologic malignancies and solid tumors. As reviewed in this issue of The ASCO Post, Muro and colleagues now repo...

Breast Cancer

Pembrolizumab in Triple-Negative Breast Cancer: Emerging New Treatment Modality

The ASCO Post  / June 25, 2016

We are in a new era of cancer therapies. — Lajos Pusztai, MD, DPhil Lajos Pusztai, MD, DPhil, Professor of Medicine, Chief of Breast Medical Oncology and Co-Director of Cancer Genetics Research Program at Yale Cancer Center, New Haven, Connecticut, commented on ­KEYNOTE-012. He r...

Breast Cancer

ASCO Clinical Practice Guideline Update on Ovarian Suppression/Adjuvant Endocrine Therapy in Hormone Receptor–Positive Breast Cancer

Matthew Stenger  / June 10, 2016

Clinicians should be alert to the possibility of incomplete ovarian suppression with gonadotropin-releasing hormone agonist therapy and evaluate patients for whom there is concern about residual ovarian function. — Harold J. Burstein, MD, PhD and colleagues As reported in the Jou...

Breast Cancer

Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer

Katarzyna J. Jerzak, MD, FRCPC, and Kathleen I. Pritchard, MD, FRCPC  / June 10, 2016

Given a loosely defined target population and a lack of overall survival benefit, the ASCO guideline supporting ovarian suppression in premenopausal women with stage II and III breast cancer should not serve as a mandate, but rather as a guide for discussing its relative risks an...

Supportive Care

Cancer and Fertility Program Improves Patient Satisfaction With Information on Fertility Risks and Preservation

Matthew Stenger  / June 10, 2016

Improvements in patient satisfaction with information received demonstrate the potential for fertility programs in cancer care settings to improve the quality of clinician-patient discussions about fertility. — Joanne F. Kelvin, MSN, RN, CNS, AOCN As reported by Joanne F. Kelvin,...

Supportive Care

Learning About Fertility Is Important to Young Patients With Cancer

Kathryn J. Ruddy, MD, MPH  / June 10, 2016

The fact that more than one-third of male respondents and nearly two-thirds of female respondents who were diagnosed with cancer after the initiation of the Cancer and Fertility Program still were not satisfied with certain aspects of the information they received about fertility is a call...

Breast Cancer

Prolonged Progression-Free Survival With Addition of Palbociclib to Fulvestrant in HER2-Negative Metastatic Breast Cancer

Matthew Stenger  / June 10, 2016

Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irrespective of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. — Massim...

Breast Cancer

PALOMA-3 Trial in HER2-Negative Metastatic Breast Cancer: Challenge of Moving Beyond Estrogen Receptor Positivity

Richard S. Finn, MD  / June 10, 2016

A biomarker that could identify patients with estrogen receptor–positive breast cancer who do just as well with endocrine therapy alone and may not benefit from the addition of a second agent would be useful, sparing women both the expense and additional side effects of the combination. ...

Multiple Myeloma

Daratumumab Shows High Activity in Heavily Pretreated and Refractory Multiple Myeloma

Matthew Stenger  / June 10, 2016

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favorable safety profile in this population of patients. — Sagar Lonial, MD, and colleagues In the phase II SIRIUS trial reported in The Lancet, Sagar L...

Lung Cancer

Pembrolizumab Improves Survival vs Docetaxel in Previously Treated PD-L1–Positive Advanced Non–Small Cell Lung Cancer

Matthew Stenger  / June 10, 2016

As reported in The Lancet by Roy S. Herbst, MD, PhD, of Yale School of Medicine, and colleagues,1 the phase II/III KEYNOTE-010 trial showed that pembrolizumab (Keytruda) significantly improved overall survival vs docetaxel in patients with previously treated programmed cell death ligand 1 (PD-L1)-po...

Health-Care Policy

ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention

Matthew Stenger  / June 10, 2016

As reported in the Journal of Clinical Oncology by Howard H. Bailey, MD, of the University of Wisconsin Carbone Cancer Center, and colleagues, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States.1  In the United Stat...

CNS Cancers

Improvement in Overall Survival With Addition of Chemotherapy to Radiotherapy in Low-Grade Glioma

Matthew Stenger  / June 10, 2016

Jan C. Buckner, MD Final results of the RTOG 9802 phase III trial reported in The New England Journal of Medicine by Jan C. Buckner, MD, of Mayo Clinic, Rochester, and colleagues, showed that the addition of chemotherapy with procarbazine, lomustine, and vincristine to radiotherapy signific...

Prostate Cancer

Increased Survival and Toxicity With Docetaxel, No Benefit of Zoledronic Acid, When Added to First-Line Hormone Therapy in Prostate Cancer

Matthew Stenger  / June 10, 2016

Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. — Nicholas D. James, BSc, MBBS, PhD, and colleagues As reported in The Lancet by Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, and colleagues...

Breast Cancer

Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer

Matthew Stenger  / May 25, 2016

To our knowledge, neratinib taken for 12 months is the first therapeutic intervention to significantly improve invasive disease–free survival beyond trastuzumab-based adjuvant therapy in women with HER2-positive early-stage breast cancer. — Arlene Chan, MD, and colleagues In the ...

Breast Cancer

ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer

Edward H. Romond, MD  / May 25, 2016

Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the int...

Pancreatic Cancer

No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer

Matthew Stenger  / May 25, 2016

In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine wi...

Bladder Cancer

ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers

Matthew Stenger  / May 25, 2016

Matthew I. Milowsky, MD Cheryl T. Lee, MD As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice...

Bladder Cancer

ASCO and European Association of Urology Agree on Bladder Cancer Guidelines

Derek Raghavan, MD, PhD, FACP, FRACP, FASCO  / May 25, 2016

The bottom line is that these two groups have produced a commonsense, evidence-based manifesto that guides clinicians to provide the correct treatment of advanced bladder cancer, based on evidence rather than rhetoric and hype. — Derek Raghavan, MD, PhD, FACP, FRACP, FASCO I ...

Kidney Cancer

No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma

Matthew Stenger  / May 25, 2016

These results provide a strong rationale against the use of these drugs for high-risk kidney cancer in the adjuvant setting and suggest that the biology of cancer recurrence might be independent of angiogenesis. — Naomi B. Haas, MD, and colleagues In the phase III ECOG-ACRIN E280...

Kidney Cancer

Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma

Cora N. Sternberg, MD, FACP  / May 25, 2016

The reasons for low tolerability in the adjuvant setting may relate to there being less disease present and the agents’ not exerting an antiangiogenic effect on micrometastases. In theory, patients without metastatic disease may also be less tolerant of the side effects of these agents aft...

Bladder Cancer

Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma

Matthew Stenger  / May 25, 2016

Atezolizumab showed durable activity and good tolerability in this patient population. Increased levels of PD-L1 expression on immune cells were associated with increased response. — Jonathan E. Rosenberg, MD, and colleagues In a phase II trial reported in The Lancet, Jonathan E....

Bladder Cancer

Atezolizumab in Previously Treated Advanced Urothelial Carcinoma

Nicholas J. Vogelzang, MD  / May 25, 2016

This new class of immunotherapeutic antibodies, led by atezolizumab, offers patients with metastatic or locally advanced transitional cell carcinoma hope for nontoxic, durable responses. — Nicholas J. Vogelzang, MD The recent study by Rosenberg et al in The Lancet—summarized in t...

Issues in Oncology

Increased Physical Activity Associated With Lower Risk of 13 Types of Cancer

The ASCO Post  / May 25, 2016

Our results support that these associations are broadly generalizable to different populations, including people who are overweight or obese or those with a history of smoking. Health-care professionals counseling inactive adults should promote physical activity as a component of a healthy...

Sarcoma

Eribulin Improves Overall Survival vs Dacarbazine in Previously Treated Advanced Liposarcoma or Leiomyosarcoma

Matthew Stenger  / May 25, 2016

Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eribulin could be a treatment option for advanced soft-tissue sarcoma. — Patrick Schöffski, MD, and colleagues In a phase III trial reported in T...

Sarcoma

Eribulin in Liposarcoma: A Closer Look at the Comparative Data

Margaret von Mehren, MD  / May 25, 2016

Eribulin appears to have a unique mechanism of action, with data suggesting its benefits are due less to direct cytotoxic effects and more to changes in the tumor microenvironment or malignant cells. — Margaret von Mehren, MD Sarcoma therapy is a challenge for oncologists. Soft-t...

Prostate Cancer

Enzalutamide Produces Large Progression-Free Survival Benefit vs Bicalutamide in Two Trials in Castration-Resistant Prostate Cancer

Matthew Stenger  / May 10, 2016

In the randomized phase II TERRAIN trial reported in The Lancet Oncology, Neal D. Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, and colleagues found that use of the androgen receptor inhibitor enzalutamide (Xtandi) more than doubled median progression-free survival vs bicalutamide i...

Prostate Cancer

Moving Forward in Castration-Resistant Prostate Cancer: The TERRAIN and STRIVE Studies

E. David Crawford, MD  / May 10, 2016

It was over 2 decades ago that my colleagues and I reported in The New England Journal of Medicine that a first-generation oral antiandrogen, flutamide, when added to a luteinizing hormone–releasing hormone (LHRH) agonist, improved survival by nearly 6 months compared to an LHRH agonist alone in men...

Breast Cancer

ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer

Matthew Stenger  / May 10, 2016

As reported in the Journal of Clinical Oncology by Lyndsay N. Harris, MD, and colleagues,1 ASCO has released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with ear...

Breast Cancer

Shedding Light on a Cornucopia of Breast Tumor Biomarker Assays

Melanie Royce, MD, PhD  / May 10, 2016

As our understanding of the complexities of breast cancer expands, so does our treatment armamentarium—and along with it the range of factors that must be included in our treatment decisions. Gone is the simple algorithm of adjuvant chemotherapy for almost every patient with a ≥ 2-cm tumor, except f...

Colorectal Cancer

Transcription Factor CDX2 May Be a Prognostic Biomarker in Stage II and III Colon Cancer

Matthew Stenger  / April 25, 2016

In a study reported in The New England Journal of Medicine, Piero Dalerba, MD, of Columbia University, and colleagues found that absence of the transcription factor CDX2 was prognostic for poor outcome in patients with stage II and III colon cancer vs cancers with CDX2 expression.1 However, adjuvant...

Colorectal Cancer

CDX2 in Stage II Colon Cancer: Ready for Prime Time?

Kimmie Ng, MD, MPH  / April 25, 2016

In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying new prognostic and predictive biomarkers in patients with stage II and III colon cancer (see summary in this issue of The ASCO Post).1 The...

Prostate Cancer

ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer

Matthew Stenger  / April 25, 2016

As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer. ASC...

Prostate Cancer

Active Surveillance Has Become Standard Care for Men With Low-Risk Localized Prostate Cancer

Ethan Basch, MD  / April 25, 2016

Active surveillance has been increasingly adopted as a standard approach for men with Gleason score ≤ 6 localized prostate cancer, with major guidelines and consensus statements encouraging this approach,1 including a recently published guideline from Cancer Care Ontario (CCO),2 and endorsement of t...

Breast Cancer

ACS/ASCO Breast Cancer Survivorship Care Guideline

Matthew Stenger  / April 25, 2016

The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians.1,2 The guideline recommendations were formulated by a multidisciplinary expert work group and are based o...

Breast Cancer

Praise for the ACS/ASCO Breast Cancer Survivorship Care Guideline

Ann H. Partridge, MD, MPH  / April 25, 2016

The recent publication of the American Cancer Society (ACS)/ASCO breast cancer survivorship care guideline is a tremendous contribution to the literature and should provide a roadmap for providers who care for patients with a history of breast cancer for years to come.1,2 The guideline, reported by ...

Lung Cancer

Atezolizumab Improves Survival vs Docetaxel in Previously Treated NSCLC: Increased Benefit With Increased PD-L1 Expression

Matthew Stenger  / April 10, 2016

Louis Fehrenbacher, MD In the phase II POPLAR trial reported in The Lancet, Louis Fehrenbacher, MD, of Kaiser Permanente Medical Center, and colleagues found that the investigational anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab improved overall survival vs docetaxel in ...

Lung Cancer

The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer

Jean-Charles Soria, MD, PhD  / April 10, 2016

The randomized phase II ­POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell lun...

Lung Cancer

Update of ASCEND-1 Trial Shows Ceritinib Highly Active in ALK-Rearranged NSCLC, Including Intracranial Disease

Matthew Stenger  / April 10, 2016

Updated results of the phase I ­ASCEND-1 trial, reported by Kim et al in The Lancet Oncology, indicate that the ALK inhibitor ceritinib (Zykadia) produced high response rates in advanced ALK-rearranged non–small cell lung cancer (NSCLC), including intracranial disease, in both patients with and with...

Prostate Cancer

Decreased PSA Screening and Decreased Diagnosis of Early-Stage Prostate Cancer

Matthew Stenger  / April 10, 2016

While the 2008 USPSTF recommendations against PSA screening in men aged 75 years or older were not associated with changes in screening practices, we found a decrease in the prevalence of PSA screening following the 2012 recommendations, particularly in men younger than 75 years. —...

Neuroendocrine Tumors

Everolimus Improves Progression-Free Survival in Advanced Neuroendocrine Tumors of the Lung or Gastrointestinal Tract

Matthew Stenger  / April 10, 2016

In a phase III trial (RADIANT-4) reported in The Lancet, James C. Yao, MD, of the University of Texas MD Anderson Cancer Center, and colleagues found that everolimus (Afinitor) and supportive care significantly prolonged progression-free survival vs placebo and supportive care in patients with advan...

Leukemia
Lymphoma

First-Line Ibrutinib Improves Progression-Free and Overall Survival vs Chlorambucil in Older Patients With Chronic Lymphocytic Leukemia

Matthew Stenger  / March 25, 2016

As reported in The New England Journal of Medicine and at the 2015 American Society of Hematology Annual Meeting, Jan A. Burger, MD, PhD, and colleagues found that first-line treatment with the oral Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) improved progression-free and overall surviv...

Leukemia

Chronic Lymphocytic Leukemia: The Golden Drug Only for Golden Agers?

Stephan Stilgenbauer, MD, PhD  / March 25, 2016

As reviewed in this issue of The ASCO Post, Burger and colleagues recently reported findings of the RESONATE-2 trial of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) as initial therapy for elderly patients with chronic lymphocytic leukemia (CLL).1 The study met its primary endpoint of independent...

Survivorship

Reduction in Late Mortality in Childhood Cancer Survivors

Matthew Stenger  / March 25, 2016

In a study reported in The New England Journal of Medicine, Gregory T. Armstrong, MD, MSCE, of St. Jude Children’s Research Hospital, Memphis, and colleagues found that late mortality has decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort.1 T...

Survivorship

Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes

Lisa Diller, MD  / March 25, 2016

Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for th...

CNS Cancers

No Apparent Benefit of Long-Term Mifepristone in the Treatment of Unresectable Meningioma

Matthew Stenger  / March 25, 2016

In a phase III trial (SWOG S9005) reported in the Journal of Clinical Oncology,1 YongLi Ji, MD, PhD, and Claire Verschraegen, MD, of the University of Vermont Cancer Center; and colleagues found no benefit of treatment with the antiprogestin agent mifepristone vs placebo in patients with unresectabl...

Gastrointestinal Cancer

Scandinavian Sarcoma Group Trial Shows Continued Benefit With 3 Years vs 1 Year of Adjuvant Imatinib in High-Risk GIST

Matthew Stenger  / March 25, 2016

Heikki Joensuu, MD, PhD As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, PhD, of the Comprehensive Cancer Center Helsinki, Finland, and colleagues, the second planned analysis in the Scandinavian Sarcoma Group XVIII/AIO trial showed a recurrence-free survival benefit a...

Leukemia

Two Types of Asparaginase Compared in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia

Matthew Stenger  / March 25, 2016

Andrew E. Place, MD Intravenous pegylated (PEG) Escherichia coli (E coli) asparaginase was associated with similar toxicity and efficacy compared with intramuscular native E coli L-asparaginase in children with newly diagnosed acute lymphoblastic leukemia, according to the results of a phas...

Breast Cancer

Potential Overdiagnosis of Contralateral Breast Cancer With Preoperative Breast MRI in Older Women With Breast Cancer

Matthew Stenger  / March 25, 2016

In an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database reported in the Journal of Clinical Oncology, Shi-Yi Wang, MD, PhD, of Yale School of Public Health, and colleagues found that the use of preoperative magnetic resonance imaging (MRI) was associated with overd...

Breast Cancer

Introduction of New Diagnostic Devices in Oncology: New Is Not Necessarily Better

Daniel F. Hayes, MD, FASCO  / March 25, 2016

“New!” “Improved!” “Throw out that old [fill in the blank] and go buy a new [fill in the blank]!” Sound familiar? The key to marketing is to convince customers that they need a product without which they had previously been quite happy. All too often, this strategy is accompanied by a caveat emptor ...

Leukemia

Minimal Residual Disease Identified by NPM1 Mutation Is a Powerful Marker for Poorer Outcome in Standard-Risk AML

Matthew Stenger  / March 25, 2016

In a study reported in The New England Journal of Medicine, Adam Ivey, MSc, from Guy’s Hospital, London, and colleagues found that a leukemia-specific marker consisting of mutation in the gene encoding nucleophosmin (NPM1) can be used to identify minimal residual disease in peripheral blood in stand...

Leukemia

Minimal Residual Disease in AML: Worth Looking?

Selina M. Luger, MD, and Marlise R. Luskin, MD, MSCE  / March 25, 2016

As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML) induc...

Prostate Cancer

PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA-Repair Defects

Matthew Stenger  / March 25, 2016

In the TOPARP-A phase II trial reported in The New England Journal of Medicine, Joaquin Mateo, MD, of the Institute of Cancer Research and The Royal Marsden in London, and colleagues, found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated ...

Prostate Cancer

Biomarkers in Prostate Cancer: PARP Inhibitors and Defects in DNA Repair

Oliver Sartor, MD  / March 25, 2016

New data on molecular biomarkers in advanced prostate cancer are accumulating at a fast pace. The studies in this area can now be broadly grouped in two distinct areas—those that broadly relate to androgen signaling and those that relate to DNA-repair pathways. The Androgen-Signaling Pathway With ...

Hematologic Malignancies

Adding Ibrutinib to Bendamustine/Rituximab Improves Outcome in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Matthew Stenger  / March 10, 2016

In the phase III HELIOS trial reported in The Lancet Oncology, Asher Chanan-Khan, MD, of the Mayo Clinic Cancer Center, Jacksonville, Florida, and colleagues found that addition of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increa...

Leukemia

Adding Targeted Therapy to Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia: Questions as to Optimal Strategy Remain

Jennifer Woyach, MD  / March 10, 2016

The HELIOS study is an international phase III trial of bendamustine (Treanda) plus rituximab (Rituxan) in combination with ibrutinib (Imbruvica) vs placebo in patients with previously treated chronic lymphocytic leukemia. As reported by Chanan-Khan in The Lancet Oncology1 and reviewed in this issue...

Supportive Care

Rolapitant Reduces Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately and Highly Emetogenic Chemotherapy

Matthew Stenger  / February 25, 2016

In three phase III studies reported in The Lancet Oncology, the addition of the neurokinin-1 (NK-1) receptor antagonist rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in the prevention of chemotherapy-induced nausea and ...

Prostate Cancer

Dose-Intensified vs Standard Salvage Radiation for Biochemically Recurrent Prostate Cancer After Prostatectomy

Matthew Stenger  / February 10, 2016

Initial results of a European phase III trial (SAKK 09/10), reported in the Journal of Clinical Oncology by Ghadjar et al of the Swiss Group for Clinical Cancer Research, showed little difference in acute toxicity with salvage radiotherapy of 70 vs 64 Gy in patients with biochemical recurrence of pr...

Breast Cancer

Comparing Recurrence Risk With Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ

Matthew Stenger  / February 10, 2016

Two recently reported phase III trials compared adjuvant anastrozole vs tamoxifen in postmenopausal women with hormone receptor–positive ductal carcinoma in situ. As reported in The Lancet by Margolese et al,1 the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial, performed in w...

New AJCC Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients

The ASCO Post  / February 10, 2016

A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were publis...

Colorectal Cancer

Study Finds Colorectal Cancer More Likely to Affect Minorities at Younger Age

The ASCO Post  / January 25, 2016

Researchers at the University of Missouri School of Medicine reported that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and more advanced stages than non-Hispanic whites. The study was recently published in Cancer Medicine.1 “While we know the risk of develo...

Pancreatic Cancer

Pancreas Cancer Liquid Biopsy: Proof-of-Principle Study

The ASCO Post  / January 25, 2016

Pancreatic cancer tumors are ripe for analysis with a liquid biopsy, according to researchers at The University of Texas MD Anderson Cancer Center. In a proof-of-principle study published recently in Annals of Oncology,1 the investigators reported on research in which they conducted whole-genome, wh...

Survivorship

Computerized Cognitive Training Promising for Reducing Cognitive Late Effects in Childhood Cancer Survivors

The ASCO Post  / January 25, 2016

In a study reported in the Journal of Clinical Oncology, Heather M. Conklin, PhD, of St. Jude Children’s Research Hospital, and colleagues found that computerized cognitive training showed promise in reducing cognitive late effects in survivors of childhood cancer.1 Study Details In the study, con...

Lung Cancer

Global and North American Phase II Studies Show Alectinib Is Highly Active in Crizotinib-Resistant/Refractory ALK-Rearranged NSCLC

Matthew Stenger  / January 25, 2016

In two phase II trials, reported in the Journal of Clinical Oncology and The Lancet Oncology, the ALK inhibitor alectinib (Alecensa), which is active against acquired crizotinib resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable activity...

Hematologic Malignancies
Lymphoma

Lenalidomide Plus Rituximab Highly Active in  Initial Treatment of Mantle Cell Lymphoma

Matthew Stenger  / January 25, 2016

In a phase II trial reported in The New England Journal of Medicine by Jia Ruan, MD, PhD, and colleagues, first-line treatment with the immunomodulatory agent lenalidomide (Revlimid) and the anti-CD20 antibody rituximab (Rituxan) followed by maintenance lenalidomide and rituximab produced a high res...

Breast Cancer

Study Reveals Potential Therapy Targets for Triple-Negative Breast Cancer

The ASCO Post  / January 25, 2016

A multi-institutional international investigation led by scientists at The University of Texas MD Anderson Cancer Center, Houston, has revealed new information about how molecules called long noncoding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-...

Evolution

John V. Cox, DO, MBA, FACP, FASCO and James O. Armitage, MD, FASCO  / January 25, 2016

Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as pra...

Journal of Oncology Practice Expands Research Coverage and Debuts a New Look

Jo Cavallo  / December 25, 2015

Launched by ASCO in 2005 to provide oncologists with original research on the delivery of high-quality cancer care, the Journal of Oncology Practice (JOP) enters its 11th year with a new look and feel. Beginning in January 2016, JOP will be copublished by ASCO and Harborside Press, the publisher of ...

Solid Tumors
Colorectal Cancer

Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer

Matthew Stenger  / December 25, 2015

Two phase III trials, reported in JAMA by James Fleshman, MD, of Baylor University Medical Center, Dallas, and colleagues1 and Andrew R. Stevenson, MBBS, FRACS, of the University of Queensland, Brisbane, Australia, and colleagues,2 failed to show noninferiority of surgical outcome for laparoscopic v...

Breast Cancer

Surgical Excision Without Radiation Therapy in Women With Low-Risk Ductal Carcinoma in Situ

Matthew Stenger  / December 25, 2015

Lawrence J. Solin, MD, of Albert Einstein Healthcare Network, Philadelphia, and colleagues reported the 12-year results from the ECOG-ACRIN E5194 trial in the Journal of Clinical Oncology. Among women with ductal carcinoma in situ with low-risk clinical and pathologic characteristics, they found tha...

Lung Cancer

ASCO Endorses ACCP Guideline on Treatment of Small Cell Lung Cancer

Matthew Stenger  / December 25, 2015

As reported in the Journal of Clinical Oncology,1 ASCO has endorsed the current American College of Chest Physicians (ACCP) guideline on treatment of small cell lung cancer (SCLC), released in 2013.2 After review of evidence from an updated literature search covering 2011 to March 2015, an ASCO endo...

Hematologic Malignancies
Leukemia

BRAF Inhibition Successful in Relapsed/Refractory Hairy Cell Leukemia

Matthew Stenger  / December 10, 2015

In two phase II studies reported in The New England Journal of Medicine, ­Enrico Tiacci, MD, of the University of Perugia, Italy, and colleagues found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia that relapsed a...

Sarcoma

Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Chemotherapy Failure in Liposarcoma or Leiomyosarcoma

Matthew Stenger  / December 10, 2015

In a phase III trial reported in the Journal of Clinical Oncology, George D. Demetri, MD, of Harvard Medical School and Dana-Farber Cancer Institute, Boston, and colleagues found that treatment with trabectedin (Yondelis) significantly improved progression-free survival vs dacarbazine in patients wi...

Breast Cancer

Convergence of Breast Cancer Incidence but Continued Divergence of Mortality in Black Women and White Women

Matthew Stenger  / December 10, 2015

In an article published in CA: A Cancer Journal for Clinicians, Carol E. ­DeSantis, MPH, and colleagues from the American Cancer Society reported that the incidence of breast cancer in black women has caught up to that in white women, whereas the risk of mortality continues to be higher in black wom...

Lung Cancer

Nivolumab Improves Overall Survival vs Docetaxel in Advanced Previously Treated Squamous Cell NSCLC

Matthew Stenger  / December 10, 2015

In a phase III trial reported in The New England Journal of Medicine, ­Julie Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, and colleagues found that treatment with the programmed cell death protein 1 (PD-1) immune checkpoint inhibitor antibody nivolumab (...

Breast Cancer

ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer

Matthew Stenger  / December 10, 2015

As reported in the Journal of Clinical Oncology by Catherine Van Poznak, MD, and colleagues, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer.1 The statement is based on an ASCO expert panel review of...

Breast Cancer

Regional Nodal Irradiation in Early Breast Cancer Yields Significant Disease-Free Survival Benefit in Two Trials

Matthew Stenger  / December 10, 2015

Two phase III trials recently reported in The New England Journal of Medicine indicated that the addition of regional nodal irradiation was associated with no or marginal overall survival benefit but significantly improved disease-free survival in patients with early-stage breast cancer.1,2 NCIC MA...

Skin Cancer

Gut Bacteria May Facilitate Efficacy of Anti–PD-L1 Agents

Caroline Helwick  / December 10, 2015

Could the manipulation of bacteria in the gut pack the same punch in melanoma as antibodies targeting the programmed cell death protein and its ligand (PD-1/PD-L1)? It’s possible, at least in mice, according to research from the University of Chicago, recently published in Science.1 The researchers ...

Breast Cancer
Issues in Oncology

ACS Guideline Update on Breast Cancer Screening for Women at Average Risk

Matthew Stenger  / November 25, 2015

As reported in JAMA by Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, the American Cancer Society (ACS) has issued an update to its 2003 guideline on breast cancer screening for women at average risk of breast cancer.1 Robert A. Smith, PhD, of the Cancer...

Lung Cancer

ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC

Matthew Stenger  / November 25, 2015

As reported in the Journal of Clinical Oncology by Gregory A. Masters, MD, and colleagues, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC).1 Recommendations are based on an update committee systematic review of randomized contr...

Lung Cancer

Checkmate 057: Nivolumab Improves Survival vs Docetaxel  in Advanced Nonsquamous Non–Small Cell Lung Cancer

Matthew Stenger  / November 25, 2015

In the phase III CheckMate 057 trial, reported in The New England Journal of Medicine by Hossein Borghaei, DO, of Fox Chase Cancer Center, and colleagues, the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) improved overall survival vs docetaxel in patients with advanced nonsquam...

Breast Cancer

Mediterranean Diet Supplemented With Extra-Virgin Olive Oil Reduces Risk for Invasive Breast Cancer

Matthew Stenger  / November 25, 2015

As reported in JAMA Internal Medicine by Estefania Toledo, MD, MPH, PhD, and colleagues, a large Spanish primary prevention nutrition intervention trial in patients at high cardiovascular risk (PREDIMED) showed a large reduction in the risk for invasive breast cancer among women 60 to 80 years of ag...

Lymphoma
Solid Tumors

ASCO Clinical Practice Guideline Update: Recommendations for the Use of White Blood Cell Growth Factors

Matthew Stenger  / November 10, 2015

ASCO has issued a clinical practice guideline update on use of hematopoietic colony-stimulating factors, as reported in the Journal of Clinical Oncology by Thomas J. Smith, MD, FACP, FASCO, FAAHMP, and colleagues.1 This update to the ASCO 2006 guideline was based on a systematic review of randomized...

Breast Cancer

Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early HER2-Negative Breast Cancer

Matthew Stenger  / November 10, 2015

The phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel + anthracycline-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early H...

Issues in Oncology

A Cancer Diagnosis Can Lead to Significant Loss of Working Hours, Income

The ASCO Post  / November 10, 2015

A new analysis indicates that when American adults are diagnosed with cancer, they experience significant decreases in the probability of working, in the number of hours they work, and correspondingly, in their incomes. Such negative impacts of a cancer diagnosis are particularly pronounced among wo...

Gynecologic Cancers

ASCO Endorses ASTRO Guideline on Postoperative Radiation Therapy for Endometrial Cancer

Matthew Stenger  / November 10, 2015

As reported in the Journal of Clinical Oncology by Larissa A. Meyer, MD, MPH, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) guideline on postoperative radiation therapy for endometrial cancer.1 The ASCO clinical practice guideline endorsemen...

Breast Cancer

Endocrine Therapy Alone Linked to Low Risk of Breast Cancer Recurrence in Women With a Low-Risk Score on 21-Gene Assay

Matthew Stenger  / October 25, 2015

A prospective validation study of a 21-gene expression assay showed that treatment with endocrine therapy alone in women with hormone receptor–positive, HER2-negative breast cancer who had a low recurrence risk score resulted in low risk of recurrence. All patients included in the study were eligibl...

Kidney Cancer

Nivolumab and Cabozantinib Improve Outcomes vs Everolimus in Previously Treated Advanced Renal Cell Carcinoma

Matthew Stenger  / October 25, 2015

The CheckMate 025 trial, reported in The New England Journal of Medicine by Robert J. Motzer, MD, and colleagues, showed that treatment with the programmed cell death protein (PD-1) checkpoint inhibitor nivolumab (Opdivo) increased overall survival vs the mTOR inhibitor everolimus (Afinitor) in pati...

Lung Cancer

Addition of Necitumumab to First-Line Gemcitabine/Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC

Matthew Stenger  / October 25, 2015

In the phase III SQUIRE trial reported in The Lancet Oncology, Nick Thatcher, PhD, FRCP, of The Christie Hospital NHS Trust, Manchester, UK, and colleagues found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line gemcitabine/cisplati...

Gynecologic Cancers

Addition of Bevacizumab to Standard Chemotherapy Improves Overall Survival Only in High-Risk Ovarian Cancer

Matthew Stenger  / October 25, 2015

Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Amit M. Oza, MD, and colleagues indicate no significant improvement with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer.1 However, an overall su...

Breast Cancer

EBCTCG Meta-analyses Show Improved Outcomes With Aromatase Inhibitors vs Tamoxifen and a Potential Benefit of Adjuvant Bisphosphonates Limited to Postmenopausal Women

Matthew Stenger  / October 10, 2015

The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) patient-level meta-analyses, concurrently reported in The Lancet, sought to clarify the effects of adjuvant aromatase inhibitor vs tamoxifen treatment and adjuvant bisphosphonate treatment in early breast cancer.1,2 The endocrine treat...

Prostate Cancer

Adding Docetaxel to Androgen-Deprivation Therapy Prolongs Overall Survival in Metastatic Prostate Cancer

Matthew Stenger  / October 10, 2015

In a phase III trial (E3805) reported in The New England Journal of Medicine, Christopher J. Sweeney, MBBS, of Dana-Farber Cancer Institute, Boston, and colleagues found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median o...

Issues in Oncology

ASCO Statement: Improving the Evidence Base for Treating Older Adults With Cancer

Matthew Stenger  / October 10, 2015

Older persons are the fastest-growing segment of the U.S. population and account for the majority of cancer diagnoses and deaths and the majority of cancer survivors. However, since this population is underrepresented in clinical trials, the evidence base for treating older patients is poor. As repo...

Breast Cancer

Increased Risk of Death From Breast Cancer for Women With Ductal Carcinoma in Situ vs General Population

Matthew Stenger  / October 10, 2015

In a study reported in JAMA Oncology, Steven A. Narod, MD, FRCPC, of Women’s College Research Institute, Women’s College Hospital, and the University of Toronto, and colleagues found that the risk of breast cancer mortality was elevated in patients with ductal carcinoma in situ compared with the gen...

Skin Cancer

Pembrolizumab Increases Progression-Free Survival in Ipilimumab-Refractory Advanced Melanoma

Matthew Stenger  / October 10, 2015

In a randomized phase II trial (KEYNOTE-002) reported in The Lancet Oncology, Antoni Ribas, MD, of UCLA Jonsson Comprehensive Cancer Center, Los Angeles, and colleagues found that treatment with the anti–PD-1 (programmed cell death protein 1) antibody pembrolizumab (Keytruda) prolonged progression-f...

Survivorship

ASCO Statement Addresses Recommendations for Obesity Clinical Trials in Cancer Survivors

Matthew Stenger  / September 25, 2015

As reported in the Journal of Clinical Oncology by Jennifer A. ­Ligibel, MD, of Dana-Farber Cancer Institute, and colleagues, ASCO has issued a statement providing recommendations for obesity clinical trials in cancer survivors.1 ASCO convened the Research Summit on Advancing Obesity Clinical Trials...

Lung Cancer

Immune Checkpoint Inhibitor Nivolumab Is Active in Patients With Heavily Pretreated Advanced Non–Small Cell Lung Cancer

Matthew Stenger  / September 25, 2015

In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Scott N. Gettinger, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo) produce...

Breast Cancer

Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone

Matthew Stenger  / September 25, 2015

In an analysis of Women’s Health Initiative trials reported in JAMA Oncology, Rowan T. Chlebowski, MD, PhD, of Harbor-UCLA Medical Center, and colleagues found differing patterns of breast cancer risk among women receiving menopausal hormone therapy with estrogen plus progestin or estrogen alone.1 W...

Prostate Cancer

Statin Use at Start of Androgen-Deprivation Therapy Increases Time to Progression During Treatment of Prostate Cancer

Matthew Stenger  / September 25, 2015

Statin use has been associated with improved outcomes in prostate cancer. In a study reported in JAMA Oncology, Lauren C. Harshman, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that statin use at the time of the initiation of androgen-deprivation therapy was associated with prol...

Issues in Oncology

ASCO Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

Matthew Stenger  / September 25, 2015

As reported in the Journal of Clinical Oncology by Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a policy statement update on genetic and genomic testing for cancer susceptibility.1 The statement, commissioned by ASCO’s Cancer Prevention and Ethics Co...

Multiple Myeloma

Adding Elotuzumab to Lenalidomide Plus Dexamethasone Improves Progression-Free Survival in Refractory Multiple Myeloma

Matthew Stenger  / September 10, 2015

In an interim analysis of the phase III ELOQUENT-2 trial reported in The New England Journal of Medicine, Sagar Lonial, MD, of Emory University School of Medicine, Meletios Dimopoulos, MD, of National and Kapodistrian University of Athens, and colleagues found that the addition of elotuzumab to lena...

Leukemia

Novel Combination Increases Progression-Free Survival in CLL Patients Who Are Not Candidates for Fludarabine

Matthew Stenger  / September 10, 2015

In the phase III COMPLEMENT 1 trial reported in The Lancet, ­Peter Hillmen, MB, ChB, of St. James’s University Hospital, Leeds, and colleagues found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chr...

Skin Cancer

Dabrafenib Plus Trametinib Improves Overall Survival vs Dabrafenib in BRAF V600–Mutant Melanoma

Matthew Stenger  / September 10, 2015

Overall survival results of the phase III COMBI-d trial reported in The Lancet by Georgina V. Long, MD, and colleagues showed that the combination of the BRAF inhibitor ­dabrafenib (Tafinlar) with the MEK inhibitor trametinib (Mekinist) resulted in significantly prolonged overall survival vs dabrafe...

Colorectal Cancer

Regorafenib Improves Overall Survival in Asian Patients  With Previously Treated Metastatic Colorectal Cancer

Matthew Stenger  / August 25, 2015

In a phase III trial (CONCUR) reported in The Lancet Oncology, Jin Li, MD, and colleagues found that the multikinase inhibitor regorafenib (Stivarga) improved overall survival vs placebo in Asian patients with previously treated metastatic colorectal cancer.1 Regorafenib is approved in the United S...

Breast Cancer

Adding Everolimus to First-Line Trastuzumab/Paclitaxel Does Not Increase Progression-Free Survival in HER2-Positive Metastatic Breast Cancer

Matthew Stenger  / August 25, 2015

In the phase III BOLERO-1 trial, reported in The Lancet Oncology, Sara A. Hurvitz, MD, of the University of California, Los Angeles, and colleagues found that the addition of the mTOR inhibitor everolimus (Afinitor) to trastuzumab (Herceptin)/paclitaxel did not significantly increase progression-fre...

CNS Cancers

New Molecular Classifications of Gliomas Established

Matthew Stenger  / August 25, 2015

Two studies reported in The New England Journal of Medicine identified new molecular classifications of glioma that capture biologic and prognostic differences. The Cancer Genome Atlas Research Network identified three prognostically significant subtypes of lower-grade glioma that were identified by...

Prostate Cancer

Magnetic Resonance Imaging/Ultrasound Fusion–Guided Biopsy Improves Detection of High-Risk Prostate Cancer

Matthew Stenger  / August 10, 2015

In a study reported in JAMA, M. Minhaj Siddiqui, MD, currently of the University of Maryland School of Medicine, and colleagues found that targeted magnetic resonance imaging (MRI)/ultrasound fusion–guided prostate biopsy increased diagnosis of high-risk prostate cancer and reduced detection of low-...

Breast Cancer

No Survival Benefit for Eribulin vs Capecitabine in Advanced Breast Cancer

Matthew Stenger  / August 10, 2015

Eribulin (Halaven) currently is indicated in the United States for treatment of patients with metastatic breast cancer who previously received at least two chemotherapy regimens for metastatic disease and an anthracycline and a taxane in either the adjuvant or metastatic setting. Its approval was ba...

Lung Cancer

Early-Phase Studies Show Activity of Novel EGFR Inhibitors Rociletinib and AZD9291 in T790M-Positive NSCLC

Matthew Stenger  / July 25, 2015

Two early-phase studies have shown that the novel epidermal growth factor receptor (EGFR) inhibitors rociletinib and AZD9291 exhibit high activity in non–small cell lung cancer (NSCLC) patients with the EGFR T790M mutation who had progressed on prior EGFR inhibitor therapy.1,2 The T790M mutation con...

Lung Cancer

ASCO Endorses ASTRO Guideline on Definitive and Adjuvant Radiotherapy in Locally Advanced NSCLC

Matthew Stenger  / July 25, 2015

As reported in the Journal of Clinical Oncology by Andrea Bezjak, MD, of Princess Margaret Cancer Center, Toronto, and colleagues,1 ASCO has recently endorsed the American Society for Radiation Oncology (ASTRO) evidence-based guideline on external-beam radiotherapy for patients with locally advanced...

Skin Cancer

Adjuvant Ipilimumab Increases Recurrence-Free Survival After Complete Resection of High-Risk Stage III Melanoma

Matthew Stenger  / July 25, 2015

In the phase III European Organisation for Research and Treatment of Cancer (EORTC) 18071 trial reported in The Lancet Oncology, Alexander M.M. Eggermont, MD, PhD, Director General of the Gustave Roussy Cancer Center in Villejuif, France, and colleagues found that adjuvant therapy with the immune ch...

Kidney Cancer

16-Gene Assay Recurrence Score Predicts Recurrence After Surgery for Localized Renal Cell Carcinoma

Matthew Stenger  / July 10, 2015

In a study reported in The Lancet Oncology, Brian Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues developed a 16-gene assay and recurrence score that predicted postoperative outcome in patients with stage I to III clear cell renal cell carcinoma.1 Development Phase In th...

Lung Cancer

PD-1 Inhibitor Pembrolizumab Active in Advanced NSCLC: Outcomes Better With Higher PD-L1 Expression

Matthew Stenger  / July 10, 2015

In the phase I KEYNOTE-001 trial reported in The New England Journal of Medicine,1 Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) produce...

Gynecologic Cancers

Meta-analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormone Therapy

Matthew Stenger  / June 25, 2015

In a study reported in The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer found that use of menopausal hormone therapy was associated with increased risk of ovarian cancer, with risk being highest among current users.1 The study consisted of meta-analyses of individual...

Gynecologic Cancers

Hormonal Therapy and Risk of Ovarian Cancer

Ana I. Tergas, MD, MPH  / June 25, 2015

Ovarian cancer is the second most common gynecologic malignancy in the United States, with an estimated 21,290 new cases expected this year. Ovarian cancer causes 5% of all cancer deaths in women, making it responsible for the highest number of gynecologic cancer deaths.1 Age, family history, and in...

Gynecologic Cancers

Long-Term Survival Advantage Seen With Intraperitoneal vs Intravenous Chemotherapy in Advanced Ovarian Cancer

Matthew Stenger  / June 10, 2015

In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Devansu Tewari, MD, of Kaiser Permanente Irvine Medical Center, and colleagues found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemother...

Lung Cancer

Outcomes of the CUSTOM ‘Basket’ Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies

Matthew Stenger  / June 10, 2015

In the phase II CUSTOM trial reported in the Journal of Clinical Oncology, Ariel Lopez-Chavez, MD, Anish Thomas, MD, and colleagues performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or thymic malignancies and assigned...

Skin Cancer

Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma Progressing After Anti–CTLA-4 Treatment

Matthew Stenger  / June 10, 2015

In a phase III trial (CheckMate 037) reported in The Lancet Oncology, Jeffrey S. Weber, MD, PhD, of the Moffitt Cancer Center, and colleagues found that treatment with the PD-1 (programmed cell death protein 1) inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs chemoth...

Colorectal Cancer

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

Matthew Stenger  / June 10, 2015

In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody ramuci...

Prostate Cancer

ASCO Endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines

Matthew Stenger  / May 25, 2015

As reported in the Journal of Clinical Oncology by Matthew J. Resnick, MD, of Vanderbilt University Medical Center, and colleagues, ASCO has endorsed the 2014 American Cancer Society Prostate Cancer Survivorship Care Guidelines.1,2 The ASCO endorsement panel was co-chaired by Dr. Resnick and David F...

Prostate Cancer

Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  / May 25, 2015

In the phase III MAINSAIL trial reported in The Lancet Oncology, Daniel P. Petrylak, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate ca...

Breast Cancer

Higher-Than-Expected Incidence of Marrow Neoplasms After Adjuvant Therapy for Breast Cancer

Matthew Stenger  / May 25, 2015

In a study reported in the Journal of Clinical Oncology, Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy for...

Breast Cancer

High Invasive Disease-Free Survival With Adjuvant Paclitaxel and Trastuzumab in Small, Node‑Negative, HER2-Positive Breast Cancers

Matthew Stenger  / May 25, 2015

In a phase II study reported in The New England Journal of Medicine, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that adjuvant paclitaxel and trastuzumab (Herceptin) was associated with high invasive disease-free survival in women with small, node-negative, HER2-p...

Breast Cancer

Racial/Ethnic Differences in Diagnosis of Breast Cancer at Stage I and Subsequent Survival Reflect Biologic Differences

Matthew Stenger  / May 25, 2015

In a study reported in JAMA, Javaid Iqbal, MD, of Women’s College Research Institute, Toronto, and colleagues found racial/ethnic differences in the likelihood of breast cancer diagnosis at stage I and subsequent survival in U.S. breast cancer patients.1 These differences seemed largely to reflect i...

Thyroid Cancer

Large Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Thyroid Cancer

Matthew Stenger  / May 25, 2015

In a phase III trial reported in The New England Journal of Medicine, Martin Schlumberger, MD, of Institut Gustave Roussy, and colleagues found that the multikinase inhibitor lenvatinib (Lenvima) produced a large improvement in progression-free survival vs placebo in patients with advanced radioiodi...

Supportive Care

Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer

Matthew Stenger  / May 25, 2015

In a randomized trial reported in the Journal of Clinical Oncology, William Breitbart, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in patient...

Skin Cancer

Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma

Matthew Stenger  / May 25, 2015

In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine,1 Caroline Robert, MD, PhD, Head of the Dermatology Unit at the Institut Gustave Roussy, Paris, and colleagues found that the anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab (Keytruda) increased pro...

Breast Cancer

CLEOPATRA Overall Survival Analysis: Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer

Matthew Stenger  / May 25, 2015

As reported in The New England Journal of Medicine by Sandra M. Swain, MD, of Washington Cancer Institute, MedStar Washington Hospital Center, and colleagues, the final prespecified overall survival analysis in the phase III CLEOPATRA study showed a significant 15.7-month increase in median overall ...

Lymphoma

Improved Progression-Free Survival With Brentuximab Vedotin After Transplantation in Hodgkin Lymphoma Patients

Matthew Stenger  / May 10, 2015

In the phase III AETHERA trial reported in The Lancet, Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs plac...

Breast Cancer
Issues in Oncology

Impact of Informed Decision-Making on Breast Cancer Screening

Matthew Stenger  / May 10, 2015

In a study reported in Lancet, Jolyn Hersch, MApplSc, of the University of Sydney, and colleagues found that use of a decision aid containing information on overdetection in breast cancer screening was associated with an increased rate of informed choice regarding screening, a reduced rate of positi...

Breast Cancer
Issues in Oncology

Radiotherapy or Not in Older Women Receiving Breast-Conserving Surgery and Endocrine Treatment?

Matthew Stenger  / April 25, 2015

In the phase III PRIME II trial, designed to assess whether whole-breast irradiation could be omitted in women aged ≥ 65 years with early-stage breast cancer undergoing breast-conserving surgery and receiving adjuvant endocrine treatment, Ian H. Kunkler, MB BChir, FRCR, of Western General Hospital, ...

Breast Cancer

Analysis Shows No Link Between Aromatase Inhibitor–Related Musculoskeletal/Vasomotor Symptoms and Relapse-Free Survival

Matthew Stenger  / April 25, 2015

Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. In a study reported in the Journal of Clinical Oncology, Vered Stearns, MD, Professor...

Colorectal Cancer

Evidence of Recurrence-Free, Disease-Free, and Overall Survival Benefit of Aspirin and COX‑2 Inhibitor Use in Stage III Colon Cancer

Matthew Stenger  / April 25, 2015

In an analysis from the Cancer and Leukemia Group B (CALGB) 89803 adjuvant trial reported in the Journal of the National Cancer Institute, Kimmie Ng, MD, MPH, of Dana-Farber Cancer Institute, Boston, and colleagues found consistent trends suggesting benefit of aspirin use and cyclo-oxygenase-2 (COX-...

Breast Cancer

Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Matthew Stenger  / April 10, 2015

In a study reported in the Journal of Clinical Oncology, Edith A. Perez, MD, of the Mayo Clinic, Jacksonville, and colleagues found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who ha...

Lung Cancer

No Benefit of High- vs Standard-Dose Radiotherapy or Addition of Cetuximab to Chemoradiation in Stage IIIA/IIIB NSCLC

Matthew Stenger  / April 10, 2015

As reported in The Lancet Oncology by Jeffrey D. Bradley, MD, of Washington University, and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or addition of cetuximab (Erbitux) to concurrent pacli­taxel/carboplatin...

Bladder Cancer

No Overall Survival Difference for Immediate vs Deferred Chemotherapy After Radical Cystectomy in Muscle-Invasive Bladder Cancer

Matthew Stenger  / April 10, 2015

In the European Organisation for Research and Treatment of Cancer (EORTC) 30994 trial, a phase III intergroup study reported in The Lancet Oncology,1 Cora N. Sternberg, MD, FACP, Chief of Medical Oncology at San Camillo and Forlanini Hospitals, Rome, and colleagues found no overall survival differen...

Multiple Myeloma

Increased Progression-Free Survival With Addition of Carfilzomib to Lenalidomide/Dexamethasone in Relapsed Multiple Myeloma

Matthew Stenger  / April 10, 2015

In a planned interim analysis of the phase III ASPIRE trial reported in The New England Journal of Medicine, A. Keith Stewart, MB, ChB, of the Mayo Clinic, Scottsdale, Arizona, and colleagues found that the addition of the proteasome inhibitor carfilzomib (Kyprolis) to lenalidomide (Revlimid)/dexame...

Colorectal Cancer

Adding Cetuximab to First-Line FOLFIRI Does Not Benefit Metastatic Colorectal Cancer Patients With RAS Mutations

Matthew Stenger  / April 10, 2015

The phase III CRYSTAL trial showed that the addition of cetuximab (Erbitux) to first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) significantly improved overall survival, progression-free survival, and objective response rates in patients with KRAS codon 12/13 (exon 2) wild-type metastati...

Breast Cancer

Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery Used in Up to One-Third of Eligible Patients

Matthew Stenger  / March 25, 2015

In a study reported in JAMA, Justin E. Bekelman, MD, of the University of Pennsylvania Perelman School of Medicine, and colleagues found that approximately two-thirds of patients with early-stage breast cancer for whom hypofractionated whole-breast irradiation (for 3–5 weeks) was endorsed received c...

Breast Cancer
Survivorship
Thyroid Cancer

New Analysis Reports Increased Risk of Thyroid Cancer After Breast Cancer Diagnosis

The ASCO Post  / March 25, 2015  / 29939

Breast cancer survivors are at increased risk of developing thyroid cancer, especially within 5 years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results were presented at the Endocrine Society’s 97th Annual Meeting.1 “Recognition of this as...

Breast Cancer

Adjuvant Ovarian Suppression May Benefit Women With Premenopausal Breast Cancer Who Received Prior Chemotherapy

Matthew Stenger  / March 25, 2015

In a phase III trial (SOFT) reported in The New England Journal of Medicine, Prudence A. Francis, MD, of Peter MacCallum Cancer Centre, Melbourne, Australia, Meredith M. Regan, ScD, of IBCSG Statistical Centre at Dana-Farber Cancer Institute, Boston, and colleagues found that the addition of ovarian...

Issues in Oncology

Physician-Controlled Decisions in Cancer Care Linked to Lower Quality Rating

The ASCO Post  / March 25, 2015

Patients who described physician-controlled decisions about their cancer care vs shared decision-making were less likely to report receiving excellent quality of care, according to a study published by JAMA Oncology.1 The Institute of Medicine has called for shared decision-making and accommodation...

Breast Cancer
Gastrointestinal Cancer

Gastric, Breast Cancer Risk in Carriers of CDH1 Gene Mutations

The ASCO Post  / March 25, 2015

In a new study,1 more precise estimates of age-associated risks of gastric and breast cancer were derived for carriers of the CDH1 gene mutation, a cancer-predisposing gene that is abnormal in families meeting criteria for clinically defined hereditary diffuse gastric cancer (HDGC). David G. Huntsm...

Issues in Oncology

Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits

Jo Cavallo  / March 25, 2015

A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the major...

Kidney Cancer

Nivolumab Shows Activity in Previously Treated Metastatic Renal Cell Carcinoma

Matthew Stenger  / March 10, 2015

In a randomized phase II trial reported in the Journal of Clinical ­Oncology, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the programmed cell death protein-1 (PD-1) immune checkpoint inhibitor antibody nivolumab (Opdivo) was associated with an...

Lung Cancer

First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC

Matthew Stenger  / March 10, 2015

In a phase III trial (PROFILE 1014) reported in The New England Journal of Medicine, Benjamin J. Solomon, MB, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in first-li...

Hematologic Malignancies

Clonal Hematopoiesis With Somatic Mutations Increases Risk of Hematologic Cancer, Mortality, and Cardiovascular Disease

Matthew Stenger  / March 10, 2015

In two studies recently reported in The New England Journal of Medicine,1,2 whole-exome sequencing of DNA from peripheral blood cells of individuals unselected for hematologic phenotype showed that clonal hematopoiesis with somatic mutations is increasingly common with increasing age and is associat...

Breast Cancer

Combination Treatment Every 2 Weeks May Benefit Some Women With High-Risk Early-Stage Breast Cancer

Matthew Stenger  / March 10, 2015

In a phase III trial (SWOG S0221) reported in the Journal of Clinical Oncology, George T. Budd, MD, of Taussig Cancer Center, Cleveland Clinic, and colleagues found no difference in disease-free survival among four different combinations of continuous or every-other-week doxorubicin/cyclophosphamide...

Lymphoma

PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma

Matthew Stenger  / March 10, 2015

Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the programmed cell death protein 1 (PD-1) pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of the PD-1 l...

Issues in Oncology

Clinically Inappropriate Patient Demands of Oncologists Happen More Infrequently Than Expected

The ASCO Post  / March 10, 2015

A new study1 conducted at outpatient oncology centers found that only 1% of 5,050 patient-clinician encounters resulted in a clinically inappropriate request, of which very few were complied with by physicians. Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania, and colleagues analyzed ...

Colorectal Cancer

ASCO Endorses ESMO Guideline on Hereditary Colorectal Cancer Syndromes

Matthew Stenger  / February 25, 2015

Approximately 5% to 6% of cases of colorectal cancer are associated with germline mutations conferring an inherited predisposition for disease. As reported by Stoffel and colleagues in the Journal of Clinical Oncology,1 ASCO has endorsed, with qualifying statements, the European Society for Medical ...

Breast Cancer

No Benefit of Adding Iniparib to Gemcitabine/Carboplatin in Metastatic Triple‑Negative Breast Cancer

Matthew Stenger  / February 25, 2015

In a phase III trial reported in Journal of Clinical Oncology, Joyce O’Shaughnessy, MD, of Baylor Charles A. Sammons Cancer Center, Dallas, and colleagues found that the addition of iniparib to gemcitabine and carboplatin did not improve overall survival or progression-free survival in patients with...

Bladder Cancer

Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer

Matthew Stenger  / February 10, 2015

As reported in the Journal of the National Cancer Institute, Anirban P. Mitra, MD, PhD, of the University of Southern California, and colleagues identified a novel genome-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer.1 Use of the sign...

Gynecologic Cancers

Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer

The ASCO Post  / February 10, 2015

Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature Genetics...

Colorectal Cancer

Vitamin D Protects Against Colorectal Cancer by Boosting the Immune System

The ASCO Post  / January 25, 2015

A study by investigators at Dana-Farber Cancer Institute has demonstrated that vitamin D can protect some people with colorectal cancer by heightening the immune system’s vigilance against tumor cells. The research, released earlier this month by the journal Gut, shows a link between vitamin D and ...

Skin Cancer

Nivolumab Improves Outcomes vs Dacarbazine in Previously Untreated Advanced Melanoma Without a BRAF Mutation

Matthew Stenger  / January 25, 2015

In a phase III trial reported in The New England Journal of Medicine, Robert and colleagues found that the programmed cell death protein-1 (PD-1) immune-checkpoint–inhibitor antibody nivolumab (Opdivo) significantly increased overall survival, progression-free survival, and objective response rate c...

Head and Neck Cancer
Lung Cancer

Coupling Head and Neck Cancer Screening and Lung Cancer Scans Could Improve Early Detection, Survival

The ASCO Post  / January 25, 2015

Adding head and neck cancer screenings to recommended lung cancer screenings would likely improve early detection and survival, according to a multidisciplinary team led by scientists affiliated with the University of Pittsburgh Cancer Institute (UPCI), a partner with the University of Pittsburgh Me...

Breast Cancer

No Benefit of Adding Lapatinib to Fulvestrant in Hormone Receptor–Positive Advanced Breast Cancer

Matthew Stenger  / January 25, 2015

In a phase III trial (Cancer and Leukemia Group B [CALGB] 40302/Alliance) reported in the Journal of Clinical Oncology, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues found that the addition of the dual EGFR-HER2 inhibitor lapatinib (Tykerb) to endocrine therapy...

Prostate Cancer

Physical Activity Improves Survival for Men With Localized Prostate Cancer

The ASCO Post  / January 25, 2015

Among a large group of men with localized prostate cancer, those who engaged in higher levels of physical activity had lower rates of overall mortality and lower rates of prostate cancer-specific mortality, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.1 “Our re...

Breast Cancer
Gynecologic Cancers

Study Finds Whole-Genome Sequencing Is Successful in Identifying Patients’ Risk for Inherited Cancers

Jo Cavallo  / January 25, 2015

A study by researchers at The University of Texas Southwestern Medical Center in Dallas and The Ohio State University in Columbus of whole-genome sequencing on patients found to have BRCA1 or BRCA2 mutations as well as on those who were not carriers of a BRCA1/2 mutation has found cancer risk of pot...

Breast Cancer
Supportive Care
Integrative Oncology

SIO Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer

Matthew Stenger  / January 25, 2015

The Society for Integrative Oncology (SIO) Guidelines Working Group has recently released clinical practice guidelines on the use of integrative therapies as supportive care in patients receiving treatment for breast cancer. The guidelines, reported by Heather Greenlee, ND, PhD, MPH, of Mailman Scho...

Survivorship

ASCO Clinical Expert Statement on Cancer Survivorship Care Planning

Matthew Stenger  / December 15, 2014

Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete them, the lack of role clarity, and the lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship Care Planning W...

Lung Cancer

Crizotinib Is Highly Active in ROS1-Rearranged NSCLC

Matthew Stenger  / December 15, 2014

Crizotinib (Xalkori) produced a high response rate and durable responses in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to a study reported in The New England Journal of Medicine.1 Lead authors Alice T. Shaw, MD, PhD, of Massachusetts General Hospital Cancer Center, a...

Skin Cancer

Phase II Study Shows Improved Survival With Addition of Sargramostim to Ipilimumab in Metastatic Melanoma

Matthew Stenger  / December 15, 2014

Use of the granulocyte-macrophage colony-stimulating factor (GM-CSF) sargramostim (Leukine) together with the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor ipilimumab (Yervoy) prolonged overall survival but not progression-free survival in patients with metastatic melanoma, accordin...

Solid Tumors

Immune-Suppressing Protein in Noncancerous Cells of Cancer Patients Offers Clue to Drug Response

The ASCO Post  / December 15, 2014

A multicenter phase I study using an investigational immune therapy drug has found that the presence of the immune-suppressing protein PD-L1 in noncancerous immune cells can predict how patients with different types of advanced cancer will respond to treatment.  The study, led by a Yale Cancer Cente...

Head and Neck Cancer

Antacids Linked to Better Survival in Patients With Head and Neck Cancer

The ASCO Post  / December 15, 2014

Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a study from the University of Michigan Comprehensive Cancer Center. Results of the study were published in Cancer Prevention Research.1 Reflux can be a common side effect ...

Leukemia

CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory Acute Lymphoblastic Leukemia

Matthew Stenger  / December 1, 2014

In a study reported in The New England Journal of Medicine, Shannon L. Maude, MD, PhD, of Children’s Hospital of Philadelphia, and Noelle Frey, MD, of the Perelman School of Medicine, University of Pennsylvania, and colleagues reported achieving sustained remissions in children and adults with relap...

Issues in Oncology

Power Behind ‘Master’ Gene for Cancer Discovered

The ASCO Post  / December 1, 2014

A study at The University of Texas MD Anderson Cancer Center, Houston, led by Mong-Hong Lee, PhD, Professor of Molecular and Cellular Oncology, has demonstrated the significance of CSN6 in regulating Myc which may well open up a new pathway for treating and killing tumors. The study results are publ...

New Imaging Technique Identifies Receptors for Targeted Cancer Therapy

The ASCO Post  / December 1, 2014

Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in a recently published article in Cancer Research.1 “Protein overexpression is a hallmark of certai...

Colorectal Cancer

NORCCAP Trial Shows Reduced Colorectal Cancer Incidence and Mortality With Flexible Sigmoidoscopy Screening at 11 Years

Matthew Stenger  / December 1, 2014

The Norwegian Colorectal Cancer Prevention (NORCCAP) trial comparing colorectal cancer screening with flexible sigmoidoscopy vs no screening showed no reduction in colorectal cancer incidence or mortality after 7 years of follow-up. As reported by Øyvind Holme, MD, of Sorlandet Hospital Kristiansand...

Prostate Cancer

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: ASCO/CCO Clinical Practice Guideline

Matthew Stenger  / December 1, 2014

The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline was published in the Journal of Clinical Oncolog...

Gynecologic Cancers

Cancer-Killing Virus Plus Chemotherapy Studied in Recurrent Ovarian Cancer

The ASCO Post  / December 1, 2014

In 6 out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and 5-year survival is only 27%. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease. Researchers at The Ohio S...

Multiple Myeloma

Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma

Matthew Stenger  / December 1, 2014

In the phase III PANORAMA 1 trial reported in The Lancet Oncology, Jesus F. San-Miguel, MD, of Clinica Universidad de Navarra-CIMA, Pamplona, Spain, and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free surviva...

Study Finds Wide Variation in Quality, Content of Clinical Cancer Guidelines

The ASCO Post  / December 1, 2014

What’s the best way to treat rectal cancer? Consult any of five top clinical guidelines for rectal cancer and you will get a different answer, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. Their findings were published online in the journal Cancer...

Solid Tumors
Issues in Oncology

Proteome-Scale Map of the Human Interactome Network Created

The ASCO Post  / December 1, 2014

Researchers have produced a new largest-scale map of human protein interactions that will better enable scientists to trace how genetic changes lead to diseases ranging from cancer to Huntington’s disease. The expanded map, published in the journal Cell,1 is about 30% larger than the combination of ...

Palliative Care

Use of Hospice Care by Medicare Patients Associated With Lower Rate of Hospitalization, ICU Admission, Invasive Procedures, and Costs

The ASCO Post  / December 1, 2014

Medicare patients with poor­prognosis cancers who received hospice care had significantly lower rates of hospitalization, intensive care unit (ICU) admissions and invasive procedures at the end of life, along with significantly lower health care expenditures during the last year of life, according t...

Skin Cancer

Memorial Sloan Kettering Team Discovery Advances Understanding of Immunotherapy’s Successes—and Its Failures

The ASCO Post  / December 1, 2014

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to the CTLA-4 blocking antibody ipilimumab ­(Yervoy), an immunotherapy drug, while others do not. A rep...

Prostate Cancer

ASCO Endorses AUA/ASTRO Guideline on Adjuvant and Salvage Radiotherapy After Prostatectomy

The ASCO Post  / November 15, 2014

ASCO has issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical literature. The ASCO endorsement was published ...

Multiple Myeloma

Continuous Lenalidomide/Dexamethasone Improves Progression-Free  Survival in Transplant-Ineligible Patients With Myeloma

Matthew Stenger  / November 15, 2014

In the phase III FIRST trial reported in The New England Journal of Medicine, Lotfi Benboubker, MD, Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France, and colleagues found that continuous lenalidomide (Revlimid) plus dex...

Breast Cancer

Study Finds Significant Increase in Bilateral Mastectomy for Unilateral Breast Cancer Despite Lack of Survival Benefit

Matthew Stenger  / November 15, 2014

In an observational cohort study reported in JAMA, Allison W. Kurian, MD, MSc, Assistant Professor of Medicine and of Health Research and Policy at Stanford University School of Medicine, and colleagues assessed use of and mortality after bilateral mastectomy, breast-conserving surgery plus radiatio...

Gynecologic Cancers

Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer

Matthew Stenger  / November 15, 2014

In a phase III trial reported in the Journal of Clinical Oncology, ­Andreas du Bois, MD, PhD, Professor of Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany, and colleagues found that maintenance therapy with the vascular endothelial growth factor receptor (VEGFR) and platelet-derived g...

Skin Cancer
Cost of Care

U.S. Skin Cancer Costs Rise From 2002 Through 2011

The ASCO Post  / November 15, 2014

The costs associated with skin cancer increased five times as fast as treatments for other cancers between 2002 and 2011, according to a Centers for Disease Control and Prevention (CDC) study published online in the American Journal of Preventive Medicine.1 The average annual cost for skin cancer t...

Pancreatic Cancer

Study Sheds Light on Factors That May Contribute to Pancreatic Cancer

The ASCO Post  / November 15, 2014

New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings were recently published early online in Cancer.1 Pancreatic cancer is usually detected at a very late stage and has a 5-year survival rate of less than 5%. Strategies...

Skin Cancer

Ipilimumab/Sargramostim Improves Overall Survival vs Ipilimumab Alone in Patients With Advanced Metastatic Melanoma

Jo Cavallo  / November 15, 2014

A randomized clinical trial of patients with advanced metastatic melanoma treated with ipilimumab (Yervoy), an immune checkpoint inhibitor, in combination with sargramostim (Leukine), an immune stimulant, vs ipilimumab alone, has found a 1-year survival rate of 68.9% vs 52.9% in the ipilimumab-only ...

Survivorship
Lymphoma

Vigorous Exercise Lowers Risk of Cardiovascular Events in Adult Survivors of Childhood Hodgkin Lymphoma

Matthew Stenger  / November 15, 2014

In a report from the Childhood Cancer Survivor Study published in the Journal of Clinical Oncology,1 Lee W. Jones, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues found that vigorous exercise reduces the risk of major cardiovascular events in adult survivors of childhood Hodgkin lymph...

Multiple Myeloma

Impact of High-Dose Melphalan/Autologous Stem Cell Transplant and Lenalidomide Maintenance in Myeloma Patients ≤ Age 65

Matthew Stenger  / November 15, 2014

In a phase III trial reported in The New England Journal of Medicine, Antonio Palumbo, MD, Chief of the Myeloma Unit at the University of Turin, Italy, and colleagues found that high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival comp...

Breast Cancer

Long-Term Overall Survival Benefit Seen With Trastuzumab Added to Adjuvant Chemotherapy in Early-Stage HER2-Positive Breast Cancer

Matthew Stenger  / November 15, 2014

Earlier planned joint analyses of outcomes in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and the North Central Cancer Treatment Group (NCCTG) N9831 trial showed that adding trastuzumab (Herceptin) to adjuvant chemotherapy improved disease-free survival and overall sur...

Breast Cancer

Joint Analysis Further Confirms Well-Established Standard of Care in Early Breast Cancer

Edith A. Perez, MD  / November 15, 2014

This analysis demonstrates excellent news related to the long-term benefit of adding 1 year of trastuzumab (Herceptin) starting with the paclitaxel portion of adjuvant chemotherapy for patients with resected HER2-positive breast cancer. The study reflects the fact that excellent science in collabora...

Lung Cancer
Cost of Care

Dartmouth Study Finds Lung Cancer Screening With Low-Dose CT Could Be Cost-Effective

The ASCO Post  / November 15, 2014

Dartmouth researchers say lung cancer computed tomographic (CT) screening in the National Lung Screening Trial (NLST) meets a commonly accepted standard for cost-effectiveness as reported recently in The New England Journal of Medicine.1 The screening test uses annual low-dose CT scans to spot lung ...

Skin Cancer

Two Phase III Trials Show Benefit With BRAF/MEK Inhibitor Combination vs BRAF Inhibitor Alone in Advanced Melanoma

Matthew Stenger  / November 15, 2014

Two phase III trials have shown that the strategy of adding MEK inhibitor therapy to BRAF inhibitor therapy significantly improves progression-free survival in previously untreated patients with advanced BRAF-mutant melanoma.1,2 Overall survival benefit is also suggested by interim analysis in both ...

Gastrointestinal Cancer

Adding VEGFR2 Inhibitor Ramucirumab to Paclitaxel Increases Overall Survival as Second-Line Treatment for Advanced Gastric Cancer

Matthew Stenger  / November 15, 2014

In the phase III RAINBOW trial reported in The Lancet Oncology, Hansjochen Wilke, MD, Director of Medical Oncology/Hematology at Kliniken Essen-Mitte, Essen, Germany, and colleagues found that adding the vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor ramucirumab (Cyramza) to paclit...

Issues in Oncology
Colorectal Cancer

Half of Premature Colorectal Cancer Deaths Due to Socioeconomic Inequality

The ASCO Post  / November 15, 2014

Half of all premature deaths from colorectal cancer (described as deaths in people ages 25 to 64) in the United States are linked to ethnic, socioeconomic, and geographic inequalities, and therefore could be prevented according to a new study by American Cancer Society researchers. The report, which...

Leukemia

Kinase-Activating Alterations Identified in Most Cases of  Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia May Be Targetable With Available Tyrosine Kinase Inhibitors

Matthew Stenger  / November 15, 2014

In a study reported in The New England Journal of Medicine, Kathryn G. Roberts, PhD, of St. Jude Children’s Research Hospital, and colleagues performed detailed genomic analysis of patients with Philadelphia chromosome–like acute lymphoblastic leukemia (ALL) and identified kinase-activating alterati...

Lung Cancer

ASCO Endorses Guideline for Molecular Testing for Selecting Lung Cancer Patients for EGFR and ALK Inhibitor Treatment

Matthew Stenger  / November 15, 2014

ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor tr...

CNS Cancers

Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery Improves Survival in Better-Prognosis Patients With Brain Metastases

Joseph Cupolo  / November 15, 2014

In a secondary analysis utilizing the graded prognostic assessment—an improved diagnosis-specific index—patients with one to three brain metastases had no survival advantage when treated with whole-brain radiation therapy and stereotactic radiosurgery, compared with whole-brain radiotherapy alone, a...

Issues in Oncology

E-Cigarettes Unhelpful in Smoking Cessation Among Patients With Cancer

The ASCO Post  / November 1, 2014

In a new study of patients with cancer who smoke, those using e-cigarettes in addition to traditional cigarettes were more nicotine-dependent and equally or less likely to have quit smoking traditional cigarettes than nonusers.1 The rising use of e-cigarettes has raised many questions among patient...

Head and Neck Cancer

No Benefit Seen for Cetuximab Added to Cisplatin and Accelerated Radiotherapy in Advanced Head and Neck Carcinoma

Matthew Stenger  / November 1, 2014

Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in th...

Lung Cancer

Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC

Matthew Stenger  / October 15, 2014

In the phase III REVEL trial reported in Lancet, Edward B. Garon, MD, of the David Geffen School of Medicine at UCLA/Translational Research in Oncology–US Network, Los Angeles, and colleagues found that the addition of the antiangiogenic vascular endothelial growth factor receptor (VEGFR)-2 inhibito...

Breast Cancer

ASCO Clinical Practice Guideline: Chemotherapy and Targeted Therapy in Advanced HER2-Negative or HER2 Status–Unknown Breast Cancer

Matthew Stenger  / October 15, 2014

The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or HER2 status–unknown breast cancer. The guideline is published in the Journal of Clinical Oncology.1 In formulating the consensus gui...

Colorectal Cancer

Lower- vs Higher-Than-Expected Long-Term Colorectal Cancer Mortality After Removal of Lower- vs Higher-Risk Adenomas

Matthew Stenger  / October 15, 2014

Few data are available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Magnus Løberg, MD, of the Department of Health Management and Health Economics, University of Oslo, and colleagues found that patients ...

Pancreatic Cancer

Early Study Reports Modified Vitamin D Has Potential in Treatment for Pancreatic Cancer

The ASCO Post  / October 15, 2014

Researchers at the Salk Institute have reported on a synthetic derivative of vitamin D able to collapse the barrier of cells shielding pancreatic tumors, making this challenging cancer more susceptible to therapeutic drugs. The discovery has led to human trials for pancreatic cancer, even in advance...

Lymphoma

Time to Treatment Failure Similar With Rituximab Retreatment vs Maintenance in Low–Tumor Burden Follicular Lymphoma

Matthew Stenger  / October 15, 2014

Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low–tumor burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial ­(RESORT), reported in the Journal of Clinical Oncology, Brad S. Kahl, MD, of the University of Wis...

CNS Cancers

CENTRIC Trial Shows No Benefit of Adding Cilengitide to Therapy in Glioblastoma With Methylated MGMT Promoter

Matthew Stenger  / October 15, 2014

In the phase III CENTRIC/European Organisation for Research and Treatment of Cancer (EORTC) 26071-22072 trial reported in The Lancet ­Oncology, Roger Stupp, MD, of University Hospital Zurich, and colleagues found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard temo...

Gynecologic Cancers

Genetic ‘Hotspot’ Linked to Endometrial Cancer Aggressiveness

The ASCO Post  / October 15, 2014

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone, and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same. W...

Prostate Cancer

Primary Androgen Deprivation Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer

Matthew Stenger  / October 15, 2014

Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite the absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Grace L. Lu-Yao, MPH, PhD, of Rutgers Cancer Institute of...

Gynecologic Cancers

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

The ASCO Post  / October 15, 2014

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers &...

Supportive Care
Survivorship

Expert Consensus Recommends Echocardiograph as Cornerstone to Protecting Cancer Patients’ Heart Health

The ASCO Post  / October 15, 2014

Patients with cancer and survivors of cancer are living longer than ever before as a result of significant advances made over the past decade. Importantly, however, cardiovascular complications of their cancer treatment may present a life-threatening issue after their cancer treatment has ended. Sig...

Prostate Cancer

European Researchers at 13-Year Follow-up: Increased Absolute Benefit of PSA Screening in Prostate Cancer Mortality, but Time for Population-Based Screening Has Not Arrived

Matthew Stenger  / September 15, 2014

The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer ­(ERSPC), reported by Fritz H. Schröder, MD, PhD, Professor Emeritus of Urology at Erasmus University Medical Center, Rotterdam, the Netherlands, and colleagues in The Lancet, showed that prostate-specific antige...

Gynecologic Cancers

Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer

Matthew Stenger  / September 15, 2014

Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from vascular endothelial growth factor (VEGF) inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial ...

Breast Cancer

Study Quantifies Risk of Hereditary Breast Cancer in Carriers of PALB2 Mutations

Matthew Stenger  / September 15, 2014

In a study reported in The New England Journal of Medicine, Antonis C. Antoniou, PhD, Reader in Cancer Risk Prediction and Cancer Research UK Senior Cancer Research Fellow at the University of Cambridge, and colleagues identified lifetime risk of breast cancer in families with germline loss-of-funct...

Bladder Cancer

No Difference in Complication Rates or Hospital Stay With  Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer

Matthew Stenger  / September 15, 2014

Retrospective analyses indicate that robot-assisted laparoscopic surgery for radical cystectomy in patients with bladder cancer is associated with reduced risk of complications and shorter hospital stay compared with open surgery. In a small single-institution randomized trial reported in a letter t...

Breast Cancer

Adding Tomosynthesis to Digital Mammography Decreased Recall Rate, Increased Cancer Detection Rate in Breast Cancer Screening

Matthew Stenger  / September 15, 2014

In a large multicenter study reported in JAMA, Sarah M. Friedewald, MD, of the Advocate Lutheran General Hospital, Center for Advanced Care, Park Ridge, Illinois, and colleagues found that use of tomosynthesis plus digital mammography reduced the recall rate and increased the cancer detection rate i...

Breast Cancer

Study Finds Increased Breast Cancer Screening Costs in Medicare Population but No Increase in Cancer Detection

Matthew Stenger  / September 15, 2014

In a study of the use of breast cancer screening modalities in the Medicare population reported in Journal of the National Cancer Institute, Brigid K. Killelea, MD, MPH, FACS, and colleagues at Yale University School of Medicine, Yale Cancer Center, and Yale–New Haven Hospital, New Haven, Connecticu...

Issues in Oncology

Using Electronic Health Records to Improve Communication With Patients

Charlotte Bath  / September 15, 2014

Clinicians may argue that electronic health records (EHRs) interfere with the patient-physician relationship, and patients may complain about “distracted doctors,” too busy with computer screens to make eye contact, but according to Thomas W. LeBlanc, MD, MA, of Duke University School of Medicine an...

Issues in Oncology

Oncology Practice: What Are the Factors Driving Change?

Caroline McNeil  / September 1, 2014

Clinical practice changes in response to new medical evidence, but not always immediately or all at once. So what else determines whether and how quickly practice changes in response to evidence, for instance, that a widely used drug is effective only in patients with a certain biomarker? In a new ...

Lymphoma

Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma

The ASCO Post  / September 1, 2014

Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the National...

Prostate Cancer

Systematic Model Identifies Factors Associated With Adherence in Prostate Cancer Prevention Trial

The ASCO Post  / September 1, 2014

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo an end-of-study biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The Prostate Cancer Prevention Trial was...

Lung Cancer

Lung Screening–Detected Abnormalities Other Than Cancer Result in Smoking Cessation: National Lung Screening Trial Analysis

Matthew Stenger  / September 1, 2014

In a study reported in the Journal of the National Cancer Institute, Martin C. Tammemägi, PhD, of Brock University, Ontario, and colleagues assessed smoking cessation rates among participants undergoing chest x-ray or computed tomography (CT) screening for lung cancer in the National Lung Screening ...

Lung Cancer

Phase III Trial of Figitumumab Plus Chemotherapy in Advanced NSCLC Stopped Early for Futility and Increased Harm

Matthew Stenger  / September 1, 2014

In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal antibody fig...

Gastroesophageal Cancer
Palliative Care

No Overall Survival Improvement but Some Palliative Benefit With Gefitinib in Esophageal Cancer Progressing Postchemotherapy

Matthew Stenger  / August 15, 2014

In what may be the first randomized trial of systemic therapy in this setting, Susan J. Dutton, MSc, of University of Oxford, United Kingdom, and colleagues evaluated the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib vs placebo in patients with esophageal cancer progres...

Prostate Cancer

PREVAIL Trial: Enzalutamide Before Chemotherapy Prolongs Survival in Metastatic Prostate Cancer

Matthew Stenger  / August 15, 2014

The androgen-receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Tomasz M. Beer, MD, of OHS...

Pancreatic Cancer

Study Finds New Genetic Risk Markers in Pancreatic Cancer

The ASCO Post  / August 15, 2014

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the disease, report scientists from ­Dana-Farber Cancer Institute and other institutions worldwide. The markers are variations in the inherited DNA co...

Breast Cancer

Adjuvant Endocrine Therapy for Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Matthew Stenger  / August 15, 2014

ASCO has released a focused update of its clinical practice guideline on adjuvant endocrine therapy in women with hormone receptor–positive breast cancer.1 The focused update, formulated by Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues in the ASCO Update Commit...

Breast Cancer

Early Change in Chemotherapy Based on Elevated Circulating Tumor Cells Does Not Improve Outcome in Metastatic Breast Cancer

Matthew Stenger  / August 15, 2014

Elevated circulating tumor cells are associated with poor prognosis in metastatic breast cancer. In a phase III trial (Southwest Oncology Group [SWOG] S0500) reported in Journal of Clinical Oncology, Jeffrey B. Smerage, MD, PhD, Clinical Associate Professor in Medical Oncology at the University of M...

Prostate Cancer

Minority of Older Patients With Low-Risk Prostate Cancer Managed by Observation, Rates Vary Widely Among Urologists and Radiation Oncologists

Matthew Stenger  / August 15, 2014

Most older men with low-risk prostate cancer receive upfront treatment, despite the absence of a clear survival benefit and potential for morbidity. In a retrospective cohort study reported in JAMA Internal Medicine, Karen E. Hoffman, MD, MHSc, MPH, of The University of Texas MD Anderson Cancer Cent...

Survivorship

Childhood Cancer Survivors Hospitalized Frequently Years After Cancer Treatment

The ASCO Post  / August 15, 2014

Survivors of childhood cancers were hospitalized more often and for longer durations because of blood disorders and other problems, many years after cancer treatment was completed, compared with the general population, according to a study published in Cancer Epidemiology, Biomarkers & Preventio...

Thyroid Cancer

Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine–Refractory Differentiated Thyroid Cancer

Matthew Stenger  / July 25, 2014

Patients with radioactive iodine–­refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Marcia S. Brose, MD, PhD, of Abramson Cancer Center of the University of Pennsylvania, and colleagues ...

Gastroesophageal Cancer

Rilotumumab Added to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Matthew Stenger  / July 25, 2014

Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Timothy Iveson, MD, of the University Hospital Southampton NHS Foundatio...

Breast Cancer

Swiss Medical Board Members Discuss Recommendation to Phase Out Mammography Screening

Matthew Stenger  / July 25, 2014

In a New England Journal of Medicine “Perspective” article, Nikola Biller-Andorno, MD, PhD, of the University of Zurich and Harvard Medical School, and Peter Jüni, MD, of the University of Bern, provide the rationale for a recent report by the Swiss Medical Board advocating the phasing out of mammog...

Issues in Oncology

HIV-Infected People With Early-Stage Cancers Are Up to Four Times More Likely to Go Untreated for Cancer

The ASCO Post  / July 25, 2014

Human immunodeficiency virus (HIV)-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a large retrospective study from researchers in Penn Medicine’s Abramson Cancer Center and the National Can...

Lung Cancer

Surgical Biopsy Proves Safe for Selected Patients With Late-Stage Lung Cancer

The ASCO Post  / July 25, 2014

Researchers at the University of California Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (...

Breast Cancer

Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Advanced HER2-Positive Breast Cancer

Matthew Stenger  / July 10, 2014

There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute, Bo...

Breast Cancer

ASCO Clinical Practice Guideline: Disease Management in Advanced HER2-Positive Breast Cancer With Brain Metastases

Matthew Stenger  / July 10, 2014

As many as half of all patients with metastatic HER2-positive breast cancer develop brain metastases over time. The American Society of Clinical Oncology recently released a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases,...

Lung Cancer

Lung Cancer Mutation Consortium Finds Oncogenic Drivers in Majority of Metastatic Lung Adenocarcinomas

Matthew Stenger  / July 10, 2014

The Lung Cancer Mutation Consortium (LCMC) was formed to test adenocarcinomas of the lung for 10 oncogenic drivers in order to enable clinicians to select targeted treatments and enroll patients into suitable clinical trials. As recently reported in JAMA by Mark G. Kris, MD, William and Joy Ruane Ch...

Leukemia

Nonadherence With Maintenance Medication an Issue in Children With Leukemia

The ASCO Post  / July 10, 2014

An estimated 25% of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of the oral agent mercaptopurine, a maintenance medication that minimizes their risk of relapse when taken every day for 2 years, according to a study recently published online in Blood.1 The s...

Lung Cancer

Stronger Nicotine Dependency Associated With Higher Lung Cancer Risk

The ASCO Post  / July 10, 2014

A study by investigators at the National Cancer Institute (NCI) has indicated that people who are highly addicted to nicotine, ie, those who smoke their first cigarette within 5 minutes after awakening, are at higher risk of developing lung cancer than those who wait for 1 hour or more to smoke. The...

Breast Cancer

ASCO Clinical Practice Guideline: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer

Matthew Stenger  / June 25, 2014

Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein and these patients can benefit from HER2-targeted therapies. The American Society of Clinical Oncology recently released a clinical practice guideline on systemic therapy for patients with advanced HER2-po...

Colorectal Cancer

Colonoscopy Adenoma Detection Rate Inversely Proportional to Risk of Interval Colorectal Cancer and Colorectal Cancer Mortality

Matthew Stenger  / June 25, 2014

In a study of health-care organization data reported in The New England Journal of Medicine, Douglas A. Corley, MD, PhD, of Kaiser Permanente, and colleagues assessed the relationship between proportion of colonoscopies performed by a gastroenterologist that detect an adenoma and risk of subsequent ...

Issues in Oncology

Physician Attitudes About Multiplex Tumor Genomic Testing: Variation in Projected Use and Confidence

Matthew Stenger  / June 25, 2014

It is a widely expressed belief that predictive multiplex somatic genomic testing represents the ability to transform cancer care by identifying targetable alterations in multiple cancer genes. Do oncologists share this belief? How do they intend to use such tests in practice? In a study reported i...

Survivorship

Study Calls for Revisiting Guidelines for Screening Childhood Cancer Survivors at Risk of Congestive Heart Failure

The ASCO Post  / June 10, 2014

One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit. The researche...

Breast Cancer

ASCO Clinical Practice Guideline Update: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer

Matthew Stenger  / June 10, 2014

ASCO recently convened an update committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy to develop evidence-based recommendations that update the ASCO 2005 clinical practice guideline on use of sentinel node biopsy in patien...

Breast Cancer

Postmastectomy Radiotherapy Reduces Breast Cancer Recurrence and Mortality in Women With One to Three Positive Nodes

Matthew Stenger  / June 10, 2014

Meta-analyses have shown that postmastectomy radiotherapy reduces risks of recurrence and breast cancer mortality in the population of all women with node-positive disease, but outcomes in those with only one to three positive nodes have not been specifically examined. As reported by Paul McGale, Ph...

Issues in Oncology

Hookah Tobacco Smoking Among Students

The ASCO Post  / June 10, 2014

Educational campaigns meant to dissuade college students from initiating hookah tobacco smoking may be more successful if they combat positive perceptions of hookah use as attractive and romantic, rather than focusing solely on the harmful components of hookah tobacco smoke, a new University of Pitt...

Breast Cancer

ASCO Endorses SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I/II Breast Cancer

Matthew Stenger  / June 10, 2014

As reported in the Journal of Clinical Oncology,1 ASCO has endorsed the recently published Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive brea...

Issues in Oncology

Water Pipe Smoking May Increase Risk for Cancer

The ASCO Post  / June 10, 2014

Young adults who smoked water pipes in hookah bars had elevated levels of nicotine, cotinine, tobacco-related cancer-causing agents, and volatile organic compounds in their urine, and this may increase their risk for cancer and other chronic diseases, according to a study published in Cancer Epidem...

Survivorship
Symptom Management

ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers

Matthew Stenger  / May 15, 2014

ASCO has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology.1 The guidelines resulted from the efforts of an expert panel, with representation from the fields of med...

Supportive Care

ASCO Releases Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer

Matthew Stenger  / May 15, 2014

Detection of depression is suboptimal, and its severity is underestimated in the general population, but it is known psychiatric disorders are more common in patients with cancer than in those with any other chronic illness. Although studies in cancer patients have yielded varying figures, it is est...

Supportive Care
Survivorship

ASCO Releases Adapted Guideline on Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer

Matthew Stenger  / May 15, 2014

A majority of cancer patients experience some level of fatigue during the course of their treatment, and approximately 30% contend with persistent fatigue for years after treatment. Fatigue is among the most common and distressing long-term effects of cancer treatment and significantly affects patie...

Lung Cancer

Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC

Matthew Stenger  / May 15, 2014

Non-small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Alice T. Shaw, MD, PhD, of Dana-Farber/Harvard Cancer Center, Boston, and colle...

Lung Cancer

Phase III Study Explores Addition of Nintedanib to Docetaxel in Second-Line Treatment of Non–Small Cell Lung Cancer

Matthew Stenger  / May 15, 2014

In a phase III trial (LUME-Lung 1) reported in The Lancet Oncology, Reck et al assessed the addition of nintedanib to docetaxel in second-line treatment of non–small cell lung cancer (NSCLC).1 The combination significantly improved progression-free survival in all patients and improved overall survi...

Prostate Cancer

Continued Survival Benefits Seen With Radical Prostatectomy vs Watchful Waiting in Long-Term Follow-up of the SPCG-4 Trial

Matthew Stenger  / May 15, 2014

The long-term benefits of radical prostatectomy vs watchful waiting in men with localized prostate cancer has remained a debated issue. As reported in The New England Journal of Medicine by Anna Bill-Axelson, MD, of Uppsala University Hospital, and colleagues, additional long-term follow-up in the S...

Colorectal Cancer

Neoadjuvant Chemotherapy Without Routine Radiotherapy Shows Promise in Patients With Locally Advanced Rectal Cancer

Matthew Stenger  / May 15, 2014

In a pilot study reported in the Journal of Clinical Oncology, Deborah Schrag, MD, MPH, and colleagues from Memorial Sloan Kettering Cancer Center, New York, assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with selective use of chemoradiotherap...

Pain Management

Phase III Trial Reports Focused Ultrasound Reduces Cancer Pain

The ASCO Post  / May 15, 2014

A phase III clinical trial has shown that noninvasive magnetic resonance-guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited. The results were published recently in the Journal of th...

Breast Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer

ASCO Committee Defines Clinically Meaningful Goals for Clinical Trials in Pancreas, Breast, Lung, and Colorectal Cancers

Matthew Stenger  / May 15, 2014

The ASCO Cancer Research Committee recently convened four disease-specific working groups—in pancreas, breast, lung, and colon cancers—to “consider the design of future clinical trials that would produce results that are clinically meaningful to patients.” An ASCO perspective statement, reported in ...

Thyroid Cancer

Increased Incidence of Thyroid Cancer: An Epidemic of Diagnosis?

Matthew Stenger  / May 15, 2014

In a study reported in JAMA Otolaryngology Head & Neck Surgery,1 Davies and Welch found that the incidence of thyroid cancer has nearly tripled since 1975. However, the increase appears to represent an “epidemic of diagnosis” and to almost exclusively represent increased diagnosis of papillary t...

Survivorship

Elevated Morbidity/Mortality Risks for Childhood Cancer Survivors Further Increase After Fourth Decade

Charlotte Bath  / May 15, 2014

An analysis of the first generation of childhood cancer survivors, who are now aging into their fourth and fifth decades, shows further increases in the survivors’ morbidity and mortality risks. “By age 50 years, more than half of survivors have experienced a severe, disabling, or life-threatening e...

Gynecologic Cancers

AURELIA Trial: Adding Bevacizumab to Chemotherapy Improves Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

Matthew Stenger  / May 1, 2014

Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, and colleagues found that the addition of bevacizumab (Avastin) to chemoth...

Lung Cancer

Lack of Insurance Coverage a Barrier to Lung Cancer Screening

The ASCO Post  / May 1, 2014

The majority of current and former smokers would welcome screenings for lung cancer if their insurance covered the spiral computed tomography (CT) scans, according to research from Roswell Park Cancer Institute and the Medical University of South Carolina. The study by Jennifer Delmerico, MPH, and c...

Breast Cancer

SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery in Stage I/II Invasive Breast Cancer

Matthew Stenger  / April 15, 2014

The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) formed a multidisciplinary expert panel in 2013 to examine the relationship between surgical margin width and ipsilateral breast tumor recurrence and develop guidelines on margins for breast-conserving surgery...

Bladder Cancer

Bladder Cancer Patient With Rare Genetic Mutations Shows Exceptional Response to Everolimus/Pazopanib Combination

The ASCO Post  / April 15, 2014

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus (Afinitor) and pazopanib (Votrient) in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a s...

Breast Cancer

No Mortality Benefit of Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study

Matthew Stenger  / April 15, 2014

As reported in BMJ by Anthony B. Miller, MD, Professor Emeritus at the Dalla Lana School of Public Health, University of Toronto, and colleagues, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer com...

Colorectal Cancer

FACS Trial: Intensive Follow-up Increases Surgical Treatment of Recurrence With Curative Intent in Colorectal Cancer

Matthew Stenger  / April 15, 2014

In the FACS trial, reported in JAMA, John N. Primrose, MD, FRCS, of University of Southampton, England, and colleagues compared outcomes with intensive follow-up with carcinoembryonic antigen (CEA) measurement, computed tomography (CT), both, or minimum follow-up after curative surgery for primary c...

Prostate Cancer

Complications Other Than Incontinence or Erectile Dysfunction After Prostatectomy or Radiotherapy for Prostate Cancer

Matthew Stenger  / April 15, 2014

Studies of complications of surgery or radiotherapy for prostate cancer generally focus on incontinence and erectile dysfunction. In a population-based cohort study reported in The Lancet Oncology, Robert Nam, MD, MSc, FRCS(C), Professor of Surgery, Sunnybrook Health Sciences Centre, University of T...

Breast Cancer

Study Shows Pathologic Complete Response to Neoadjuvant Therapy for Breast Cancer of Prognostic Value but Not for Use as Surrogate for Survival

Matthew Stenger  / April 15, 2014

Pathologic complete response to neoadjuvant therapy has been proposed as a surrogate endpoint for long-term clinical benefit in breast cancer. The U.S. Food and Drug Administration (FDA) established the international Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) working group to perfor...

Prostate Cancer

Does ‘Specialist Bias’ Contribute to Overtreatment of Prostate Cancer?

Charlotte Bath  / April 15, 2014

Specialist bias, in which specialists recommend the therapy that they are capable of delivering, is thought to influence the treatment of patients with localized prostate cancer and to contribute to overtreatment of men with limited life expectancy,” Ayal A. Aizer, MD, MPH, and colleagues, from the ...

Supportive Care

Two Behavioral Interventions Help Cancer Patients Struggling With Sleep Issues, Penn Medicine Study Finds

The ASCO Post  / April 15, 2014

Patients with cancer who are struggling with sleep troubles, due in part to pain or side effects of treatment, can count on two behavioral interventions for relief—cognitive behavioral therapy for insomnia and mindfulness-based stress reduction—Penn Medicine researchers reported in a recent study pu...

Colorectal Cancer

Colorectal Cancer Screening: Quality Measures Should Focus on Patient Benefit Over Age Alone, Study Reports

The ASCO Post  / March 15, 2014

Screening for colorectal cancer based on age alone may contribute to both underuse and overuse of colonoscopy, sigmoidoscopy, and fecal occult blood testing among older people, according to a study by investigators at the University of Michigan and the Veterans Affairs Center for Clinical Management...

Prostate Cancer
Skin Cancer

History of Prostate Cancer Increases Risk of Melanoma in White Men

Matthew Stenger  / March 15, 2014

History of severe acne, which is a surrogate for high androgen activity, has been associated with increased risk of prostate cancer, and recent data suggest that severe teenage acne is a risk factor for melanoma. Such findings suggest a role of androgens in etiology for both prostate cancer and mela...

Leukemia
Cost of Care

Higher Copayment Associated With Greater Discontinuation of and Nonadherence to Tyrosine Kinase Inhibitor Treatment in CML

Matthew Stenger  / March 15, 2014

The availability of the tyrosine kinase inhibitor imatinib (Gleevec) has dramatically increased survival in chronic myeloid leukemia (CML). Nonadherence to therapy with imatinib and other tyrosine kinase inhibitors is associated with disease progression and treatment resistance. In a study reported ...

Skin Cancer

Brigham and Women’s Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Outperforms AJCC and UICC Staging

Matthew Stenger  / March 15, 2014

In a study reported in the Journal of Clinical Oncology, Pritesh S. Karia, MPH, and Chrysalyne D. Schmults, MD, MSCE, of Brigham and Women’s Hospital, Boston, and colleagues compared Brigham and Women’s Hospital, American Joint Committee on Cancer (AJCC), and International Union Against Cancer (UICC...

Breast Cancer

Delayed Adjuvant Chemotherapy Associated With Poorer Overall Survival in Breast Cancer

Matthew Stenger  / March 15, 2014

In a study reported in the Journal of Clinical Oncology, de Melo Gagliato et al from The University of Texas MD Anderson Cancer Center, Houston, assessed the association between time to adjuvant chemotherapy and survival in breast cancer patients.1 They found that delay of therapy is associated with...

Issues in Oncology

Telephone Education and Counseling Effective in Programs Targeting Familial/Genetic Cancer Risk Screening

Matthew Stenger  / March 15, 2014

Two studies recently reported in the Journal of Clinical Oncology indicate that telephone-based education or counseling initiatives can be successful in educating individuals at familial or genetic risk of cancer and in inducing these at-risk individuals to undergo recommended screening. In the Fam...

Survivorship
Leukemia
Lymphoma

Long-Term Decline in Neuropsychological Function Seen After Cranial Radiotherapy for Pediatric Lymphoid Malignancy

Matthew Stenger  / March 15, 2014

Central nervous system–directed chemotherapy and cranial radiotherapy for childhood acute lymphoblastic leukemia or lymphoma have neurotoxic effects. In a study reported in Journal of Clinical Oncology, Ilse Schuitema, MSc, of Leiden University, and colleagues evaluated white matter changes and neur...

Breast Cancer
Supportive Care

Cognitive-Behavioral Therapy Plus Hypnosis Controls Fatigue in Breast Cancer Patients Receiving Radiotherapy

Matthew Stenger  / March 15, 2014

In a study reported in the Journal of Clinical Oncology,1 Guy H. ­Montgomery, PhD, Icahn School of Medicine at Mount Sinai, New York, and colleagues found that an intervention consisting of cognitive-behavioral therapy plus hypnosis produced better control of fatigue than supportive meetings with tr...

Breast Cancer

No Mortality Benefit of Breast Cancer Mammography Screening in 25-Year Follow-up of Canadian National Breast Screening Study

Matthew Stenger  / March 1, 2014

As reported in BMJ by Anthony B. Miller, MD, Professor Emeritus at the Dalla Lana School of Public Health, University of Toronto, and colleagues, the 25-year follow-up of the Canadian National Breast Screening Study has shown no mortality benefit of annual mammography screening for breast cancer com...

Pain Management

Short-Term Follow-Up Reveals Suboptimal Pain Relief and Marked Pain Worsening in Ambulatory Patients With Cancer

Matthew Stenger  / March 1, 2014

In an analysis reported in the Journal of Clinical Oncology, Fengmin Zhao, MS, PhD, Dana-Farber Cancer Institute, Boston, and colleagues assessed factors associated with pain severity changes in ambulatory patients with invasive solid tumors (breast, prostate, colon/rectum, or lung) in the Eastern C...

Lymphoma

Breast Implant–Associated Anaplastic Large Cell Lymphoma Shows Better Outcome in Cases With No Distinct Tumor Mass

Matthew Stenger  / February 15, 2014

Only recently described, breast implant–associated anaplastic large cell lymphoma usually presents as an effusion-associated fibrous capsule surrounding the implant and less frequently as a mass. Little is known about the natural history and long-term outcomes of such disease. In a study reported in...

Breast Cancer

ASCO and College of American Pathologists Guideline Update: Recommendations for HER2 Testing in Breast Cancer

Matthew Stenger  / February 15, 2014

The American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) recently convened an Update Committee to conduct a systematic literature review and update recommendations for optimal HER2 testing. In particular, the Committee identified criteria and areas requiring clarif...

Prostate Cancer

Long-Term Follow-up Indicates Increased Telomere Length With Lifestyle Change in Men With Low-Risk Prostate Cancer

Matthew Stenger  / February 15, 2014

Short telomere length in peripheral blood mononuclear cells is associated with aging and age-related diseases such as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal r...

Skin Cancer

Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas Subset May Be Sensitive to MEK Inhibition 

Jo Cavallo  / January 15, 2014

A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular subset of melan...

Breast Cancer

Younger Women With Younger Children Less Likely to Receive Radiation Therapy After Breast-Conserving Surgery for Breast Cancer

Matthew Stenger  / January 15, 2014

In a study reported in the Journal of the National Cancer Institute, Pan et al assessed factors associated with noncompliance with recommended radiation therapy following breast-conserving surgery for breast cancer.1 A primary factor in underuse of radiation therapy was younger patients having child...

Gynecologic Cancers

Genetic Flaw That Drives Some Ovarian Cancers Identified

The ASCO Post  / January 15, 2014

Researchers at Dana-Farber Cancer Institute, Boston, have identified an overactive gene that drives about one-third of high-grade serous ovarian tumors—the most common and malignant type of ovarian cancer. The gene, GAB2, isn’t mutated or abnormal, but triggers cancerous cell growth because the gene...

Kidney Cancer

Tivozanib Improves Progression-Free but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Matthew Stenger  / January 15, 2014

The investigational agent tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3. In a phase III trial reported in the Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC), and colleag...

Colorectal Cancer

Study Explores Protective Effect of Aspirin Against Colorectal Cancer

Matthew Stenger  / January 15, 2014

It has been posited that aspirin treatment may reduce risk for colorectal cancer through inhibition of WNT/cadherin-associated protein β1 (CTNNB1, or β-catenin) signaling. In a study reported recently in the Journal of the National Cancer Institute, Nan et al investigated the potential role of the s...

Colorectal Cancer

Overall Survival Improved by Adding Panitumumab to FOLFOX4 but Only in Metastatic Colorectal Cancer Without RAS Mutation

Matthew Stenger  / January 15, 2014

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 and patients with  other activating RAS mutations do not benefit from anti–epidermal growth factor receptor (EGFR) therapy and may in fact be harmed by it. In an analysis reported in The New England Journal of Medicine ...

Breast Cancer

Targeted Intraoperative Radiotherapy Plus Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Breast Cancer Recurrence

Matthew Stenger  / January 15, 2014

In the randomized noninferiority TARGIT-A trial reported in The Lancet, Jayant S. Vaidya, PhD, FRCS, and Michael Baum, MD, FRCS, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiot...

Breast Cancer

Cautious Comments on the TARGIT-A Trial

Thomas A. Buchholz, MD, and Benjamin D. Smith, MD  / January 15, 2014

Numerous randomized trials have demonstrated that whole-breast irradiation plays an important role after breast-conserving surgery for invasive breast cancer. A recent meta-analysis of these trials indicated that whole-breast irradiation decreased the risk of total breast cancer relapse events and i...

Prostate Cancer

L-Type Amino Acid Transporters (LAT) Inhibition May Be a New Therapeutic Option for Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  / January 15, 2014

L-type amino acid transporters (LATs) uptake neutral amino acids including L-leucine into cells, stimulating mTOR complex 1 (mTORC1) signaling and protein synthesis. LAT1 and LAT3 are overexpressed at different stages of prostate cancer and are involved in increasing nutrients and stimulating cell g...

Prostate Cancer

Inhibition of LAT Transporters and Leucine Uptake: A Step Forward for Therapeutic Strategies in Prostate Cancer  

Elizabeth R. Kessler, MD, and E. David Crawford, MD  / January 15, 2014

The seminal study by Wang and colleagues reported in the Journal of the National Cancer Institute1 and reviewed in this issue of The ASCO Post suggests a potential new therapeutic option in the treatment of advanced prostate cancer. The authors draw attention to the reliance of cancer cells on amino...

Hematologic Malignancies

Donor KIRDL1-R245 Allele Predicts Improved Survival and Reduced Progression in Pediatric Allogeneic Stem Cell Transplant

Matthew Stenger  / January 15, 2014

Killer-cell immunoglobulin-like receptors (KIRs) that regulate natural-killer cells are highly polymorphic, and some KIR2DL1 alleles (ie, KIR2DL1-R245) encode receptors characterized by stronger signaling function than others (ie, KIR2DL1-C245). In a study reported in the Journal of Clinical Oncolog...

Survivorship

Improvements Needed in Use of Survivorship Care Plans 

Matthew Stenger  / January 15, 2014

Survivorship care plans, consisting of treatment summaries and follow-up plans, are intended to promote coordination of post-treatment cancer care, but little is known about how survivorship care plans are being used in routine oncology practice. In a study reported in the Journal of the National Ca...

Survivorship

Making Progress in Survivorship Care Planning

Mary McCabe, RN, MS  / January 15, 2014

The recommendation that a survivorship care plan be provided to patients and their primary care providers was first presented in the 2006 Institute of Medicine (IOM) report, From Cancer Patient to Cancer Survivor: Lost in Transition. The IOM committee proposed that this document include two parts—a ...

Issues in Oncology

Sharing Treatment Decision-Making With Patients: Where’s the Evidence of Value?

Caroline Helwick  / December 15, 2013

Though certainly not new to oncologists, “shared decision-making” between doctors and patients is receiving increased attention in the medical community today. While it’s an idea with merit, Steven J. Katz, MD, MPH, a specialist in quality care issues, maintains that expectations about the potential...

Lymphoma

Autologous Transplantation as Consolidation Improves Progression-Free Survival in Aggressive Non-Hodgkin Lymphoma

Matthew Stenger  / December 15, 2013

The strategy of autologous stem-cell transplantation as consolidation in high-intermediate– or high-risk diffuse aggressive non-Hodgkin lymphoma (NHL) has not been specifically examined in the rituximab (Rituxan) era. In the phase III Southwest Oncology Group (SWOG)-led intergroup 9704 trial reporte...

Breast Cancer

Long-Term Follow-up of the HERA Trial Shows No Benefit of 2 Years vs 1 Year of Trastuzumab in Early Breast Cancer 

Matthew Stenger  / December 15, 2013

As reported in The Lancet by Aron Goldhirsch, MD, of the European Institute of Oncology in Milan, Italy, and colleagues from the Breast International Group (BIG), the comparison of 1 vs 2 years of trastuzumab (Herceptin) in patients with HER2-positive early breast cancer in the phase III HERA trial ...

Breast Cancer

Similar High Complete Response Rate With Neoadjuvant Trastuzumab, Lapatinib, and Combined Therapy in HER2-Positive Breast Cancer

Matthew Stenger  / December 15, 2013

In a phase III trial (NSABP B-41) performed to assess the potential benefit of neoadjuvant dual HER2 blockade in HER2-positive breast cancer, André Robidoux, MD, of Centre Hospitalier de l’Université de Montréal, and colleagues in the National Surgical Adjuvant Breast and Bowel Project (NSABP) evalu...

Prostate Cancer

Adding Abiraterone to Prednisone Significantly Prolongs Time to Pain Progression in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  / December 15, 2013

An interim analysis of the COU-AA-302 phase III trial in asymptomatic or mildly symptomatic chemotherapy-naive men with metastatic castration-resistant prostate cancer showed that the addition of abiraterone (Zytiga) to prednisone significantly delayed radiographic progression and improved overall s...

Lung Cancer

No Apparent Benefit of Adjuvant Gefitinib in Resected NSCLC in Prematurely Closed Trial

Matthew Stenger  / December 15, 2013

As reported in Journal of Clinical Oncology by Glenwood D. Goss, MD, of the Ottawa Hospital Cancer Center, and colleagues, the prematurely closed NCIC CTG BR19 study showed no apparent survival benefit of adjuvant gefitinib (Iressa, withdrawn from U.S. market) vs placebo in patients with completely ...

CNS Cancers

Investigators Report Valganciclovir May Increase Survival in Glioblastoma

Matthew Stenger  / December 15, 2013

In a letter to The New England Journal of Medicine, Cecilia Söderberg-­Nauclér, MD, PhD, and colleagues from the Karolinska Institutet, Stockholm, described experience with the anti-cytomegalovirus (CMV) agent valganciclovir (Valcyte) in the treatment of glioblastoma, citing dramatically improved ov...

Issues in Oncology

NCI-Led Scientists Develop Criteria for 'Omics' Tests Used in Clinical Investigations

Caroline Helwick  / December 15, 2013

High-throughput “omics” technologies that generate molecular profiles on tumor specimens are increasingly being incorporated into clinical trials, but some of these assays have not been well validated, leading many in the research community to question their fitness for use in patient-care decisions...

Breast Cancer

GeparTrio Long-Term Data Show Response-Guided Neoadjuvant Therapy for Breast Cancer Improves Survival

Matthew Stenger  / December 1, 2013

In an exploratory analysis of long-term survival data from the GeparTrio trial reported in the Journal of Clinical Oncology, Gunter von Minckwitz, MD, PhD, of the German Breast Group in Neu-Isenburg and the University of Frankfurt, Germany, and colleagues found that response-guided neoadjuvant chemo...

Pancreatic Cancer

Adjuvant Gemcitabine Improves Long-Term Survival in Patients With Resected Pancreatic Cancer

Matthew Stenger  / December 1, 2013

An initial report from the phase III Charité Onkologie (CONKO) 001 trial of adjuvant gemcitabine vs observation in patients with completely resected pancreas cancer showed that gemcitabine treatment was associated with a significant prolongation of disease-free survival.1 As reported in JAMA by Helm...

Pancreatic Cancer

Addition of Nab-Paclitaxel to Gemcitabine Improves Survival in Previously Untreated Metastatic Pancreas Cancer 

Matthew Stenger  / December 1, 2013

In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of albumin-bound paclitaxel (nab-paclitaxel [Abraxane]) to gemcitabine in patients with previously untreated met...

Gastroesophageal Cancer
Gastrointestinal Cancer

Anti–VEGFR-2 Antibody Ramucirumab Prolongs Survival in Previously Treated Advanced Gastric or Gastroesophageal Cancer

Matthew Stenger  / December 1, 2013

Vascular endothelial growth factor (VEGF)– and VEGF receptor-2 (VEGFR-2)–mediated signaling and angiogenesis seem to have an important role in the pathogenesis of gastric cancer. In the phase III REGARD trial reported in Lancet, Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, Boston, and...

Lymphoma

Rituximab Does Not Improve Outcome in B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found 

Matthew Stenger  / December 1, 2013

In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in the Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...

Breast Cancer

No Survival Benefit of Adjuvant Ibandronate in High-Risk Early Breast Cancer: Potential Activity in Low-Estrogen Patients 

Matthew Stenger  / December 1, 2013

The effect of bisphosphonate treatment in early breast cancer is controversial, with some data indicating survival benefit in the adjuvant setting. In a study reported in the Journal of Clinical Oncology (German Adjuvant Intergroup Node-Positive Study, GAIN), Gunter von Minckwitz, MD, PhD, Chairman ...

Breast Cancer

Alliance Trial Evaluates Sentinel Node Surgery After Neoadjuvant Chemotherapy for Node-Positive cN1 Breast Cancer

Matthew Stenger  / December 1, 2013

Sentinel lymph node surgery provides reliable nodal staging information and is associated with less morbidity than axillary lymph node dissection in patients with clinically node-negative (cN0) breast cancer. The American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) trial examined th...

Head and Neck Cancer

Spanning a Spectrum of Issues Related to Head and Neck Cancers

Charlotte Bath  / December 1, 2013

Five recent articles in JAMA Otolaryngology–Head & Neck Surgery1-5 span a spectrum of issues related to head and neck cancers. These include risk factors, concentration of care to teaching hospitals, avoiding venous thromboembolism, and encouraging patients to eat and do swallowing exercises to ...

Breast Cancer
Cost of Care

Cost-Effectiveness of MRI Screening for Women With Familial Risk of Breast Cancer in the Netherlands 

Matthew Stenger  / December 1, 2013

Annual screening for breast cancer with magnetic resonance imaging (MRI) has been found to be cost-effective in women aged 30 to 60 years who are BRCA1 or BRCA2 carriers or who have a 50% chance of being a carrier, and such screening is recommended in these women by many authorities. It is unclear w...

Colorectal Cancer

Impact of Deficient DNA Mismatch Repair on Disease-Free Survival in Stage III Colon Cancer 

Matthew Stenger  / November 15, 2013

In an analysis reported in the Journal of Clinical Oncology, Frank A. Sinicrope, MD, of the Mayo Clinic and North Central Cancer Treatment Group (NCCTG), and colleagues investigated the association of deficient DNA mismatch repair with prognosis in patients with stage III colon cancer treated with a...

In Mismatch Repair–Deficient Colon Cancer, Side Matters

Leonard B. Saltz, MD  / November 15, 2013

In general, we have come to think of mismatch repair–deficient colon cancer as having a more favorable prognosis, being less likely to metastasize to regional nodes or distant sites, and being resistant to fluoropyrimidines. Much of our data, however, come from trials combining stage II and III pati...

Gynecologic Cancers

One Dose of HPV 16/18 Vaccine Produces Durable Response, Study Finds

Jo Cavallo  / November 15, 2013

Results from the Costa Rica HPV 16/18 Vaccine Trial indicate that 4-year efficacy against 12-month HPV 16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle vaccine (Cervarix). The findings sugg...

Colorectal Cancer

Long-Term Colorectal Cancer Incidence and Mortality After Lower Endoscopy

Matthew Stenger  / November 15, 2013

Colonoscopy and sigmoidoscopy have been shown to provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against proximal colon cancer, remain undefined. A study of long-term colorectal cancer incidence and mortality after lower endoscopy reported in ...

Hepatobiliary Cancer

Brivanib Studied in First- and Second-Line Therapy for Advanced Hepatocellular Carcinoma 

Matthew Stenger  / November 15, 2013

The investigational drug brivanib is a dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. The agent was recently evaluated in two phase III trials, one comparing first-line brivanib with sorafenib (Nexavar) in adv...

Hepatobiliary Cancer

Brivanib Fails to Live Up to the Promise of Early Studies

Laura Williams Goff, MD, MS  / November 15, 2013

Hepatocellular carcinoma is a devastating disease worldwide. Although advances in liver transplantation, surgery, and locoregional therapies have made tumor control or even cure possible for a minority of patients, the majority of patients diagnosed with hepatocellular carcinoma will develop advance...

Prostate Cancer

No Difference in Long-Term Survival With Finasteride or Placebo in the Prostate Cancer Prevention Trial 

Matthew Stenger  / November 15, 2013

In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...

Prostate Cancer

Finasteride for Prostate Cancer Prevention: Long-Term Results Disappointing but Reassuring

Michael L. LeFevre, MD, MSPH  / November 15, 2013

All medical care should seek to achieve one or more of three goals: to relieve suffering, to prevent future suffering, or to prolong life. Care for cancer is no exception, and minimizing suffering from cancer and prolonging life has primarily resulted from advances in treatment. Although there are a...

Breast Cancer

Breast Cancer Index Assay Prognostic for Distant Recurrence in Estrogen Receptor–Positive, Node-Negative Breast Cancer

Matthew Stenger  / November 15, 2013

In a study reported in The Lancet Oncology, Dennis C. Sgroi, MD, of Massachusetts General Hospital, and colleagues compared the ability of the breast-cancer index (BCI) assay, 21-gene recurrence score (Oncotype DX), and an immunohistochemical prognostic model (IHC4) to predict early and late distant...

Lymphoma

Multicenter Analysis of Outcomes of Lymphoma in Pregnancy

Matthew Stenger  / November 15, 2013

Lymphoma is the fourth most frequent cancer to occur in pregnant women. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, Chief of Hematology/Oncology at Tufts University Medical Center, Boston, and colleagues examined treatment, complication...

Lymphoma

Two Patients in One, Mom and Baby: Managing Coincident Pregnancy and Lymphoma

Joseph M. Connors, MD  / November 15, 2013

The news that she is both pregnant and has been found to have a potentially lethal malignancy is one of the most emotionally wrenching events any young woman ever faces. Understandably, the patient, her partner, their families, and even their caregivers find this experience fraught with anxiety and ...

Issues in Oncology

Vertebral Compression Fracture Risk Increased After Spinal Stereotactic Body Radiotherapy 

Matthew Stenger  / November 15, 2013

In a study reported in Journal of Clinical Oncology, Arjun Sahgal, MD, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the occurrence of vertebral compression fractures in patients undergoing spinal stereotactic body radiotherapy.1 Vertebral compression fractures occurred in ...

Issues in Oncology

High-Dose Spinal Stereotactic Body Radiotherapy Associated With Increased Risk of Vertebral Compression Fracture

Eric Lis, MD  / November 15, 2013

As reviewed in this issue of The ASCO Post, Sahgal et al reported a multi-institutional analysis aimed at clarifying the risk of developing either new or progressive vertebral body compression fractures following high-dose spinal stereotactic body radiation therapy. In the period studied, they encou...

Breast Cancer

Circulating Estrogens and Androgens Associated With Breast Cancer Risk in Premenopausal Women

Matthew Stenger  / November 15, 2013

In a study reported in The Lancet Oncology, Timothy Key, DPhil, of Oxford University, and colleagues in the Endogenous Hormones and Breast Cancer Collaborative Group analyzed data from seven prospective studies to determine associations between sex hormones and risk of breast cancer in premenopausal...

Breast Cancer

Evidence-Based Opportunity to Personalize Breast Cancer Risk: The Data Are Building

Victor G. Vogel, MD, MHS  / November 15, 2013

The worldwide data from prospective studies of the relationship between levels of endogenous sex hormones and breast cancer risk in postmenopausal women show multiple and complex relationships.1 Nine prospective studies (different from those reported here) of women not taking exogenous sex hormones ...

Breast Cancer

In International Study, Patients Prefer Subcutaneous Over Intravenous Trastuzumab for Breast Cancer

Matthew Stenger  / November 15, 2013

Subcutaneous trastuzumab (not available in the United States) has been shown to have noninferior efficacy and similar pharmacokinetic and safety profiles compared with intravenous trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer. In the PrefHer trial reported in Lance...

CNS Cancers

No Progression-Free Survival Difference for Cediranib or Cediranib/Lomustine vs Lomustine in Recurrent Glioblastoma

Matthew Stenger  / November 15, 2013

In a phase III study (REGAL trial) reported in the Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of the Massachusetts General Hospital Cancer Center, and colleagues compared oral monotherapy with the investigational pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase ...

Supportive Care

Yoga Improves Sleep Quality in Patients With Cancer Suffering From Sleep Disruption

Matthew Stenger  / November 15, 2013

It is estimated that 30% to 90% of patients with cancer experience impairment of sleep quality post-treatment, and such impairment can be severe enough to increase morbidity and mortality. Preliminary evidence indicates that yoga may improve sleep in cancer patients. In a study reported in the Jour...

Colorectal Cancer

Bevacizumab/Capecitabine Improves Progression-Free Survival in Older Patients With Treatment-Naive Metastatic Colorectal Cancer 

Matthew Stenger  / November 1, 2013

Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In the phase III AVEX trial reported in The Lancet ­Oncology,1 David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine in pa...

Colorectal Cancer

The AVEX Trial

Stuart M. Lichtman, MD, FACP  / November 1, 2013

As reported in The Lancet Oncology by Cunningham and colleagues and reviewed in this issue of The ASCO Post, the AVEX trial was an open-label randomized phase III trial limited to patients over the age of 70 years with previously untreated, unresectable metastatic colorectal cancer who were not deem...

Survivorship

Modifiable Risk Factors Potentiate Therapy-Associated Risk for Major Cardiac Events in Adult Survivors of Childhood Cancer 

Matthew Stenger  / November 1, 2013

In a study reported in the Journal of Clinical Oncology, Gregory T. Armstrong, MD, of St. Jude Children’s Research Hospital in Memphis, and colleagues assessed the frequency of major cardiac events and cardiovascular risk factors among adult survivors of childhood cancer and their siblings.1 They fo...

Survivorship

Cardiovascular Risk Factors in Cancer Survivors 

Smita Bhatia, MD, MPH  / November 1, 2013

Armstrong et al evaluated the prevalence of self-reported hypertension, diabetes mellitus, dyslipidemia, and obesity and the incidence of self-reported major cardiac events such as coronary artery disease, heart failure, valvular disease, and arrhythmias in adult survivors of childhood cancer in the...

Thyroid Cancer

Cabozantinib Improves Disease-Free Survival in Progressive Medullary Thyroid Cancer 

Matthew Stenger  / November 1, 2013

Cabozantinib (Cometriq) is an inhibitor of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2 (VEGFR2), and rearranged during transfection (RET) tyrosine kinases. In a phase III trial reported in Journal of Clinical Oncology, Rossella Elisei, MD, of University of ...

Thyroid Cancer

Cabozantinib in Medullary Thyroid Cancer: A Landscape-Shaping New Treatment 

Mingzhao Xing, MD, PhD  / November 1, 2013

Medullary thyroid cancer is derived from parafollicular C cells in the thyroid gland. The disease is sporadic in about 75% of cases and hereditary in the remaining 25%.1 Oncogenic mutations in the gene for tyrosine kinase receptor rearranged during transfection (RET) are driver genetic alterations o...

Lung Cancer

Low-Dose CT Screening Identifies More Early Lung Cancer but Has Lower Positive Predictive Value vs Radiography  

Matthew Stenger  / November 1, 2013

Results of the two rounds of annual incidence screening with low-dose computed tomography (CT) vs radiography in the National Lung Screening Trial (NLST) were recently reported by Denise R. Aberle, MD, Professor of Radiology and Bioengineering at the University of California at Los Angeles and nati...

Lung Cancer

Lung Cancer Screening: Actionable Evidence 

James L. Mulshine, MD  / November 1, 2013

This recent paper in The New England Journal of Medicine outlines the details of the clinical outcomes with two incidence screens that were conducted as part of the National Lung Screening Trial (NLST).1 In the wake of the positive review of the U.S. Preventive Services Task Force (USPSTF) draft rec...

Prostate Cancer

Telomere Length May Be a Prognostic Marker for Prostate Cancer

The ASCO Post  / October 15, 2013

Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient’s prognosis, according to a study1 led by scientists at Johns Hopkins. “Doctors are looking for new ways to accurately predict prostat...

Survivorship

Study Shows Increased Risk of Mental Disorders in Childhood Cancer Survivors and Potential Increased Risk in Young Siblings  

Matthew Stenger  / October 15, 2013

Survivors of childhood cancer are at risk for long-term adverse physical and mental effects, but little is known about the effects of illness in siblings of these patients. In a study reported in The Lancet Oncology, Lasse Wegener Lund, MD, of the Danish Cancer Society Research Centre and Paediatric...

Survivorship

Psychosocial Health in Long-Term Survivors of Childhood Cancer 

Kevin R. Krull, PhD  / October 15, 2013

The study by Lund and colleagues discussed in this issue of The ASCO Post reinforces concerns about psychosocial health in long-term survivors of childhood cancer. Taking advantage of national registries, these investigators demonstrated that, when compared to the general population, survivors are a...

Issues in Oncology

More Active Physician Intervention Needed to Keep Patients From Smoking  

Charlotte Bath  / October 15, 2013

More active support and interventions by physicians are required to get patients who still smoke to stop, according to two articles published online by the Journal of Oncology Practice (JOP),1,2 and to prevent school-aged children and adolescents from starting to use tobacco, according to a U.S. Pre...

Breast Cancer

10-Year Breast Cancer Survival Similar Regardless of BRCA1 Mutation Status  

Matthew Stenger  / October 15, 2013

In a study reported in Journal of Clinical Oncology, Tomasz Huzarski, MD, PhD, of Pomeranian Medical University, Szczecin, Poland, and colleagues from the Polish Hereditary Breast Cancer Consortium assessed survival among women with early-onset breast cancer with and without BRCA1 mutation and ident...

Kidney Cancer

Progression-Free Survival With Pazopanib Not Inferior to Sunitinib Benefit in Metastatic Renal Cell Carcinoma  

Matthew Stenger  / October 15, 2013

Pazopanib (Votrient) and sunitinib (Sutent) have been shown to provide progression-free survival benefit compared with placebo or interferon in phase III trials in metastatic renal cell carcinoma. In a noninferiority trial reported in The New England Journal of Medicine by Robert J. Motzer, MD, of M...

Kidney Cancer

Pazopanib vs Sunitinib in Metastatic Renal Cell Carcinoma: How Do We Choose?  

Brian I. Rini, MD  / October 15, 2013

Over the past decade, the field of metastatic renal cell carcinoma therapy has witnessed the development of multiple drugs targeting the vascular endothelial growth factor (VEGF) pathway, based on the underlying biology of renal cell carcinoma that leads to reliance on angiogenic signaling. The init...

Breast Cancer

Accelerated Partial-Breast Irradiation Using 3D Conformal Radiation Therapy Causes More Adverse Events Compared With Whole-Breast Irradiation 

Matthew Stenger  / October 15, 2013

The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. ­Olivotto, MD, FRCPC, of the British Columbia Cancer Agency...

Breast Cancer

Increased Alcohol Consumption Between Menarche and Pregnancy Increases Breast Cancer Risk  

Matthew Stenger  / October 15, 2013

Adult alcohol consumption during the previous year is related to breast cancer risk, and breast tissue is particularly susceptible to carcinogens between menarche and first full-term pregnancy. In a study reported in Journal of the National Cancer Institute, Ying Liu, MD, PhD, of Washington Universi...

Breast Cancer

Alcohol Consumption Between Menarche and Pregnancy and Breast Cancer Risk: Factors in Risk Accumulation   

Graham A. Colditz, MD, DrPH  / October 15, 2013

In a study recently published in the Journal of the National Cancer Institute and summarized in this issue of The ASCO Post, we found a relationship between alcohol intake between menarche and first pregnancy and risk for breast cancer. Placing this study in context can help us interpret the data an...

Prostate Cancer

ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate Cancer 

Matthew Stenger  / October 15, 2013

In a trial (ALSYMPCA trial) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, UK, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and bone meta...

Prostate Cancer

Radium-223 and Beyond in Metastatic Castration-Resistant Prostate Cancer 

Maha Hussain, MD, FACP, FASCO  / October 15, 2013

Metastasis to bone is the hallmark of prostate cancer and a major source of disease-related morbidity and mortality. In addition to prostate cancer cells, other major players in the vicious interactive cycle of prostate cancer bone metastasis are osteoblasts, osteoclasts, and mineralized bone matrix...

Leukemia

No Benefit/Detriment of Donor Change in Second Stem Cell Transplant for Leukemia Relapse 

Matthew Stenger  / September 15, 2013

Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after a first transplant in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian Christopeit, MD, of University Ho...

Breast Cancer

Cohort Analysis: Adjuvant Tamoxifen Reduces Risk of Contralateral Breast Cancer in BRCA1/2 Mutation Carriers 

Matthew Stenger  / September 15, 2013

In a study reported in the Journal of Clinical Oncology, Kelly-Anne Phillips, MBBS, MD, of the University of Melbourne, and colleagues analyzed the association of adjuvant tamoxifen use and risk of contralateral breast cancer among women carrying BRCA1 and BRCA2 mutations in the International BRCA1 ...

Gynecologic Cancers

What Para-Aortic Nodal Involvement Predicts About Survival in PET-CT–Negative Locally Advanced Cervical Cancer 

Matthew Stenger  / September 15, 2013

In a study reported in the Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy and colleagues evaluated survival outcomes in patients with locally advanced cervical cancer and negative positron-emission tomography/computed tomography (PET-CT) imaging results who underwent la...

Gynecologic Cancers

Pretreatment Lymph Node Dissection May Improve Survival in Advanced Cervical Cancer, But for Too Few? 

Kathleen Moore, MD  / September 15, 2013

Women with cervical cancer metastasized to para-aortic lymph nodes have historically had a poor prognosis, with 3-year overall survival rates of 25% to 40%.1-3 This has been attributed to the presence of occult systemic disease at the time of presentation and a high rate of distant recurrences follo...

Gynecologic Cancers

Progesterone and Estrogen Receptor Expression Are Prognostic Markers for Endometrioid and High-Grade Serous Ovarian Cancer 

Matthew Stenger  / September 15, 2013

Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in The Lancet Oncology, Weiva Sieh, MD, PhD, Assistant Professor of Health Research and Policy...

Breast Cancer

No Invasive Disease–Free Survival Benefit for Bevacizumab Added to Adjuvant Chemotherapy in Triple-Negative Breast Cancer 

Matthew Stenger  / September 15, 2013

In a study (BEATRICE trial) reported in Lancet Oncology, David Cameron, MD, Professor of Oncology and Director of Cancer Services, NHS Lothian at the University of Edinburgh, and colleagues evaluated the strategy of adding the antiangiogenic agent bevacizumab (Avastin) to adjuvant chemotherapy in wo...

CNS Cancers

Postresection Adenovirus-Mediated Gene Therapy Improves Time to Death/Reintervention but Not Survival in Adult Glioblastoma 

Matthew Stenger  / September 15, 2013

In an open-label phase III trial (ASPECT) reported in Lancet Oncology, Manfred Westphal, MD, of University Hospital Eppendorf in Hamburg, and colleagues assessed the effects of locally applied adenovirus-mediated gene therapy with sitimagene ceradenovec followed by IV ganciclovir after surgical rese...

CNS Cancers

Sitimagene Ceradenovec/IV Ganciclovir in Glioblastoma: Legitimizing the Gene Therapy Approach for Brain Tumors 

William T. Curry, MD  / September 15, 2013

The ASPECT study,1 a randomized, open-label, phase III trial examining adenovirus-mediated gene therapy with sitimagene ceradenovec followed by IV ganciclovir for patients with operable high-grade glioma, is an important achievement for both neuro-oncology and gene therapy. As vector engineering bec...

Lymphoma

Potential Prognostic Significance Shown for Interaction of Follicular Lymphoma Cells with Immune Microenvironment 

Matthew Stenger  / September 15, 2013

It has been shown that CD4 and CD8 tumor-infiltrating lymphocytes in follicular lymphoma have impaired function and suppressed recruitment of critical signaling proteins to the immunologic synapse, and a number of studies have indicated the prognostic importance of the immune microenvironment in fol...

Lung Cancer

Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual's Treatment Response

The ASCO Post  / September 1, 2013

Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in patients with non–small cell lung cancer that can help predict survival and treatment response. Their findings, published in Carcinogenesis,1 could help lead to more personalized treatment options and improve...

Lymphoma

Molecular Profiling Improves Classification of Nodal Peripheral T-Cell Lymphomas 

Matthew Stenger  / September 1, 2013

The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a diagnostic accuracy study reported in the Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-Cell Lymphoma Study Group and Int...

Lymphoma

Molecular Profiling Improves Classification of Nodal Peripheral T-Cell Lymphomas 

Steven M. Horwitz, MD  / September 1, 2013

One of the primary obstacles we face in caring for patients with peripheral T-cell lymphomas is a too often inadequate response to chemotherapy with low rates of progression-free and overall survival.1 And while more intensive treatment programs and the availability of novel agents give a greater ho...

Lymphoma

Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma 

Matthew Stenger  / September 1, 2013

Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in the Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD, of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices Ci...

Lymphoma

Can Obinutuzumab Benefit Patients With Rituximab-Refractory Non-Hodgkin Lymphoma? 

Julie M. Vose, MD  / September 1, 2013

Obinutuzumab is a glycoengineered type II antibody that differs from type I anti-CD20 antibodies by being associated with actin reorganization and adhesion followed by direct cell death.1 Obinutuzumab has been glycoengineered by reduction in fucose content of the Fc region, which increases its affin...

CNS Cancers

No Event-Free Survival Difference With Chemotherapy Before vs After Radiotherapy in Children With High-Risk Medulloblastoma 

Matthew Stenger  / September 1, 2013

A number of different strategies for combining chemotherapy and radiation therapy have been evaluated in the effort to improve survival in patients with high-risk medulloblastoma. In a trial (POG 9031) reported in Journal of Clinical Oncology, Nancy J. Tarbell, MD, of Massachusetts General Hospital,...

Lung Cancer

Significant Improvement in Overall Survival Seen With Pemetrexed Maintenance After Pemetrexed/Cisplatin Induction in Patients With Advanced Nonsquamous NSCLC 

Matthew Stenger  / September 1, 2013

In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final overall survi...

Lung Cancer

Pemetrexed Maintenance in PARAMOUNT: Continuation Proves to Be a Strong Option for Advanced NSCLC, Although Not a Mandate 

H. Jack West, MD  / September 1, 2013

The PARAMOUNT trial1 represents an important landmark study of continuation maintenance therapy with pemetrexed (Alimta). While maintenance therapy gained a toehold in routine management of advanced non–small cell lung cancer (NSCLC) several years ago, the first trials that demonstrated a significan...

Lung Cancer

Pattern in Lung Cancer Pathology May Predict Recurrence After Surgery 

The ASCO Post  / September 1, 2013

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor’s pathology could be an important facto...

Lung Cancer

Bevacizumab/Pemetrexed Maintenance Increases Progression-Free Survival vs Bevacizumab Alone in Advanced Nonsquamous NSCLC 

Matthew Stenger  / September 1, 2013

Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in the Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille University–Assi...

Lung Cancer

Non–Small Cell Lung Cancer Maintenance Therapy: None, Single Agent, Multiple Agents? 

Philip D. Bonomi, MD  / September 1, 2013

Barlesi et al have reported results of a randomized trial comparing bevacizumab (Avastin) vs pemetrexed (Alimta)/bevacizumab as maintenance therapy in patients with stage IV nonsquamous cell non–small cell lung cancer (NSCLC). It is important to consider their observations in relation to data from o...

Survivorship

Fertility Rates in Childhood Cancer Survivors Suggest Strategies for Follow-up Care 

Caroline McNeil  / September 1, 2013

Childhood cancer survivors with clinical infertility have a good chance of achieving pregnancy, according to new findings from the Childhood Cancer Survivor Study (CCSS). Study Background As a group, women who survive childhood cancer are known to have lower fertility rates. This study, however, f...

Skin Cancer

Enhanced Treatment, Surveillance Needed for Patients With BRAF-Mutant Melanoma to Prevent Secondary Cancers

The ASCO Post  / September 1, 2013

Researchers at Moffitt Cancer Center suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF inhibitor therapy with other inhibitors, especially as they become more widely used. Th...

Prostate Cancer

Study Suggests Low-Grade Prostate Cancers May Not Progress Over Time 

Jo Cavallo  / September 1, 2013

Data analyzed from a large cohort study of men diagnosed with prostate cancer found that prostate cancer aggressiveness may be established when the tumor is formed and not changed over time. The researchers of the study, Kathryn L. Penney, ScD, Instructor in the Department of Medicine at Harvard Med...

Head and Neck Cancer

Meta-Analysis: Addition of Taxane to Cisplatin/5-FU Induction Improves Outcome in Locally Advanced Head and Neck Cancers 

Matthew Stenger  / September 1, 2013

Cisplatin plus fluorouracil (5-FU) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and 5-FU in randomized trials in locoregionally advanced head and neck cancers. An updated individual patient data meta-analysis reported in the Journal of Clinical Oncology ...

Integrative Oncology

American Ginseng Improves Cancer-Related Fatigue 

Matthew Stenger  / September 1, 2013

In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic (N07C2) reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, AOCN, FAAN, of the Mayo Clinic and colleagues, patients with cancer-related fatigue were treated with Wisconsin gin...

Integrative Oncology

Ginseng in the Spotlight 

Ollie Minton, MB, BS, PhD, FRCP  / September 1, 2013

I read the study by Barton and colleagues in Journal of the National Cancer Institute with great interest. Ginseng seems potentially to be one treatment for cancer-related fatigue, a poorly understood but debilitating symptom that patients experience during and after treatment.1 I am impressed that...

Issues in Oncology

Family Members of Children With Cancer Are Also at Risk for the Disease 

Jo Cavallo  / September 1, 2013

Parents and siblings of children with cancer have between a two- and four-times increased risk of developing cancer than first-degree relatives with no childhood cancer patients, according to a study published in the International Journal of Cancer.1 The study, led by Joshua Schiffman, MD, Medical D...

Gynecologic Cancers

Role of Epithelial-to-Mesenchymal Transition in Ovarian Cancer 

Jo Cavallo  / September 1, 2013

In a study of ovarian cancer cells taken from patients, scientists from Georgia Institute of Technology have confirmed that metastasizing cancer cells have a different molecular structure from primary tumor cells and display genetic signatures consistent with epithelial-to-mesenchymal transition. Al...

Lung Cancer

Acquired Resistance to Crizotinib from ROS1 G2032R Mutation  

Matthew Stenger  / August 15, 2013

The ALK inhibitor crizotinib (Xalkori) has also shown activity in lung cancers with ROS1 translocations. As recently reported by Mark M. Awad, MD, PhD, of Massachusetts General Hospital, Boston, and colleagues in The New England Journal of Medicine, a mutation conferring resistance to crizotinib was...

Leukemia

High Rate of Durable Remissions with Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia 

Matthew Stenger  / August 15, 2013

Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase is an essential component of B cell–receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of CLL cells. Ib...

Lymphoma

Ibrutinib Produces High Response Rate in Patients with Refractory Mantle Cell Lymphoma

Matthew Stenger  / August 15, 2013

Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase, a mediator of the B cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University of Texas MD Anderson Can...

Lymphoma

PET/CT Superior to Bone Marrow Biopsy for Diagnosis, Prognosis in Lymphoma 

The ASCO Post  / August 15, 2013

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma has been identified by researchers in a study published recently in The Journal of Nuclear Medicine.1 Imaging with 18F–fluorodeoxyglucose positron-emission tomography/computed tomography (FDG...

Multiple Myeloma

New Guidelines Issued in the Treatment of Multiple Myeloma-Related Bone Disease 

Jo Cavallo  / August 15, 2013

The International Myeloma Working Group (IMWG) has developed clinical practice recommendations for the management of multiple myeloma-related bone disease based on published study data through August 2012. Consensus of the interdisciplinary panel of clinical experts on the plasma cell cancer was use...

Lung Cancer

Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC  

Matthew Stenger  / August 15, 2013

In a phase III trial reported by Alice T. Shaw, MD, PhD, a thoracic oncologist at Massachusetts General Hospital, Boston, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients ...

Lung Cancer

Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial 

Matthew Stenger  / August 15, 2013

The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers.1 The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also rece...

Hepatobiliary Cancer

Oncofetal Protein SALL4 Is a Marker of Aggressive Hepatocellular Carcinoma and a Potential Therapeutic Target  

Matthew Stenger  / August 15, 2013

Hepatocellular carcinomas with characteristics of embryonic stem cell and progenitor cell gene expression are associated with particularly poor prognosis. SALL4 is an oncofetal protein that is expressed in the human fetal liver and normally silenced in the adult liver, but re-expressed in a subgroup...

Lung Cancer

LUX-Lung 3: Afatinib Prolongs Progression-free Survival vs Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma 

Matthew Stenger  / August 15, 2013

Afatinib (Gilotrif) is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma...

Breast Cancer

Age Not Linked to Recurrence in Observation or Trastuzumab Groups with HER2-positive Breast Cancer  

Matthew Stenger  / August 15, 2013

Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...

Issues in Oncology

Whole-exome Sequencing of NCI-60 Cell Line Panel Provides Genomic Resource for Cancer Biology and Pharmacology 

Matthew Stenger  / August 15, 2013

The NCI-60 cell lines, which represent cancers of the lung, colon, brain, ovary, breast, prostate, and kidney, as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As ...

Issues in Oncology

Infertility in Men Raises Their Risk for Cancer 

Jo Cavallo  / August 15, 2013

A cohort study of 2,238 men who were evaluated for infertility at a clinic in Texas from 1989 to 2009 found that those men who had azoospermia, a condition in which no measurable sperm is present, had a 2.2-fold higher cancer risk compared with those who were nonazoospermic. The study was published ...

Lung Cancer

First-line Carboplatin/Pemetrexed Improves Survival vs Pemetrexed Alone in Advanced Lung Cancer 

Matthew Stenger  / August 15, 2013

A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto Nacional d...

Lung Cancer

Docetaxel Superior to Erlotinib in Second-line Treatment of Advanced Non–Small Cell Lung Cancer with Wild-type EGFR  

Matthew Stenger  / August 15, 2013

There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Garassino and colleagues,1 erlotinib was compared with standard docetaxel as second-lin...

Colorectal Cancer

Link between Red Meat Consumption and Mortality Clarified in Patients with Nonmetastatic Colorectal Cancer  

Matthew Stenger  / August 15, 2013

Evidence shows that diets high in red and processed meat are associated with an increased risk of colorectal cancer. In a study reported in the Journal of Clinical Oncology, Marjorie L. McCullough, ScD, Strategic Director of Nutritional Epidemiology, and colleagues from the Epidemiology Research Pro...

Lung Cancer

Intercalated Chemotherapy/Erlotinib Improves Progression-free Survival in Advanced NSCLC  

Matthew Stenger  / August 15, 2013

EGFR mutation status may not be known at the time treatment is started in patients with advanced non–small cell lung cancer (NSCLC). Further, some data suggest that the efficacy of concurrent treatment with an EGFR tyrosine kinase inhibitor and chemotherapy is reduced because the G1 cell-cycle arres...

Lung Cancer

Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC 

Matthew Stenger  / August 15, 2013

In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final overall survi...

Colorectal Cancer

Addition of Brivanib to Cetuximab in Chemotherapy-refractory Metastatic Wild-type KRAS Colorectal Cancer: Key Results 

Matthew Stenger  / July 25, 2013

The addition of a combination of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors to chemotherapy has not improved outcome in first-line treatment of advanced colorectal cancer. However, in early-phase evaluation, the addition of the investigational VE...

Colorectal Cancer

Looking for Drivers in the Rearview Mirror 

John L. Marshall, MD  / July 25, 2013

The latest clinical trial looking at combining vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibition in metastatic colorectal cancer adds little to our overall understanding of the mechanisms for optimizing selection of patients to receive such therapies. W...

Sarcoma

Nearly Half of Sarcoma Surgeries Performed by Non-oncology Surgeons  

Caroline Helwick  / July 25, 2013

Nearly half the surgical procedures for sarcoma done at 85 academic medical centers were performed by surgeons untrained in oncology, according to national data analyzed by researchers from the University of California Davis Medical Center, Sacramento. Orthopedic oncologists and surgical oncologist...

Hematologic Malignancies
Issues in Oncology

Critically Ill Hematology Patients Admitted to ICU Have Good Survival, Disease Control, and Quality of Life 

Matthew Stenger  / July 25, 2013

A large prospective multicenter cohort study in France and Belgium, reported by Elie Azoulay, MD, of Saint-Louis Hospital, Paris, and colleagues from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique,1 has shown that critically ill patients with hematologic malignancies admitted...

Hematologic Malignancies
Issues in Oncology

Just Say 'Know'

Jeffrey S. Groeger, MD, and Kathleen N. Cathcart, MD  / July 25, 2013

In 1989, Denardo and associates reported the results of intensive care unit (ICU) therapy in a series of patients who developed acute respiratory failure and required mechanical ventilation after bone marrow transplantation. Of those on mechanical ventilatory support longer than 4 days, not one surv...

Supportive Care

Updated ASCO Clinical Practice Guideline for Venous Thromboembolism Prophylaxis and Treatment 

Matthew Stenger  / July 10, 2013

ASCO has released a new evidence-based clinical practice guideline for venous thromboembolism prophylaxis and treatment, updating the 2007 practice guideline.1 The update is based on a systematic review of literature published from December 2007 to December 2012. An Update Committee reviewed evidenc...

Breast Cancer

Study Reports 25% of Women Don't Complete Recommended Breast Cancer Treatment

The ASCO Post  / July 10, 2013

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the 5-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. For many women with hormone receptor--po...

Leukemia

Genomic and Epigenomic Characterization of Acute Myeloid Leukemia 

Matthew Stenger  / July 10, 2013

In a study by the Cancer Genome Atlas Research Network reported in The New England Journal of Medicine, genomes of 200 adult cases of de novo acute myeloid leukemia (AML) were analyzed by whole-genome sequencing (n = 50) or whole-exome sequencing (n = 150) to identify mutations and relationships bet...

Breast Cancer

Measurement of Circulating Tumor DNA Shows Promise in Monitoring Metastatic Breast Cancer 

Matthew Stenger  / July 10, 2013

Management of metastatic breast cancer requires monitoring of tumor burden to assess response to treatment, and there is a need for biomarkers that can measure tumor burden with high sensitivity and specificity. Assays measuring serum cancer antigen (CA) 15-3 and circulating tumor cells have been re...

Lung Cancer

Immunohistochemistry Effectively Detects ALK Rearrangement in Non-small Cell Lung Cancer Study

The ASCO Post  / July 10, 2013

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer. It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and relia...

Breast Cancer

Outcomes with Adjuvant Trastuzumab in HER2-positive Breast Cancer Not Affected by PTEN Status 

Matthew Stenger  / July 10, 2013

PTEN is a negative regulator of PI3K/AKT signaling. PI3K/AKT signaling can be activated by HER2, and it has been hypothesized that alteration in this pathway may affect sensitivity to trastuzumab (Herceptin). Preclinical data and some of the limited available clinical data suggest that loss or inact...

Gynecologic Cancers

Integrated Genomic Characterization of Endometrial Carcinomas Suggests New Classification Scheme 

Matthew Stenger  / July 10, 2013

As recently reported in Nature, investigators in The Cancer Genome Atlas Research Network performed an integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial carcinomas, including 307 endometrioid and 66 serous or mixed histology cases, using array- and sequencing-base...

Gastrointestinal Cancer

SEER Analysis Shows Increased Survival with Surgery and Radiation Therapy in Metastatic Gastric Cancer 

Matthew Stenger  / July 10, 2013

A Surveillance, Epidemiology, and End Results (SEER) database analysis reported by Ravi Shridhar, MD, PhD, and colleagues in Cancer indicates that patients receiving surgery and radiation therapy for metastatic gastric cancer have prolonged survival compared with those receiving either alone or neit...

Lymphoma

Radiation-sparing Dose-adjusted EPOCH-Rituximab for Primary Mediastinal B-cell Lymphoma 

Matthew Stenger  / June 25, 2013

Tumor control is frequently not achieved with standard immunochemotherapy in patients with primary mediastinal B-cell lymphoma, requiring consolidation with mediastinal radiotherapy. However, radiotherapy is associated with serious late adverse effects and is still associated with disease progressio...

Lung Cancer

KRAS Status Not Associated with Survival in Pooled Adjuvant Therapy Trials in Early-stage Lung Cancer 

Matthew Stenger  / June 25, 2013

KRAS mutations have been reported in approximately 30% of lung adenocarcinomas. They occur most frequently in codons 12 and 13 in non–small cell lung cancer (NSCLC), and are most common in cancer in smokers and in nonsquamous NSCLC. Some data suggest that KRAS mutation is associated with poorer outc...

Lung Cancer

Study Shows High Concordance of Recurrent Somatic Alterations in Primary and Matched Metastatic NSCLC

Matthew Stenger  / June 25, 2013

In a study reported in Journal of Clinical Oncology, Stéphane Vignot, MD, of Institut National de la Santé et de la Recherche Medicale (INSERM) Unit 981, Paris, and Gustave Roussy Institute, Villejuif, France, and colleagues used next-generation sequencing to identify somatic alterations in archived...

Issues in Oncology

Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half

The ASCO Post  / June 25, 2013

A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published onlin...

Lung Cancer

No Survival Benefit of ERCC1 and RRM1 Expression-based Chemotherapy in Patients with Advanced NSCLC 

Matthew Stenger  / June 25, 2013

A trial reported by Gerold Bepler, MD, PhD, of Karmanos Cancer Institute, Detroit, and colleagues in Journal of Clinical Oncology assessed whether chemotherapy selected on the basis of in situ ERCC1 and RRM1 protein levels could improve outcomes in patients with advanced non–small cell lung cancer (...

Colorectal Cancer

Similar Short-term Outcomes with Laparoscopic vs Open Surgery for Rectal Cancer 

Matthew Stenger  / June 25, 2013

As recently reported in Lancet Oncology by Martijn H.G.M. van der Pas, MD, of VU University Medical Center, Amsterdam, and colleagues, the phase III COLOR II trial has shown that laparoscopic surgery can produce similar safety outcomes, resection margins, and completeness of resection compared with ...

Leukemia

Identification of Oncogenic Mutations in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia 

Matthew Stenger  / June 25, 2013

Among the hematologic cancers for which molecular causes remain unclear are chronic neutrophilic leukemia and atypical (BCR-ABL1–negative) chronic myeloid leukemia. Both disorders currently are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic factors know...

Supportive Care

Once-daily Moxifloxacin for Low-risk Patients with Febrile Neutropenia 

Susan London  / June 10, 2013

Once-daily oral moxifloxacin works at least as well as twice-daily oral ciprofloxacin plus amoxicillin–clavulanic acid when it comes to treating febrile neutropenia in patients who are at low risk for complications, according to a randomized, double-blind trial reported in the Journal of Clinical On...

Hematologic Malignancies
Leukemia

Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia

The ASCO Post  / June 10, 2013

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood.1 Acute mye...

Breast Cancer

Higher Fruit and Vegetable Consumption Associated with Reduced Risk of ER-negative Breast Cancer 

Matthew Stenger  / June 10, 2013

An analysis of a large pooled data set from the Pooling Project of Prospective Studies of Diet and Cancer reported by Seungyoun Jung, ScD, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, and colleagues in Journal of the National Cancer Institut...

Issues in Oncology

Determining the Best Diet for Patients with Cancer  

Jo Cavallo  / June 10, 2013

How much does diet and body weight influence the effectiveness of cancer treatment and reduce the risk of cancer recurrence? What is the optimal diet for patients with cancer and survivors to follow? There are currently no hard and fast rules, but some dietary clues are starting to emerge. Search f...

Solid Tumors
Colorectal Cancer
Issues in Oncology

Geriatric Factors Predict Severe Toxicity in Elderly Patients on First-line Treatment for Metastatic Colorectal Cancer 

Matthew Stenger  / June 10, 2013

Elderly patients differ with respect to tolerance of therapy for colorectal cancer. In a study reported in Journal of Clinical Oncology, Thomas Aparicio, MD, PhD, of the University of Paris, and colleagues analyzed geriatric factors for potential association with severe toxicity, dose-intensity redu...

Solid Tumors
Kidney Cancer

No Difference in Overall Survival with Axitinib or Sorafenib in Second-line Treatment for Advanced Renal Cell Carcinoma 

Matthew Stenger  / June 10, 2013

The phase III open-label AXIS trial comparing axitinib (Inlyta) vs sorafenib (Nexavar) as second-line treatment for metastatic renal cell carcinoma showed significantly prolonged independent radiology committee–assessed progression-free survival with axitinib treatment (hazard ratio [HR] = 0.665, P ...

Solid Tumors

HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma

The ASCO Post  / June 10, 2013

Liver transplantation for hepatocellular carcinoma is feasible for HIV-infected patients, with no differences in post-transplant survival or hepatocellular carcinoma recurrence rates compared with liver transplantation for hepatocellular carcinoma in HIV-uninfected patients. The study, published in ...

Solid Tumors
Head and Neck Cancer

Genetic Diversity May Predict Outcomes in Head and Neck Cancer

The ASCO Post  / June 10, 2013

A new measure of cell heterogeneity within a tumor may predict treatment outcomes of patients with squamous cell carcinoma of the head and neck.  In a recent report,1 investigators at Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary reported how the mutant allele tumor heterog...

Solid Tumors
Breast Cancer

EGFR Prevents Maturation of microRNAs under Hypoxic Conditions

The ASCO Post  / June 10, 2013

The epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs under conditions of hypoxia, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The results were reported in an early online publ...

Solid Tumors
Colorectal Cancer

Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer 

Matthew Stenger  / June 10, 2013

According to an analysis reported by Amanda Phipps, PhD, MPH, Assistant Professor of Epidemiology at the University of Washington and Assistant Member at Fred Hutchinson Cancer Research Center, Seattle, and colleagues in the Journal of Clinical Oncology, patients with stage III colon cancer who ever...

Prostate Cancer
Issues in Oncology

Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer

The ASCO Post  / June 10, 2013

Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appeared online recently in the journal Cancer Research.1 Gleason Patte...

Gynecologic Cancers

Gold Nanoparticles Can Help Fight Ovarian Cancer

The ASCO Post  / June 10, 2013

Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current online...

Issues in Oncology
Legislation

Innovative State Program Reduces Colorectal Cancer Disparities, Mortality Rates Among African American Patients

The ASCO Post  / June 10, 2013

A study analyzing the impact of the Delaware Cancer Consortium, the state’s cancer control program, reports a 41% reduction in colorectal mortality rates for African Americans.1 The recently published study provided analysis on a novel design and approach used to eliminate colorectal cancer disparit...

Solid Tumors
Leukemia

Profound and Rapid Molecular Remission with CD19-targeted T Cells in Relapsed B-cell ALL 

Matthew Stenger  / May 15, 2013

As was recently reported in Science Translational Medicine, Renier J. Brentjens, MD, and colleagues at Memorial Sloan-Kettering Cancer Center, New York, found that profound molecular remission was rapidly induced in patients with relapsed B-cell acute lymphoblastic leukemia (ALL) using autologous T ...

Proof of Principle for Adoptive T-cell Therapy in Cancer 

Matthew Stenger  / May 15, 2013

In a recently published study, Memorial Sloan-Kettering Cancer Center investigators demonstrated the considerable antitumor efficacy of 19-28z chimeric antigen receptor (CAR)-modified T cells in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The ASCO Post asked lead aut...

Issues in Oncology
Health-Care Policy

ASCO Announces New Conflict of Interest Policy 

Jo Cavallo  / May 15, 2013

In April, ASCO released its updated conflict of interest policy in the development and presentation of scientific research and educational content. The revised policy is designed to increase transparency in financial relationships between individuals and health-care companies and impose new restrict...

Lung Cancer

New Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitor Treatment 

Matthew Stenger  / May 15, 2013

A new guideline for molecular testing to select lung cancer patients for treatment with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors has been jointly developed by the College of American Pathologists, International Association for the Study ...

Lung Cancer

Greater Prediagnosis Soy Food Consumption Associated with Improved Survival in Women with Lung Cancer 

Matthew Stenger  / May 15, 2013

As recently reported by Gong Yang, MD, MPH, Research Associate Professor at Vanderbilt University School of Medicine, Nashville, and colleagues in the Journal of Clinical Oncology,1 higher prediagnosis consumption of soy food was associated with improved overall survival in Chinese women with lung c...

Breast Cancer

Risk for Ischemic Heart Disease after Radiotherapy for Breast Cancer 

Matthew Stenger  / May 15, 2013

A population-based case-control study reported by Sarah C. Darby, PhD, Professor of Medical Statistics in the Clinical Trial Service Unit and Epidemiologic Studies Unit at the University of Oxford, and colleagues in The New England Journal of Medicine indicates that incidental exposure of the heart ...

Breast Cancer
Survivorship

Breast Cancer Survivors Not Likely to Maintain Physical Activity Sufficient for Benefits of Exercise

The ASCO Post  / May 15, 2013

Few breast cancer survivors meet national exercise recommendations during the 10 years after being diagnosed, even though they are among the women who could most benefit from regular physical activity, according to a study by researchers at Fred Hutchinson Cancer Research Center. Prior studies and a...

Hematologic Malignancies
Lymphoma

Autologous Stem Cell Transplant Improves Survival in Transformed Follicular Lymphoma  

Matthew Stenger  / May 15, 2013

As reported by the Canadian Blood and Marrow Transplant Group in Journal of Clinical Oncology,1 patients with transformed follicular lymphoma receiving autologous transplantation have improved survival outcomes compared with patients receiving rituximab (Rituxan)-containing chemotherapy alone. Allog...

Role of Stem Cell Transplantation in Follicular Lymphoma 

James O. Armitage, MD  / May 15, 2013

The place of either autologous or allogeneic hematopoietic stem cell transplantation in the care of patients with follicular lymphoma has been a point of controversy. However, for patients in whom an effective chemotherapy or chemoimmunotherapy regimen for low-grade follicular lymphoma fails, I beli...

Skin Cancer

Nonmelanoma Skin Cancer May Be Associated with Modest Increased Risk of Secondary Cancer: Further Study Needed

The ASCO Post  / May 15, 2013

A prospective study by researchers at Brigham and Women’s Hospital observed an association between risk of second primary cancer and history of nonmelanoma skin cancer in white men and women. The researchers found that people with a history of nonmelanoma skin cancer had a modestly increased risk o...

Lung Cancer
Issues in Oncology

eHealth: Caregiver Use of Online System Reduces Symptom Distress in Patients with Non–Small Cell Lung Cancer

Matthew Stenger  / May 15, 2013

The results of a study reported by David H. Gustafson, PhD, Research Professor at the University of Wisconsin-Madison, and colleagues in Cancer suggest that informal caregiver (eg, family member) use of a specifically designed online system to support palliative care reduces symptom distress in pati...

Lessons of 2 Decades' Experience with CHESS  

David H. Gustafson, PhD  / May 15, 2013

Our work on an Internet-based intervention for lung cancer confirmed what many other studies have shown about technologic interventions for health-care consumers—that such interventions can improve quality of life for caregivers and patients.1 We expected this result in part because of the clinician...

Novel Regimen Produces High Pathologic Complete Response Rates in Triple-negative Breast Cancer 

Caroline Helwick  / May 15, 2013

Interim results from a small neoadjuvant study of patients with triple-negative breast cancer has found high rates of pathologic complete response with the combination of nab-paclitaxel (Abraxane), carboplatin, and bevacizumab (Avastin).1 The study was presented at the 18th Annual Conference of the ...

Solid Tumors
Colorectal Cancer

12-Gene Recurrence Score Predicts Recurrence in Stage II Colon Cancer in CALGB 9851 Population 

Matthew Stenger  / May 15, 2013

As reported by Alan P. Venook, MD, Professor of Medicine (Hematology/Oncology) at the University of California, San Francisco, and colleagues in Journal of Clinical Oncology, a 12-gene recurrence score (Oncotype DX Colon Cancer Assay) was shown to predict recurrence in stage II colon cancer in a val...

Emerging Prognostic Markers in Colon Cancer 

Richard L. Schilsky, MD, FASCO  / May 15, 2013

Patients with stage II colon cancer generally have a favorable prognosis, with about 80% of patients surviving 5 years after surgery and the majority of these long-term survivors presumed to be cured. Clearly though, some patients are destined to recur after surgery, and there is an urgent need to d...

Gynecologic Cancers

Women with Lynch Syndrome and Endometrial Cancer Are at Increased Risk of Other Cancers 

Matthew Stenger  / May 15, 2013

Lynch syndrome is an autosomal dominantly inherited disorder due to germline mutations in DNA mismatch repair genes. Mismatch repair mutation carriers are at increased risk of several cancers, with endometrial cancer being one of the most commonly diagnosed cancers in women with Lynch syndrome. In ...

Lynch Syndrome: A Multitude of Predispositions 

Carrie L. Snyder, MSN, and Henry T. Lynch, MD  / May 15, 2013

The current uncertainty regarding the relative frequencies of cancers of various anatomic sites in Lynch syndrome poses a difficulty in commenting on the syndrome’s overall cancer spectrum. It is even more vexing to address the order in which these cancers are prone to occur. What we do know is that...

Solid Tumors
Prostate Cancer

Obese Men with Benign Biopsy at High Risk for Prostate Cancer

The ASCO Post  / May 15, 2013

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published recently in Cancer Epidemiology, Biomarkers & Prevention.1 “Our study...

Solid Tumors
Colorectal Cancer

Benefit of Continued Antiangiogenic Treatment with Bevacizumab after Progression in Metastatic Colorectal Cancer 

Matthew Stenger  / May 1, 2013

As reported recently in Lancet Oncology by Jaafar Bennouna, MD, of Institut de Cancérologie de l’Ouest, Nantes, France, and colleagues, the phase III ML18147 trial showed a survival benefit with continued bevacizumab (Avastin) treatment after first progression in metastatic colorectal cancer.1 The t...

Solid Tumors
Colorectal Cancer

More Recreational Physical Activity Associated with Reduced All-cause Mortality in Patients with Colorectal Cancer 

Matthew Stenger  / May 1, 2013

In a study recently reported in Journal of Clinical Oncology, Peter T. Campbell, PhD, and colleagues from the Epidemiology Research Program of the American Cancer Society, Atlanta, found that more recreational physical activity before and after a diagnosis of colorectal cancer was associated with lo...

Issues in Oncology

Access to Care: Who Gets Referred to a Medical Oncologist and/or Another Cancer Specialist and Who Receives Treatment for Advanced Cancer? 

Charlotte Bath  / May 1, 2013

What factors determine who is referred to a medical oncologist and receives treatment for advanced cancers? Several articles in the Journal of Oncology Practice suggest that factors influencing referral and treatment go beyond the patient’s medical condition and preference and include such details a...

Prostate Cancer

Similar 15-year Functional Outcomes after Prostatectomy or Radiotherapy for Localized Prostate Cancer 

Matthew Stenger  / April 15, 2013

Comparative longer-term functional outcomes of radical prostatectomy and external-beam radiation therapy for localized prostate cancer remain undefined. In a study recently reported in The New England Journal of Medicine,1 Matthew J. Resnick, MD, and colleagues at Vanderbilt University, Nashville, c...

Lung Cancer

Study Shows Lung Cancer CT Screening Could Save 12,000 Lives Annually 

Jo Cavallo  / April 15, 2013

Screening all current and former heavy smokers could prevent over 12,000 lung cancer deaths a year, according to a new study published in Cancer.1 The study, funded by the American Cancer Society, arrived at that number based on data from the National Lung Screening Trial (NLST),2 which found that h...

Lung Cancer

The Risk of Death From Smoking Now Nearly Identical for Men and Women 

Jo Cavallo  / April 15, 2013

Researchers from multiple organizations, including the American Cancer Society (ACS), studied the smoking trends among men and women over the last 50 years and found that women’s smoking habits in that time have significantly increased their risk of dying from lung cancer and chronic obstructive pul...

Colorectal Cancer

SIGGAR Trials Compare CT Colonography vs Barium Enema and Colonoscopy in Evaluation for Colon Cancer 

Matthew Stenger  / April 15, 2013

The companion UK Special Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) trials compared computed tomographic (CT) colonography with barium enema and colonoscopy in patients with symptoms suggestive of colon cancer. As recently reported by the SIGGAR investigators in The Lancet,1...

Leukemia

Addition of Liposomal Daunorubicin Improves Early Outcome in Patients with Pediatric Relapsed AML 

Matthew Stenger  / April 15, 2013

Optimal reinduction therapy for patients with relapsed pediatric acute myeloid leukemia (AML) remains undefined. Liposomal daunorubicin (DaunoXome), which offers the potential for reduced cardiotoxicity compared with traditional daunorubicin, is effective in this setting. Gertjan J.L. Kaspers, MD, P...

Breast Cancer

Effects of Menarche and Menopause on Breast Cancer Risk: Meta-analysis Findings 

Matthew Stenger  / April 15, 2013

Menarche and menopause mark the onset and offset of ovarian and endocrine activity associated with reproduction, and early menarche and late menopause are known to increase risk of breast cancer. In a recent Lancet Oncology article, the Collaborative Group on Hormonal Factors in Breast Cancer report...

Breast Cancer

CDC Reports Racial Disparity in Breast Cancer Mortality  

Matthew Stenger  / April 15, 2013

Breast cancer deaths have declined over the past 2 decades, with approximately half of the decrease estimated to be due to advances in early detection and treatment. However, not all racial groups have benefited equally from these advances. A recent report from the Centers for Disease Control and Pr...

Kidney Cancer

Immunoassay Test May Help Identify Early Kidney Cancer  

Jo Cavallo  / April 15, 2013

Renal cell carcinoma is the most common form of adult kidney cancer and the third most common urologic malignancy, accounting for about 2% of all malignancies and 2% of cancer-related deaths worldwide. It is also one of the most difficult cancers to detect and treat because it is usually found after...

Colorectal Cancer

Obesity, Physical Inactivity Linked with Risk for Subtype of Colorectal Cancer 

The ASCO Post  / March 15, 2013

An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research,1 a journal of the American Assoc...

Lung Cancer
Palliative Care

Patients Receiving Palliative Radiation Therapy for Metastatic Non–Small Cell Lung Cancer May Be Overtreated 

Matthew Stenger  / March 15, 2013

Many patients receiving palliative radiation therapy to the bone or chest for metastatic non–small cell lung cancer (NSCLC) may be receiving a greater number of treatments and higher doses than are supported by current evidence, according to a Cancer Care and Outcomes Research and Surveillance Conso...

Lung Cancer

No Benefit of Adding Carboplatin to Pemetrexed in Second-line Treatment of Patients With Advanced Non–Small Cell Lung Cancer 

Matthew Stenger  / March 15, 2013

An Italian randomized phase II study (GOIRC 02-2006 study) recently reported in Journal of Clinical Oncology by Andrea Ardizzoni, MD, of Azienda Ospedaliero-Universitaria in Parma, Italy, and colleagues showed no progression-free survival benefit of adding carboplatin to pemetrexed (Alimta) in secon...

Lung Cancer
Issues in Oncology

Greater Representation of Older Patients in Phase III Trials Needed

The ASCO Post  / March 15, 2013

The median age of patients diagnosed with advanced non–small cell lung cancer (NSCLC) has steadily increased in recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials. A recent study published in the March 2013 issue of the Internation...

Breast Cancer

FOXP3 Expression Linked to Better Survival with Adjuvant Anthracycline Not Followed by Taxane in Breast Cancer 

Matthew Stenger  / March 15, 2013

The French UNICANCER-PACS 01 trial compared six cycles of anthracycline-based adjuvant therapy with FEC (epirubicin, cyclophosphamide, fluorouracil; FEC6) vs three cycles of FEC followed by three cycles of docetaxel (FEC/docetaxel) in patients with node-positive primary breast cancer. After adjuvant...

Issues in Oncology

Enhanced Electronic Module Aims to Prevent Errors in Oral Chemotherapy Prescribing

Charlotte Bath  / March 15, 2013

An oral chemotherapy prescription-writing module grafted to a shared electronic medical record is part of a series of quality improvement efforts undertaken at Dana-Farber Cancer Institute in Boston to prevent errors in prescribing oral chemotherapy agents. While oncologists have readily accepted th...

Medication Safety at Home 

Charlotte Bath  / March 15, 2013

A risk assessment to identify how errors occur when oral chemotherapies are used by pediatric patients at home (and to propose risk-reduction strategies) relied on input from those primarily in charge of oral chemotherapy use at home—the parents. A total of 18 parents were recruited at three pediatr...

Gynecologic Cancers

Analysis Shows No 10-year Survival Advantage in Patients with Ovarian Cancer and BRCA1 or BRCA2 Mutations 

Matthew Stenger  / March 15, 2013

Several studies have suggested that short-term overall survival for women with ovarian cancer and BRCA1 or BRCA2 mutations is better than that in patients without such mutations. Indeed, a recent report by Kelly L. Bolton, PhD, and colleagues indicated that 5-year overall survival was 36% for mutati...

Issues in Oncology

Study Shows New Approach Connecting Smokers to Quit Lines Increases Smoking Cessation Treatment Enrollment 

The ASCO Post  / March 15, 2013

Self-identified smokers directly connected to a tobacco cessation quit line are 13 times more likely to enroll in a treatment program as compared to smokers who are handed a quit line referral card and encouraged to call on their own, according to a new study published online in JAMA Internal Medici...

Colorectal Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Multiple Myeloma
Issues in Oncology
Palliative Care

Study Shows Little Association of Multidisciplinary Tumor Boards with Measures of Care 

Matthew Stenger  / March 15, 2013

A survey of Veterans Affairs (VA) medical centers recently reported by Nancy L. Keating, MD, MPH, and colleagues at Harvard Medical School in the Journal of the National Cancer Institute showed that the presence of multidisciplinary tumor boards had little association with rates of recommended stage...

Lung Cancer

Use of Beta-blockers Associated with Improved Survival in Patients with NSCLC Receiving Definitive Radiation Therapy 

Matthew Stenger  / March 1, 2013

As reported recently in Annals of Oncology, a retrospective study by Wang and colleagues showed that use of beta-adrenergic receptor antagonists (beta-blockers), typically used in treatment of hypertension and heart disease, was associated with significantly improved distant metastasis–free survival...

Colorectal Cancer

Genetics, Mathematics, and Colorectal Cancer 

Jo Cavallo  / March 1, 2013

Two recent study reports in colorectal cancer explored new data on genetic precursors to the disease and outcome predictors once treatment is initiated. New Genetic Links to Colorectal Cancer Are Identified Investigators from Vanderbilt-Ingram Cancer Center, Nashville, and colleagues in China, Sou...

Lung Cancer

Selumetinib/Docetaxel Shows Promising Activity in Previously Treated KRAS-mutant Non-Small Cell Lung Cancer

Matthew Stenger  / February 15, 2013

Currently, there are no approved therapies for KRAS-mutant non–small cell lung cancer (NSCLC), and few clinical trials have been performed specifically in this setting. In a recent article in Lancet Oncology, Pasi A. Jänne, MD, PhD, Scientific Director, Belfer Institute for Applied Cancer Science, a...

Leukemia

ASH International Clinical Collaboration Replicates High Cure Rate of APL in Developing Countries

The ASCO Post  / February 15, 2013

The work of an American Society of Hematology (ASH) international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) has drastically improved cure rates in patients in Central and South America. In fa...

Prostate Cancer

Abiraterone Benefits Patients with Metastatic Prostate Cancer Who Have Had No Previous Chemotherapy 

Matthew Stenger  / February 15, 2013

The androgen biosynthesis inhibitor abiraterone acetate (Zytiga) has been shown to increase radiographic progression-free survival and delay clinical decline and initiation of chemotherapy in a clinical trial in castration-resistant patients with metastatic prostate cancer who have had no prior chem...

Solid Tumors

Gene in Eye Melanomas Linked to Good Prognosis

The ASCO Post  / February 15, 2013

Melanomas that develop in the eye often are fatal. Now, researchers at Washington University School of Medicine and the Siteman Cancer Center, St. Louis, Missouri, report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome. The research was publis...

Breast Cancer

Subcutaneous Trastuzumab a Potential Alternative to Intravenous Administration in Breast Cancer 

Matthew Stenger  / February 15, 2013

Subcutaneous administration of trastuzumab might offer improvements in patient convenience and resource use compared with conventional intravenous administration (Herceptin). A new subcutaneous trastuzumab formulation containing a fixed dose of 600 mg and recombinant human hyaluronidase PH-20 (rHuPH...

Issues in Oncology

Patient Expectations of Benefit in Early-phase Trials: Ethics Issues in Informed Consent 

Matthew Stenger  / February 1, 2013

It has been found that many patients in early-phase oncology trials believe their chance of benefit to be much higher than estimates derived from historical data.1-3 In a recently reported study in Journal of Clinical Oncology, Kevin P. Weinfurt, PhD, of Duke Clinical Research Institute, and colleag...

Lung Cancer

ACS Releases Lung Cancer Screening Guidelines

Ronald Piana  / February 1, 2013

As reported online in CA: A Cancer Journal for Clinicians,1 based on results from the National Lung Screening Trial (NLST) sponsored by the National Cancer Institute (NCI), the American Cancer Society (ACS) has released lung cancer screening guidelines recommending that select clinicians should init...

Prostate Cancer

Postoperative Radiation Therapy Extends Progression-free Survival in Men with High-risk Prostate Cancer

Alice Goodman  / February 1, 2013

Postoperative irradiation significantly improves biochemical progression-free survival and local control compared with a “wait-and-see” approach in men with high-risk prostate cancer, according to more than a decade of long-term follow-up in the European Organisation for Research and Treatment of Ca...

Supportive Care

Cisplatin Linked to Significantly Increased Risk of Venous Thromboembolism

Charlotte Bath  / February 1, 2013

Patients with advanced solid tumors treated with cisplatin-based chemotherapy had a significantly increased risk of venous thromboembolic events, according to a meta-analysis of 38 randomized phase II and III trials evaluating cisplatin-based vs non–cisplatin-based chemotherapy. The trials involved ...

Issues in Oncology

Most Patients Do Not Report that Cure Is Highly Unlikely with Chemotherapy for Advanced Cancer  

Matthew Stenger  / February 1, 2013

Chemotherapy for metastatic lung or colorectal cancer can provide palliation and modestly prolong life, but is not curative. In a study recently reported in The New England Journal of Medicine, Jane C. Weeks, MD, of Dana-Farber Cancer Insitute, and colleagues found that the majority of patients with...

Supportive Care

Tumor Grade Is Associated with Risk for Venous Thromboembolism

Matthew Stenger  / January 15, 2013

Recent data suggest that risk for venous thromboembolism is associated with biologic aggressiveness of cancer. Findings in the Vienna Cancer and Thrombosis Study, recently reported by Ahlbrecht and colleagues in Journal of Clinical Oncology, indicate that patients with higher-grade tumors are at sig...

Supportive Care

Expert Point of View: Agnes Y. Lee, MD

Alice Goodman  / January 15, 2013

Press conferencemoderator Agnes Y. Lee, MD, Medical Director of the Thrombosis Program and Associate Professor of Medicine at the University of British Columbia and Vancouver Coastal Health in Canada, said that apixaban is the third in a new line of anticoagulants for long-term prevention of thrombo...

Solid Tumors

Gene Profiling Directs Site-specific Therapy for Carcinoma of Unknown Primary Site

Matthew Stenger  / January 15, 2013

Patients with carcinoma of unknown primary site usually receive empiric therapy (eg, with taxane/platinum or gemcitabine/platinum regimens), resulting in a median overall survival of approximately 9 months. As reported recently in Journal of Clinical Oncology, Hainsworth and colleagues have shown th...

Hematologic Malignancies

Bone Marrow Transplants Reduce Risk of Graft-vs-Host Disease Compared to Peripheral Blood

Caroline McNeil  / December 15, 2012

Patients who receive bone marrow transplants are significantly less likely to develop chronic graft-vs-host disease than those who receive peripheral blood stem cell transplants, according to a new, large randomized trial, the first of its kind with unrelated donors. Published recently in The New En...

Issues in Oncology
Symptom Management

Statin Use Associated with Reduced Cancer-related Mortality in Danish Study

Matthew Stenger  / December 15, 2012

Cancer-related mortality among patients in the Danish population receiving a diagnosis of cancer at age ≥ 40 years between 1995 and 2007 was significantly reduced in those who were receiving statin therapy at the time of diagnosis, according to an analysis reported by Nielsen and colleagues in The N...

Prostate Cancer
Issues in Oncology

Medical and Behavioral Variables Have More Impact on Physical Functioning Than Finasteride Treatment

Charlotte Bath  / December 15, 2012

Taking finasteride over a 7-year period as part of the Prostate Cancer Prevention Trial (PCPT) “did not affect any of the three primary health-related quality-of-life domains—physical function, mental health, or vitality—either positively or negatively,” according to a study published in the Journal...

Breast Cancer

Fox Chase Researchers Find Most Medicare Patients Wait Weeks before Breast Cancer Surgery

The ASCO Post  / December 15, 2012

Although patients may feel anxious waiting weeks from the time of their first doctor visit to evaluate their breast until they have breast cancer surgery, new findings from Fox Chase Cancer Center in Philadelphia show that these waits are typical in the United States. Results were published recently...

Issues in Oncology

Significant Reduction in Cancer Risk Seen with Daily Multivitamin Use in Middle-aged and Older Men

Matthew Stenger  / December 15, 2012

Large-scale trials over the past several years have shown a general lack of effect of single vitamins or small numbers of vitamins given at high doses in preventing cancer. However, as recently reported in JAMA by Gaziano and colleagues, the Physicians’ Health Study II has found a modest but signifi...

Solid Tumors
Colorectal Cancer

Finding Lynch Syndrome among Patients with Colorectal Cancer: Routine Tumor Testing Looks Best

Caroline McNeil  / December 15, 2012

Oncologists generally agree that screening patients with colorectal cancer for Lynch syndrome is a good thing. Patients who turn out to have the hereditary syndrome can inform their first-degree relatives, who in turn can undergo genetic testing. Those who have the characteristic mutations can take ...

Study Explores Use of Radiotherapy in Last 30 Days of Life

Charlotte Bath  / December 15, 2012

While few patients receive radiation for cancer treatment in the last 30 days of life, almost 1 in 5 patients who do spend more than 10 of those days in treatment and more than half spend more than 5 days, according to a study published in the Journal of Clinical Oncology.1 The investigators used th...

No Survival Benefit for Oxaliplatin Added to Adjuvant Therapy in Stage II or Elderly Patients with Colon Cancer

Matthew Stenger  / November 15, 2012

Oxaliplatin plus fluorouracil (5-FU)/leucovorin or capecitabine (Xeloda) is a standard of care in adjuvant therapy for stage III colorectal cancer. There is ongoing debate about whether any adjuvant therapy is of benefit in patients with stage II disease, and it is not routinely recommended in this ...

Trastuzumab Emtansine Improves Survival vs Capecitabine plus Lapatinib in Second-line HER2-positive Breast Cancer

Matthew Stenger  / November 15, 2012

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of trastuzumab bound to the cytotoxic microtubule inhibitor emtansine (DM1, derivative of maytansine) by a stable linker. Trastuzumab targets the conjugate to HER2 receptors, and the linker releases the cytotoxic agent when the com...

Adjuvant Chemotherapy for Breast Cancer Predicted by Disease, Age, and Insurance Type, but Not by Race

Matthew Stenger  / November 15, 2012

Breast cancer mortality has been found to be higher among black and Hispanic women than among white women, with the differences in outcome being attributed in part to more advanced disease stage and greater frequency of unfavorable tumor biology among black and Hispanic women. Studies to date have n...

Nab-paclitaxel vs Solvent-based Paclitaxel in First-line Treatment of Advanced Non–Small Cell Lung Cancer: Final Results

Matthew Stenger  / November 15, 2012

Nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) is a solvent-free paclitaxel formulation intended to reduce solvent-related adverse reactions and improve tumor penetration via the physiologic transport properties of albumin. The final results of a phase III trial comparing nab-paclitaxel and ...

Intermittent Androgen Suppression in Prostate Cancer Noninferior to Continuous Suppression, Associated with Some QOL Benefit

Matthew Stenger  / November 15, 2012

A recently reported National Cancer Institute of Canada (NCIC) Clinical Trials Group study, reported by Crook and colleagues in The New England Journal of Medicine, showed that intermittent androgen suppression was associated with noninferior overall survival when compared with continuous suppressio...

PD-1 Blockade Increases Transferred T-cell Migration to Tumors

Matthew Stenger  / November 15, 2012

One reason that adoptive cell transfer has met with limited clinical success is that approaches based on this strategy have not fully taken into account the role of the tumor microenvironment as a limiting factor in immunotherapy. Recently reported studies by Peng and colleagues1 from The University...

Lung Cancer
Issues in Oncology

Phase II Study Suggests Advantage of Irreversible Pan-HER Inhibition in Advanced NSCLC

Matthew Stenger  / November 1, 2012

Dacomitinib is a new tyrosine kinase inhibitor that forms irreversible covalent bonds with the ATP domain of each of the three kinase-active members of the HER family—EGFR/HER1, HER2, and HER4. Agents such as erlotinib (Tarceva) and gefitinib (Iressa), which are of proven benefit in advanced non–sma...

Solid Tumors

Socioeconomic Disparity in Colorectal Cancer Rates Attributed to Obesity and Behavioral Risks

Charlotte Bath  / November 1, 2012

More than one-third of the excess risk of invasive adenocarcinoma of the colon and rectum resulting from low socioeconomic status “could be explained by differences in exposure to behavioral risk factors, particularly a healthy diet,” researchers recently reported in the Journal of the National Canc...

Successful Use of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy May Hinge on Prior Experience

Charlotte Bath  / October 15, 2012

A review of 60 consecutive patients with peritoneal carcinomatosis who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC)—sometimes called “hot chemotherapy”—found 0% mortality and 33% morbidity, with “a significant reduction of grade III/IV morbidity, perioperati...

Neuropathy Not Predictive of Outcomes with Adjuvant Taxane Therapy in Breast Cancer

Matthew Stenger  / October 15, 2012

Neuropathy is a common and potentially disabling adverse effect of taxane therapy, particularly weekly paclitaxel. A number of recent studies have identified single nucleotide polymorphisms that appear to increase risk of grade 2 to 4 neuropathy in patients with breast cancer who receive taxanes. It...

Skin Cancer
Survivorship

Radiation to the Skin and Later Risk of Basal Cell Carcinoma Studied

Charlotte Bath  / October 15, 2012

The likelihood of developing basal cell carcinoma was approximately 40 times higher among participants of the Childhood Cancer Survivor Study (CCSS) who received a dose of 35 Gy or more to the skin from radiation therapy than survivors who were not treated with radiation, according to a study publis...

Leukemia

Kinase Inhibitors Compared in First-line Treatment of CML

Matthew Stenger  / October 15, 2012

Bosutinib (Bosulif) is an oral dual Src/Abl kinase inhibitor that is active against many Bcr-Abl mutations associated with imatinib (Gleevec) resistance and that has reduced activity against nonspecific molecular targets associated with toxicities reported for other second-generation kinase inhibito...

Prostate Cancer

Hormonal Therapy with Enzalutamide Increases Survival in Castrate-resistant Prostate Cancer after Chemotherapy

Matthew Stenger  / October 15, 2012

The androgen receptor–signaling inhibitor enzalutamide (Xtandi) is reported to differ from conventional antiandrogen agents in that it inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment, has a greater affinity for the androgen receptor, and induces tumor shrin...

Survivorship

Prone Position during Radiation Therapy for Breast Cancer Is Associated with Reduced Irradiation to Lung and Heart

Charlotte Bath  / October 15, 2012

Preliminary data on prone positioning during whole-breast radiotherapy following breast-preservation surgery “suggest that radiation exposure to the heart and lung can be reduced compared with supine positioning with similar efficacy,” according to a research letter in the Journal of the American Me...

Head and Neck Cancer

Radiotherapy Not Helpful in Early-stage Parotid Acinic Cell Cancer

Charlotte Bath  / October 15, 2012

Adjuvant radiotherapy for patients with parotid acinic cell carcinoma “does not confer a therapeutic advantage in low-grade and early-stage tumors if resection is complete,” but the benefit for patients with higher-grade or higher-stage disease is uncertain because there were few of these patients i...

Prostate Cancer
Issues in Oncology

No Survival Benefit of Radical Prostatectomy vs Observation for Localized Prostate Cancer Detected by PSA Testing

Matthew Stenger  / September 15, 2012

The relative benefits of surgery or observation in men with prostate cancer detected by prostate-specific antigen (PSA) testing have not been defined. Randomized trials comparing radical prostatectomy with observation were conducted before widespread use of PSA testing and an observational study con...

Anticancer Effect of Diabetes Drug Metformin

Matthew Stenger  / September 15, 2012

Retrospective analyses have indicated that the antidiabetic agent metformin may be associated with a quite substantial reduction in risk of cancers. There is evidence that the anticancer effects of metformin are related to inhibition of the growth of certain cancers via activation of AMP kinase with...

Breast Cancer
Supportive Care

Sexual Dysfunction in Female Cancer Survivors Is Prevalent

Jo Cavallo  / September 15, 2012

Although medical experts put the proportion of female survivors facing some form of sexual dysfunction following a cancer diagnosis and treatment at nearly 100%, very few women raise sexual health concerns with their oncologist. In a study of 261 patients with gynecologic or breast cancer published ...

Breast Cancer

Physical Activity Benefits Breast Cancer Survivors, but Role in Reducing Breast Cancer Risk Is Less Clear

Charlotte Bath  / September 15, 2012

Breast cancer survivors who engage in moderate to high levels of physical activity have reduced mortality and improved quality of life, according to recent studies. In addition, exercise may play a role in lowering the risk of breast cancer. “Physical activity can hasten recovery from the immediate...

Supportive Care
Palliative Care

Dying Patients with Cancer Who Avoid Aggressive Care but Stay Connected with an Oncologist Have Better Quality of Life

Jo Cavallo  / September 15, 2012

Dying patients with cancer who avoided hospitalizations and life-prolonging measures, who worried less, prayed or meditated, were visited by a pastor, and maintained a therapeutic alliance with their oncologist had the highest quality of life at the end of life, according to a study recently publish...

Breast Cancer

Lack of Sleep Found to Be Risk Factor for Aggressive Breast Cancers

The ASCO Post  / September 15, 2012

Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center’s Seidman Cancer Center and Case Comprehensive Cancer Center at Case Wester...

Breast Cancer

No Advantage to Longer Adjuvant Chemotherapy in Women with Early Breast Cancer: CALGB 40101 Trial

Matthew Stenger  / September 1, 2012

The ideal duration of adjuvant therapy for women with lower-risk primary breast cancer remains unknown. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-15 trial, reported more than 20 years ago, found no difference in outcomes between six cycles of cyclophosphamide, methotrexate, a...

Solid Tumors

Ipsilateral Radiotherapy for Cervical Lymph Node Metastases

Charlotte Bath  / September 1, 2012

Ipsilateral neck–only radiation therapy “demonstrated excellent locoregional control with no adverse effect on disease-free survival or overall survival” among patients with cervical metastases from an unknown primary site, according to a retrospective review of medical records from 46 patients trea...

Preclinical Research Finds Gene that Permanently Stops Cancer Cell Proliferation

The ASCO Post  / September 1, 2012

Researchers at Case Western Reserve University School of Medicine, Cleveland, have discovered a mutant form of the gene Chk1 that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.1 This study illustrates ...

CNS Cancers

Chemotherapy plus Radiation Improved Progression-free Survival in Adults with Low-grade Glioma

Charlotte Bath  / September 1, 2012

Adult patients with supratentorial low-grade glioma who received chemotherapy with PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) in addition to radiation therapy had improved progression-free survival but not overall survival compared to patients receiving radiotherapy alone, acc...

Lymphoma

Study Shows Routine CT Surveillance Overused in Pediatric Hodgkin Lymphoma

Matthew Stenger  / August 15, 2012

The value of routine CT surveillance monitoring of pediatric patients for recurrence of Hodgkin lymphoma has been unclear. A study of CT surveillance recently reported by Stephan D. Voss, MD, PhD, and colleagues from the Children’s Oncology Group (COG) in the Journal of Clinical Oncology showed that...

Breast Cancer

‘Young and Strong’ Program Addresses Multiple Needs of Women in 40s and Younger Diagnosed with Breast Cancer

Charlotte Bath  / August 15, 2012

“Young and Strong” is an exportable model of a program developed at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston to address the significant challenges facing young women with breast cancer. The new model has been designed to “serve young women with breast cancer who are re...

Solid Tumors
Prostate Cancer

Radiotracer Targeting of Free Prostate-specific Antigen

Matthew Stenger  / August 15, 2012

Serum levels of prostate-specific antigen (PSA) are widely used as a biomarker for prostate cancer, although they often do not distinguish between normal tissue and cancer and do not always accurately reflect clinical outcome. In order to overcome the fact that the small proportion of tumor-associat...

Gynecologic Cancers

Adding Bevacizumab to Chemotherapy Improves Progression-free Survival in Platinum-sensitive Recurrent Ovarian Cancer

Charlotte Bath  / August 15, 2012

The addition of bevacizumab (Avastin) to gemcitabine and carboplatin, followed by bevacizumab until disease progression, resulted in significantly improved progression-free survival compared to gemcitabine and carboplatin plus placebo among women with platinum-sensitive recurrent ovarian, primary pe...

Lung Cancer

No Improvement in Overall Survival, Worse Toxicity with Motesanib Added to Chemotherapy in Non–Small Cell Lung Cancer

Matthew Stenger  / August 15, 2012

Two trials (E4599 and AVAiL) have suggested a benefit to adding the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) to chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Bevacizumab acts by binding directly to circulating V...

Lung Cancer

Lung Cancer Death Rates Increase among White Women in Some States

The ASCO Post  / July 15, 2012

A new study comparing lung cancer death rates among women by year of birth shows dramatic differences in trends between states, likely reflecting the success or failure of tobacco control efforts. The study, published early online in the Journal of Clinical Oncology,1 finds that while lung cancer de...

Colorectal Cancer

Increased Adjuvant Therapy Use and Improved Survival in Dutch Elderly Patients with Stage III Colon Cancer: A Direct Correlation?

Matthew Stenger  / July 15, 2012

A survival benefit of adjuvant chemotherapy has been reported for select elderly patients with stage III colon cancer, but many elderly patients are not candidates for or are not given adjuvant therapy due to comorbidities and fear of toxicity. In a recent Annals of Oncology article, van Steenbergen...

Leukemia

Prognostic Value of Integrated Cytogenetic and Mutational Risk Classification in Acute Myeloid Leukemia

Matthew Stenger  / July 15, 2012

Jay P. Patel, BS, and colleagues from Memorial Sloan-Kettering Cancer Center in New York recently performed mutational analysis of 18 genes in a subgroup of newly diagnosed acute myeloid leukemia (AML) patients who had been randomized to receive cytarabine plus high-dose or standard-dose daunorubici...

Mitotane-containing Regimens Explored for a Rare Tumor

Charlotte Bath  / July 15, 2012

Response rates and progression-free survival rates were significantly better among patients with advanced adrenocortical carcinoma receiving mitotane (Lysodren) plus EDP (etoposide, doxorubicin, and cisplatin) than in patients receiving mitotane with streptozocin (Zanosar), according to results of a...

Breast Cancer

New Study Examines Racial Disparities in Breast Cancer Mortality

Jo Cavallo  / July 15, 2012

According to the first national study looking at racial disparity in breast cancer mortality rates at the city level in the United States, societal factors—especially poverty and residential segregation—are resulting in the unnecessary deaths of five black women every day—more than 1,700 deaths a ye...

Supportive Care
Pain Management
Palliative Care

Early Access to Palliative/Supportive Care vs Usual Care Improves Pain Management

Matthew Stenger  / July 15, 2012

Many cancer patients remain undertreated for pain despite availability of guidelines and educational efforts to improve pain treatment. In a recent Annals of Oncology article, Bandieri and colleagues from the Italian Epidemiologia Clinico-Assistenziale del Dolore in Ospedale (ECAD-O) group report a ...

Lymphoma

Multicenter Phase II Trial Supporting Approval of Brentuximab Vedotin in Anaplastic Large-cell Lymphoma

Matthew Stenger  / July 1, 2012

Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive T-cell lymphoma subtype characterized by uniform expression of CD30. Apart from low- to intermediate-risk patients with ALK-positive disease, patients with ALCL have a poor prognosis when treated with conventional, anthracycline-based f...

Issues in Oncology

Can Whole-genome Sequencing Predict Cancer Risk and Improve Public Health?

Charlotte Bath  / June 15, 2012

If, as expected, the cost of whole-genome sequencing continues to drop, perhaps down to the $1,000 vicinity, it may become an alluring option for consumers who want to know about their risks for cancer and other diseases. But can genome sequencing really provide practical information about individua...

Hematologic Malignancies
Multiple Myeloma

Maintenance Lenalidomide Improves Progression-free Survival and Time to Progression in Patients with Multiple Myeloma

Charlotte Bath  / June 15, 2012

Three phase III, double-blind, multicenter, randomized studies showed that lenalidomide (Revlimid) maintenance therapy for patients with multiple myeloma significantly improved progression-free survival or time to progression, the primary endpoints of the studies published in The New England Journal...

Lung Cancer

Study Validates Prognostic Role of Tumor Lymphocytic Infiltration in Resectable Non–Small Cell Lung Cancer

The ASCO Post  / June 15, 2012

The benefit from platinum-based adjuvant chemotherapy in non–small cell lung cancer (NSCLC) was demonstrated in four randomized trials (International Adjuvant Lung Cancer Trial [IALT], Canadian JBR.10 trial, Cancer and Leukemia Group B [­CALGB] 9633 trial, and Adjuvant Navelbine International Triali...

Gastrointestinal Cancer

Strong Biomarker Candidates for Predicting Clinical Response to Bevacizumab

Charlotte Bath  / June 15, 2012

Plasma vascular endothelial growth factor A (VEGF-A) and tumor neuropilin-1 “are strong biomarker candidates for predicting clinical outcome in patients with advanced gastric cancer” after treatment with bevacizumab (Avastin). This was the conclusion of a mandatory biomarker program following up on ...

Prostate Cancer

Denosumab Delays Time to First Bone Metastasis in Men with Castration-resistant Prostate Cancer

Charlotte Bath  / June 15, 2012

Denosumab (Xgeva) significantly delayed time to first bone metastases among men with nonmetastatic castration-resistant prostate cancer enrolled in a phase III randomized, placebo-controlled trial. The time to first bone metastasis was 33.2 months among the 716 patients randomly assigned to receive ...

Health-Care Policy

ASCO Issues New Guideline on Chemotherapy Dosing for Obese Patients

Jo Cavallo  / May 15, 2012

In April, ASCO released a new clinical practice guideline on the appropriate dosing of chemotherapy drugs given to obese adult patients with cancer. The result of an analysis by a panel of experts assembled by ASCO, the guideline calls for the use of a patient's actual body weight when calculating c...

Prostate Cancer
Issues in Oncology

Study Shows Continued Benefit of PSA Screening in Reducing Prostate Cancer Mortality

Matthew Stenger  / May 15, 2012

Studies assessing the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality have produced conflicting results, and recommendations regarding PSA screening vary among authorities. The recently published 11-year follow-up of the European Randomized Study of Screening for Prost...

Prostate Cancer

Expert Point of View: Study Shows Continued Benefit of PSA Screening in Reducing Prostate Cancer Mortality

Fritz H. Schröder, MD  / May 15, 2012

Many of the almost 100 reports in various journals and newspapers refer to the lack of effect on overall mortality with screening in ERSPC in a very critical fashion. Clarification is necessary. Our trial did not intend to and is not powered to study the effect of screening on overall mortality. Mor...

Leukemia

Study Shows Steady Increases in Survival for Children with ALL

The ASCO Post  / May 15, 2012

A study by the Children’s Oncology Group (COG) reported that 5-year survival for acute lymphoblastic leukemia (ALL) among children treated through COG clinical trials increased from 83.7% during the period 1990-1994 to 90.4% in the period 2000-2005. The improvements in survival were observed among a...

Lung Cancer
Issues in Oncology

Analysis Suggests CT Screening Could Save Lives at Relatively Low Cost

Charlotte Bath  / May 15, 2012

Results of an actuarial analysis suggest that offering lung cancer screening with low-dose spiral computed tomography (CT) as a commercial insurance benefit to individuals who are 50 to 64 years old and have a smoking history of 30 pack-years or more could save lives at relatively low cost. Cost-be...

Lung Cancer
Prostate Cancer
Issues in Oncology

JAMA Highlights New Comparative Effectiveness Studies

Ronald Piana  / May 15, 2012

A recent press briefing moderated by Phil B. Fontanarosa, MD, MBA, Executive Editor, JAMA, presented new findings on comparative effectiveness research, and two of the studies discussed focused on cancer. Dr. Fontanarosa started by defining comparative effectiveness research, which gained prominence...

Colorectal Cancer

More New Data Support Use of Daily Aspirin to Prevent Cancers

Caroline McNeil  / May 15, 2012

Three new studies have added data to the growing evidence that low-dose, daily aspirin helps prevent colorectal cancer and other malignancies and may be useful in preventing metastases as well.1-3 Coming on the heels of other recent studies, the results appear to strengthen the case for using aspiri...

Lung Cancer

American Lung Association Provides Guidance on Lung Cancer Screening

The ASCO Post  / May 15, 2012

The American Lung Association has released new interim guidelines to assist physicians, patients, and the public in their discussions about lung cancer screening. Developed by the American Lung Association’s Lung Cancer Screening Committee chaired by Jonathan Samet, MD, MS, from the University of So...

Bladder Cancer

Chemoradiation with Fluorouracil and Mitomycin Reduces Recurrence of Muscle-invasive Bladder Cancer

Matthew Stenger  / May 15, 2012

Radiotherapy is an alternative to surgery in muscle-invasive bladder cancer, particularly in less-fit patients. However, it is associated with high rates of incomplete response or recurrence, with salvage surgery often being required. Although synchronous chemoradiotherapy has improved local control...

Issues in Oncology

Before Accepting a ‘Friend’ Request on Social Media, Carefully Consider the Potential Pitfalls and Perils

Charlotte Bath  / May 15, 2012

To friend or not to friend? That is the question many social networkers ponder daily. Oncologists and other health professionals considering “friend” requests from patients would be wise to first consider the potential pitfalls and perils of accepting such requests, according to an article written b...

Lung Cancer
Geriatric Oncology

Canadian Registry Study of Adjuvant Therapy for NSCLC Shows Increased Use in Elderly Patients and Improved Survival

Matthew Stenger  / May 15, 2012

Cisplatin-based adjuvant therapy is recommended for patients with resected stage II–IIIA non–small cell lung cancer (NSCLC). There have been no trials of adjuvant therapy in elderly patients with NSCLC, who constitute a large part of the NSCLC population. A number of analyses indicate that older pat...

Symptom Management

Oral Rivaroxaban Is Noninferior to Standard Anticoagulant Therapy in Acute Pulmonary Embolism

Matthew Stenger  / May 15, 2012

Thromboembolic disease is common in patients with cancer and increases risk of mortality. Recent studies showed that the oral factor Xa inhibitor rivaroxaban (Xarelto) was as effective and safe as standard anticoagulant therapy in treating deep-vein thrombosis, with superior efficacy of rivaroxaban ...

Breast Cancer

Brachytherapy Associated with Increased Complications Compared to Whole-breast Irradiation following Lumpectomy for Breast Cancer

The ASCO Post  / May 15, 2012

Among older women with invasive breast cancer and treated with lumpectomy, brachytherapy compared with whole-breast irradiation was associated with a decreased likelihood of long-term breast preservation and an increased likelihood of complications, but no difference in overall survival, according t...

Survivorship

Controlled Study Links ‘Chemobrain’ to Longitudinal Changes in Brain

Caroline McNeil  / April 15, 2012

The phenomenon called “chemobrain”—impaired cognitive functioning following chemotherapy—correlates with longitudinal changes in the brain’s white matter, according a recent study in the Journal of Clinical Oncology.1 Structural changes in the white matter, measured by magnetic resonance diffusion t...

Issues in Oncology

Radiation Oncologists Are Discussing Infertility Risks with Young Patients

The ASCO Post  / April 15, 2012

More than 80% of radiation oncologists discuss the impact of cancer treatments on fertility with their patients of childbearing age. This can lead to improved quality of life for young patients with cancer, according to a study in Practical Radiation Oncology.1 In the past, the clinical focus for y...

Issues in Oncology

Surgeon General Releases New Report on Youth Smoking

The ASCO Post  / April 15, 2012

The fight against tobacco use among young people was accelerated recently by Surgeon General Regina M. Benjamin, MD, MBA, with the release of the Surgeon General’s Report, Preventing Tobacco Use Among Youth and Young Adults. This report details the scope, health consequences, and influences that lea...

Lung Cancer

Not All KRAS Mutations Are Alike in Non–Small Cell Lung Cancer

Matthew Stenger  / April 15, 2012

Mutations in the KRAS oncogene play a critical role in cancer cell growth and resistance to treatment. In colorectal cancer, the presence of any mutant amino acid substitution in the K-Ras protein predicts a poorer response to targeted therapy. In non–small cell lung cancer (NSCLC), however, there i...

Palliative Care

Summary of ASCO Provisional Clinical Opinion on Palliative Care

Ronald Piana  / April 15, 2012

The ASCO provisional clinical opinion on palliative care recently published1 was based largely on data from seven published randomized controlled trials, including a phase III lung cancer trial by Temel and colleagues, which was the trigger for the new recommendations.2 The trial’s principal outcome...

Prostate Cancer

New Biomarker Predicts Survival in Advanced Prostate Cancer

Alice Goodman  / April 15, 2012

Researchers at Memorial Sloan-Kettering Cancer Center have developed the Bone Scan Index (BSI), which is the first quantitative imaging response biomarker that can assess response to treatment and prognosticates for survival in men with metastatic castration-resistant prostate cancer. Based on Bone...

Lymphoma

New Data Guide Treatment for Rare Form of Hodgkin Lymphoma

Matthew Stenger  / April 15, 2012

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of Hodgkin lymphoma cases. It is distinguished from classic Hodgkin lymphoma by a variety of clinical and pathologic features, including expression of B-cell associated antigens such as CD20. Given that the overall...

Issues in Oncology

Report to the Nation Finds Continuing Declines in Cancer Death Rates

The ASCO Post  / April 15, 2012

Death rates from all cancers combined for men, women, and children continued to decline in the United States between 2004 and 2008, according to the Annual Report to the Nation on the Status of Cancer, 1975-2008. Overall cancer incidence rates among men decreased by an average of 0.6% per year betwe...

Colorectal Cancer

Adjuvant Therapy for Stage III Colon Cancer: Survival Advantage of Oxaliplatin Reported in Clinical Trials Extends to Diverse Group of Patients

Charlotte Bath  / March 15, 2012

The survival advantage conferred by adding oxaliplatin to adjuvant chemotherapy with fluorouracil (5-FU) in stage III colon cancer, as previously shown in patients in randomized controlled trials, extends to patients in the general population, including older and minority group patients and those wi...

Leukemia

Autologous Transplant vs Consolidation Chemotherapy in Acute Myeloid Leukemia: A Recent European Trial

Matthew Stenger  / March 15, 2012

Investigators in the Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research Collaborative Group recently reported in the journal Blood that autologous peripheral blood stem cell transplantation significantly reduced relapse rate compared with intensive conso...

Skin Cancer

Answer to Secondary Cancers with RAF Inhibitors May Be Concomitant MEK Inhibition

Matthew Stenger  / March 15, 2012

Keratoacanthomas and cutaneous squamous cell carcinomas are frequently observed in patients receiving the RAF inhibitor vemurafenib (Zelboraf) for treatment of BRAF-mutated melanoma. As discussed by Lacouture and colleagues in a recent Journal of Clinical Oncology article, these effects appear to re...

Head and Neck Cancer
Survivorship

Eating Problems and Pain Prevalent in Survivors of Head/Neck Cancer

The ASCO Post  / March 15, 2012

“Eating problems due to poor oropharyngeal functioning and persistent pain are the most prevalent problems” faced by patients 5 years after being treated for head and neck cancer, according to a study published online by the Archives of Otolaryngology–Head & Neck Surgery.1 More than 50% of 5-yea...

Lung Cancer

Adding Thalidomide to Chemoradiation Increases Toxicities but Not Survival for Stage III Non–Small Cell Lung Cancer

The ASCO Post  / March 1, 2012

Adding thalidomide (Thalomid) to the third-generation chemotherapy doublet of paclitaxel and carboplatin and radiation for patients with stage III non–small cell lung cancer (NSCLC) increased toxicities but did not improve survival. These results from the Eastern Cooperative Oncology Group (ECOG) 35...

Gynecologic Cancers

Similar Morbidity, Higher Costs for Robotic vs Laparoscopic Hysterectomy in Women with Endometrial Cancer

The ASCO Post  / March 1, 2012

A population-based analysis comparing laparoscopic hysterectomy and robotic hysterectomy for endometrial cancer “found similar morbidity but increased cost compared with laparoscopic hysterectomy,” investigators reported in the Journal of Clinical Oncology.1 After adjusting for patient, surgeon, and...

Lung Cancer

Epigenetic Therapy Shows Positive Results in Late-stage Lung Cancer

Jo Cavallo  / February 15, 2012

A small phase I/II clinical study from Johns Hopkins University in Baltimore found that epigenetic therapy with a combination of azacitidine (Vidaza) and entinostat (an investigational agent) produced responses in some patients with refractory advanced non–small cell lung cancer. The study results, ...

Skin Cancer

Cancer Survivors at Greater Risk for Cutaneous Melanoma

Charlotte Bath  / February 15, 2012

Patients with a previously diagnosed cancer have an increased risk of developing cutaneous melanoma, with the highest risk among patients who have had a prior diagnosis of melanoma, according to a report published in the Archives of Dermatology.1 Key Findings Using Surveillance, Epidemiology, and ...

Kidney Cancer

Tyrosine Kinase Inhibitor Therapy Yields Complete Remission in Patients with Metastatic Renal Cell Carcinoma

Matthew Stenger  / February 15, 2012

Targeted therapies have markedly improved outcomes in patients with advanced renal cell carcinoma, with median overall survival of greater than 2 years having been observed with sunitinib (Sutent) treatment. Objective responses, consisting mostly of partial responses, are observed in approximately 8...

Hepatobiliary Cancer

Laparoscopic Liver Resections Can Be Safe and Oncologically Efficient

Charlotte Bath  / February 15, 2012

Laparoscopic resection of primary and metastatic liver cancers can be safe and oncologically efficient and reduce postoperative length of stay, a single-center study from the United Kingdom found.1 The investigators cautioned, however, that “adequate patient selection and extensive experience in hep...

Breast Cancer

Partial Breast Irradiation with Brachytherapy in Early Breast Cancer: Retrospective Analysis Looks at Trends and Guidelines

Charlotte Bath  / February 15, 2012

Accelerated partial breast irradiation using brachytherapy (APBIb) as an alternative to whole-breast irradiation (WBI) after breast-conserving surgery has been rapidly adopted in the United States, but the majority of patients receiving APBIb may not be considered suitable for it. A retrospective a...

Colorectal Cancer

Further Individualizing Staging Offers Benefits in Patients with Colon Cancer

Charlotte Bath  / January 15, 2012

Supplementing the American Joint Committee on Cancer (AJCC) TNM classification system with additional information available from tumor registries can assist in personalizing treatment and follow-up care for patients with colon cancer, according to a collaborative study by investigators at Memorial S...

Lung Cancer

Presurgical Gemcitabine/Cisplatin Improves Survival in Lung Cancer

Charlotte Bath  / January 1, 2012

Preoperative gemcitabine plus cisplatin had a statistically significant impact on outcomes among patients with stage IIB/IIIA non–small-cell lung cancer in a phase III randomized study comparing surgery alone or surgery plus preoperative chemotherapy. The 3-year progression-free survival rates were ...

Lung Cancer

NCCN Guidelines® for Lung Cancer Screening Now Available

The ASCO Post  / November 15, 2011

The new NCCN Guidelines for Lung Cancer Screening primarily refer to non–small cell lung cancer, the most common type of lung cancer, and recommend helical low-dose computed tomography (LDCT) screening for select patients at high risk for the disease. In addition to outlining the appropriate use of...

Breast Cancer

Tamoxifen vs Surgery Study Shows Older Patients with Breast Cancer Can Achieve a ‘Personal Cure’

Charlotte Bath  / November 15, 2011

A truly final review—when all the patients in the trial have died and the cause of death is known for each—of a randomized trial comparing tamoxifen to surgery in patients over the age of 70 with operable breast cancer found no differences in the survival rates or deaths attributable to breast cance...

Lung Cancer

Improved Survival with Concurrent Chemotherapy plus Radiotherapy for Patients with Stage III Non–Small Cell Lung Cancer

Charlotte Bath  / November 15, 2011

Five-year survival was statistically significantly higher for patients with stage III non–small cell lung cancer (NSCLC) who received concurrent rather than sequential cisplatin-based chemotherapy combined with thoracic radiotherapy, according to the phase III Radiation Therapy Oncology Group (RTOG)...

Breast Cancer

Adjuvant Trastuzumab in Nonanthracycline Regimen Studied

The ASCO Post  / November 15, 2011

One of four large, randomized trials to evaluate adjuvant trastuzumab (Herceptin) in early-stage HER2-positive breast cancer—and the only study to include a nonanthracycline chemotherapy regimen—found that regimen had similar efficacy to anthracycline-containing regimens, but with lower rates of car...

Lung Cancer

Time to Reconsider Treatment Paradigm for Elderly Patients with Advanced Non–Small Cell Lung Cancer?

Charlotte Bath  / November 1, 2011

Significantly longer median overall survival among elderly patients with advanced non–small cell lung cancer (NSCLC) receiving doublet chemotherapy rather than monotherapy yielded a 36% reduction in mortality risk in a phase III randomized trial. “We saw a survival benefit with doublet chemotherapy ...

Breast Cancer

BRCA Mutation Has Little Effect on Outcome with Neoadjuvant Therapy

The ASCO Post  / November 1, 2011

A retrospective analysis to determine the efficacy of neoadjuvant systemic therapy for breast cancer patients with and without BRCA mutations found the overall prognosis was similar in both groups of patients. “No significant differences were noted in survival outcomes with respect to BRCA status an...

Lung Cancer

New ASCO Focused Update Recommendation on Maintenance Treatment of Stage IV Non–Small Cell Lung Cancer

Matthew Stenger  / October 15, 2011

A focused update to the 2009 ASCO Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer reflects new evidence on maintenance therapy in patients with response or stable disease after four cycles of first-line cytotoxic chemotherapy.1 The 2009 update recommendatio...

Prostate Cancer

Short-term Androgen Deprivation plus Radiotherapy Improves Outcomes in Intermediate-risk Prostate Cancer

Alice Goodman  / October 15, 2011

The addition of short-term androgen-deprivation therapy to external-beam radiation therapy improved overall and disease-specific survival in men with nonbulky localized prostate cancer and prostate-specific antigen (PSA) levels up to 20 ng/mL, as reported recently in The New England Journal of Medic...

Solid Tumors

Tissue of Origin Test Evaluated in Patients with Cancer of Unknown Primary

The ASCO Post  / September 15, 2011

According to results of a study published in the Journal of Molecular Biomarkers and Diagnosis,1 the recently developed Tissue of Origin Test (Pathwork Diagnostics, Inc) aids in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history, parti...

Prostate Cancer

Long-term Data Show Benefit of Degarelix Beyond 3 Years in Advanced Hormone-dependent Prostate Cancer

The ASCO Post  / September 15, 2011

Degarelix (Firmagon) is effective and well tolerated beyond 3 years in patients with advanced prostate cancer, according to a recent study published in The Journal of Urology.1 The new study (CS21A) extends the conclusions of the pivotal phase III study (CS21) in which the risk of prostate-specific ...

Breast Cancer

Genomic Researchers Identify Weak Points in Breast Cancer Cells

Caroline Helwick  / September 1, 2011

A large-scale project in genetic profiling has identified weak points in breast tumor cells that not only represent potentially new “druggable” targets but could lead to an entirely new classification of all cancers. The findings were recently reported in Cancer Discovery, a journal of the American ...

Head and Neck Cancer

Circulating Tumor Cell Assay Shows Potential for Predicting Prognosis in Head and Neck Carcinoma

Matthew Stenger  / September 1, 2011

According to the NCI, an estimated 49,260 new cases of oral cavity, pharyngeal, and laryngeal cancers occurred in the United States in 2010, and approximately 11,480 deaths were attributed to these cases. It is estimated that 95% or more of these cases are squamous cell carcinomas. Currently, the pr...

Supportive Care
Symptom Management

Experts Address Cancer-related Distress—the ‘Sixth Vital Sign’

The ASCO Post  / September 1, 2011

More research is needed to investigate the effects of screening and treatment for distress in cancer care, according to a recent issue of the international journal Psycho‑Oncology. This special edition of the journal includes a review of screening for distress and depression over 40 years in cancer ...

Prostate Cancer

At 5 Years, Brachytherapy Shows Quality-of-life Advantages over Radical Prostatectomy for Favorable-risk Prostate Cancer

Charlotte Bath  / September 1, 2011

Five years after treatment for favorable-risk prostate cancer, men who either chose or were randomly assigned to receive brachytherapy reported quality-of-life advantages in urinary and sexual domains and in patient satisfaction compared to men who received radical prostatectomy, according to a stud...

Issues in Oncology

‘Unrealistic Optimism’ Poses Ethical Challenges, May Affect Informed Consent Process

Jo Cavallo  / September 1, 2011

Does a patient’s optimistic expectation of reaping a health benefit from participating in phase I and phase II oncology studies, even when he understands that these early trials are not designed to provide direct therapeutic benefit, compromise the informed consent process? And, does that optimistic...

Lymphoma

Combined Therapy Produces Good Outcomes in Primary Testicular Diffuse Large B-cell Lymphoma

Charlotte Bath  / August 15, 2011

Final results of an international phase II trial of first-line treatment for primary testicular diffuse large B-cell lymphoma show that using a combined treatment strategy including chemotherapy and central nervous system and testicular prophlaxis “was associated with a good outcome.” The results we...

Kidney Cancer

Studies Explore Potential Benefits of Sunitinib before Nephrectomy in Metastatic Clear Cell Renal Cancer

Matthew Stenger  / July 15, 2011

The multitargeted tyrosine kinase inhibitor sunitinib (Sutent) is established as first-line therapy in metastatic clear cell renal cancer. Data supporting use of cytoreductive nephrectomy in metastatic clear cell renal cancer come from the pre–targeted therapy era, when less-effective immune therapy...

Issues in Oncology

Is Subspecialization an Option or a Necessity in Community Practices?

Charlotte Bath  / July 15, 2011

Should oncologists in community practices subspecialize? What would that mean for them and for their patients? These are some of the issues tackled in a Journal of Oncology Practice (JOP) Strategies for Career Success article entitled “Subspecialization in Community Oncology: Option or Necessity?” ...

Symptom Management

Vanderbilt Oncologists Partner with Cardiologists to Research Chemotherapy-related Cardiac Toxicity

Caroline Helwick  / July 1, 2011

Cardiac toxicity related to chemotherapy is not a new topic but it is an increasingly important one, as concerns are no longer limited to the anthracyclines. Targeted agents unfortunately “target” the cardiovascular system as well, especially bevacizumab (Avastin), trastuzumab (Herceptin) when given...

Lung Cancer

Understanding Crizotinib, 1 Year after High-profile Presentation

Matthew Stenger  / July 1, 2011

The findings from a phase I study of crizotinib in non–small cell lung cancer (NSCLC) were presented in a Plenary Session at the 2010 ASCO Annual Meeting—an unusual event, since such early-phase data are not generally the topic of plenary sessions. The study showed that a majority of mostly pretreat...

Breast Cancer

‘Paradoxical’ Result Tying Estrogen to Reduced Risk of Breast Cancer Is Consistent with Laboratory Data

Charlotte Bath  / June 15, 2011

Results from the Women’s Health Initiative1 showing a decreased incidence of breast cancer among postmenopausal hysterectomized women who took estrogen replacement therapy (ERT) may seem paradoxical, but “comply exactly” with laboratory research, according to V. Craig Jordan, OBE, PhD, DSc, Scientif...

Advertisement

Advertisement



Advertisement